1
|
Garcia D, Laccourreye O. Suicide after total laryngectomy for cancer in France. Eur Ann Otorhinolaryngol Head Neck Dis 2024:S1879-7296(24)00056-5. [PMID: 38702263 DOI: 10.1016/j.anorl.2024.04.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/06/2024]
Affiliation(s)
- D Garcia
- Service d'otorhinolaryngologie et de chirurgie cervico-faciale, HEGP, université Paris Cité, AP-HP, 20-40, rue Leblanc, 75015 Paris, France
| | - O Laccourreye
- Service d'otorhinolaryngologie et de chirurgie cervico-faciale, HEGP, université Paris Cité, AP-HP, 20-40, rue Leblanc, 75015 Paris, France.
| |
Collapse
|
2
|
Valente IVB, Garcia D, Abbott A, Spruill L, Siegel J, Forcucci J, Hanna G, Mukherjee R, Hamann M, Hilliard E, Lockett M, Cole DJ, Klauber-DeMore N. The anti-proliferative effects of a frankincense extract in a window of opportunity phase ia clinical trial for patients with breast cancer. Breast Cancer Res Treat 2024; 204:521-530. [PMID: 38194131 PMCID: PMC10959833 DOI: 10.1007/s10549-023-07215-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2023] [Accepted: 12/05/2023] [Indexed: 01/10/2024]
Abstract
PURPOSE Boswellic acids, active components of frankincense, suppress tumor proliferation in vitro with a strong clinical trial safety profile in patients with inflammatory diseases. We performed a Phase Ia window of opportunity trial of Boswellia serrata (B. serrata) in patients with breast cancer to evaluate its biologic activity and safety. METHODS Patients with invasive breast cancer were treated pre-operatively with B. Serrata (2400 mg/day PO) until the night before surgery for a median of 11 days (SD 6 days; range: 5-23 days). Paraffin-embedded sections from pretreatment diagnostic core biopsies and post-treatment surgical excisions were evaluated using a tunnel assay and immunohistochemistry staining with Ki-67 antibodies. A non-intervention retrospective control arm consisting of core and surgical tissue specimens from untreated patients was used to compare patients treated with B. Serrata. The change in proliferation and apoptosis between diagnostic core specimens and surgical specimens was compared between the control and treatment groups using a two-tailed paired t-test. RESULTS Twenty-two patients were enrolled, of which 20 received treatment, and 18 had sufficient tissue for IHC. There was an increase in percent change in proliferation from core biopsy to surgical excision in the control group (n = 18) of 54.6 ± 21.4%. In the B. serrata-treated group there was a reduction in proliferation between core biopsy and excision (n = 18) of 13.8 ± 11.7%. This difference was statistically significant between the control and B. serrata-treated groups (p = 0.008). There was no difference in change in apoptosis. There were no serious adverse events related to the drug. CONCLUSION Boswellia serrata inhibited breast cancer proliferation and was well-tolerated in a Phase Ia window of opportunity trial.
Collapse
Affiliation(s)
| | - Denise Garcia
- Department of Surgery, Medical University of South Carolina, Charleston, SC, USA
| | - Andrea Abbott
- Department of Surgery, Medical University of South Carolina, Charleston, SC, USA
| | - Laura Spruill
- Department of Pathology, Medical University of South Carolina, Charleston, SC, USA
| | - Julie Siegel
- Department of Surgery, Medical University of South Carolina, Charleston, SC, USA
| | - Jessica Forcucci
- Department of Pathology, Medical University of South Carolina, Charleston, SC, USA
| | - George Hanna
- College of Pharmacy Drug Discovery and Biomedical Sciences, Medical University of South Carolina, Charleston, SC, USA
| | - Rupak Mukherjee
- Department of Surgery, Medical University of South Carolina, Charleston, SC, USA
| | - Mark Hamann
- College of Pharmacy Drug Discovery and Biomedical Sciences, Medical University of South Carolina, Charleston, SC, USA
| | - Eleanor Hilliard
- Department of Surgery, Medical University of South Carolina, Charleston, SC, USA
| | - Mark Lockett
- Department of Surgery, Medical University of South Carolina, Charleston, SC, USA
| | - David J Cole
- Department of Surgery, Medical University of South Carolina, Charleston, SC, USA
| | - Nancy Klauber-DeMore
- Department of Surgery, Medical University of South Carolina, Charleston, SC, USA.
- Medical University of South Carolina, MSC 295, Room 240, 114 Doughty Street, Charleston, SC, 29425, USA.
| |
Collapse
|
3
|
Greenwald M, Gunberg S, Ball J, Garcia D. Hearing Loss As A Surrogate Marker For Early Atherosclerosis in A High-Risk Population: A Prospective Study. Am J Cardiol 2024; 211:191-192. [PMID: 37949343 DOI: 10.1016/j.amjcard.2023.11.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/25/2023] [Revised: 10/25/2023] [Accepted: 11/04/2023] [Indexed: 11/12/2023]
Affiliation(s)
| | | | - Joann Ball
- Desert Medical Advances, Rancho Mirage, California
| | | |
Collapse
|
4
|
Abstract
This year, 2023, is the 150th anniversary of the first total laryngectomy for cancer, by Theodor Billroth. The authors reconstruct the conditions under which, on March 12, 1885, this operation was then performed for the first time in France, by Leon Labbé, and present the man himself, and also M. Cadier, the inventive genius who designed the first artificial larynx used in this country.
Collapse
Affiliation(s)
- O Laccourreye
- Université Paris Cité, service d'otorhinolaryngologie et de chirurgie cervico-faciale HEGP, AP-HP, 20-40, rue Leblanc, 75015 Paris, France.
| | - D Garcia
- Hôpital français, SO1Pho Phuong Mai District Dong Da, Hanoi, Vietnam
| | - S Guiquerro
- Université Paris Cité, bibliothèque universitaire Necker, 160, rue de Vaugirard, 75015 Paris, France
| | - A Mudry
- Department of Otolaryngology, Head & Neck Surgery, Stanford University School of Medicine, 801, Welch road, Stanford, CA, 94305-5739, USA
| |
Collapse
|
5
|
Laccourreye O, Gervais C, Garcia D, Amiri G, Mirghani H, Giraud P. Harmful impact of treatment refusal in T3-4M0 endolaryngeal squamous cell carcinoma candidates for total laryngectomy: A STROBE analysis. Eur Ann Otorhinolaryngol Head Neck Dis 2023; 140:221-225. [PMID: 37321906 DOI: 10.1016/j.anorl.2023.06.001] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/17/2023]
Abstract
PURPOSE To evaluate the consequences of treatment refusal in total laryngectomy (TL) candidates with T3-4M0 endolaryngeal squamous cell carcinoma (SCC). MATERIALS AND METHODS A retrospective observational study was conducted in an inception cohort of 576 isolated T3-4M0 endolaryngeal SCC candidates for TL consecutively managed between 1970 and 2019 in a French university teaching hospital. The main endpoint was survival time and cause of death in 2 groups. Group A, 4.5% of the cohort, consisted of 26 patients who declined any laryngeal treatment. Group B consisted of 550 patients who accepted TL. Accessory endpoints were causes of TL refusal and associated variables. The STROBE guideline was applied. The significance threshold was set at P<0.005. RESULTS One-and 3-year actuarial survival estimates increased significantly (P<0.0001) from 39% and 15% in group A, to 83% and 63% in group B, respectively. In group A, 92% of causes of death implicated index SCC progression, whereas in group B intercurrent disease, metachronous second primary, locoregional and/or metastatic SCC progression and postoperative complications accounted for 37%, 31%, 29%, and 2%, respectively. The actuarial survival estimates within group A increased significantly (P=0.0003) from 0% at 1-year in patients managed with isolated supportive care to 56% in patients managed with chemotherapy (reaching 0% at 5years). Reasons for TL refusal were fear of surgery, refusal of tracheostoma, loss of physiologic phonation, and certain comorbidities. Age and chronologic period correlated significantly with TL refusal. Median age decreased (P<0.001) from 69years in group A to 58 years in group B. Percentage TL refusal increased (P<0.0001) from 2% to 11% before and after start 1990, respectively. CONCLUSION The current study determined loss of survival with refusal of any laryngeal treatment including TL, noted benefit of chemotherapy associated to supportive care, and discussed the possible contribution of immunotherapy.
Collapse
Affiliation(s)
- O Laccourreye
- Service d'Otorhinolaryngologie et de Chirurgie Cervico-Faciale, HEGP, Université Paris Cité, AP-HP, 20-40, rue Leblanc, 75015 Paris, France.
| | - C Gervais
- Service d'Oncologie Médicale, HEGP, Université Paris Cité, AP-HP, 20-40, rue Leblanc, 75015 Paris, France
| | - D Garcia
- Hôpital Français, SO1 Pho Phuong Mai, Dong Da District, Hanoi, Viet Nam
| | - G Amiri
- Service d'Otorhinolaryngologie et de Chirurgie Cervico-Faciale, HEGP, Université Paris Cité, AP-HP, 20-40, rue Leblanc, 75015 Paris, France
| | - H Mirghani
- Service d'Otorhinolaryngologie et de Chirurgie Cervico-Faciale, HEGP, Université Paris Cité, AP-HP, 20-40, rue Leblanc, 75015 Paris, France
| | - P Giraud
- Service de Radiothérapie-Oncologie, HEGP, Université Paris Cité, AP-HP, 20-40, rue Leblanc, 75015 Paris, France
| |
Collapse
|
6
|
Laccourreye O, Chambrin G, Garcia D, Troux C, Mirghani H, Giraud P. Successful 10-year outcomes after supracricoid partial laryngectomy for selected glottic squamous cell carcinoma classified as T3N0M0: A STROBE analysis. Eur Ann Otorhinolaryngol Head Neck Dis 2023; 140:165-170. [PMID: 36609114 DOI: 10.1016/j.anorl.2022.12.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Abstract
PURPOSE To evaluate long-term oncological outcome for patients with selected glottic squamous cell carcinoma (SCC) classified as T3N0M0 treated by supracricoid partial laryngectomy (SCPL). MATERIALS AND METHODS Analysis of an inception cohort of 46 patients with isolated untreated SCC classified as T3N0M0 and minimum 10-year follow-up, consecutively treated by SCPL between 1982 and 2012 in a French university teaching hospital. The main endpoint was 5- and 10-year actuarial survival and local control estimates. Accessory endpoints comprised cause of death, screening for variables decreasing survival and increasing risk of local recurrence, oncologic consequences of local recurrence, and laryngeal preservation rate. RESULTS Five- and 10-year actuarial survival was 78.1%, and 53.3%, respectively. The main causes of death were intercurrent disease and metachronous second primary, each in 33.3% of cases. Postoperative mortality (aspiration pneumonia) was 2.1%. There were no significant correlations between survival and any study variables. Five- and 10-year local control was 90.5%. Overall local recurrence varied significantly (P=0.003), from 2.3% with negative margins (R0) to 100% with positive margins (R1) and/or dysplasia. Local recurrence was associated with a significantly (P<0.005) increased risk of nodal failure and distant metastasis, and reduced survival. Overall laryngeal preservation was 89.1%. CONCLUSION The present results suggest that SCPL should continue to be taught and that this type of partial laryngeal surgery should be included in the various organ-sparing strategies considered in advanced laryngeal cancer.
Collapse
Affiliation(s)
- O Laccourreye
- Service d'otorhinolaryngologie et de chirurgie cervico-faciale HEGP, université Paris Cité, AP-HP, 20-40 rue Leblanc, 75015 Paris, France.
| | - G Chambrin
- Service d'otorhinolaryngologie et de chirurgie cervico-faciale HEGP, université Paris Cité, AP-HP, 20-40 rue Leblanc, 75015 Paris, France
| | - D Garcia
- Hôpital Français, SO1 Pho Phuong Mai, Dong Da District, Hanoi, Vietnam
| | - C Troux
- Service d'otorhinolaryngologie et de chirurgie cervico-faciale HEGP, université Paris Cité, AP-HP, 20-40 rue Leblanc, 75015 Paris, France
| | - H Mirghani
- Service d'otorhinolaryngologie et de chirurgie cervico-faciale HEGP, université Paris Cité, AP-HP, 20-40 rue Leblanc, 75015 Paris, France
| | - P Giraud
- Service d'oncologie-radiothérapie, université Paris Cité, HEGP, AP-HP, 20-40 rue Leblanc, 75015 Paris, France
| |
Collapse
|
7
|
Aalbers J, Akerib DS, Akerlof CW, Al Musalhi AK, Alder F, Alqahtani A, Alsum SK, Amarasinghe CS, Ames A, Anderson TJ, Angelides N, Araújo HM, Armstrong JE, Arthurs M, Azadi S, Bailey AJ, Baker A, Balajthy J, Balashov S, Bang J, Bargemann JW, Barry MJ, Barthel J, Bauer D, Baxter A, Beattie K, Belle J, Beltrame P, Bensinger J, Benson T, Bernard EP, Bhatti A, Biekert A, Biesiadzinski TP, Birch HJ, Birrittella B, Blockinger GM, Boast KE, Boxer B, Bramante R, Brew CAJ, Brás P, Buckley JH, Bugaev VV, Burdin S, Busenitz JK, Buuck M, Cabrita R, Carels C, Carlsmith DL, Carlson B, Carmona-Benitez MC, Cascella M, Chan C, Chawla A, Chen H, Cherwinka JJ, Chott NI, Cole A, Coleman J, Converse MV, Cottle A, Cox G, Craddock WW, Creaner O, Curran D, Currie A, Cutter JE, Dahl CE, David A, Davis J, Davison TJR, Delgaudio J, Dey S, de Viveiros L, Dobi A, Dobson JEY, Druszkiewicz E, Dushkin A, Edberg TK, Edwards WR, Elnimr MM, Emmet WT, Eriksen SR, Faham CH, Fan A, Fayer S, Fearon NM, Fiorucci S, Flaecher H, Ford P, Francis VB, Fraser ED, Fruth T, Gaitskell RJ, Gantos NJ, Garcia D, Geffre A, Gehman VM, Genovesi J, Ghag C, Gibbons R, Gibson E, Gilchriese MGD, Gokhale S, Gomber B, Green J, Greenall A, Greenwood S, van der Grinten MGD, Gwilliam CB, Hall CR, Hans S, Hanzel K, Harrison A, Hartigan-O'Connor E, Haselschwardt SJ, Hernandez MA, Hertel SA, Heuermann G, Hjemfelt C, Hoff MD, Holtom E, Hor JYK, Horn M, Huang DQ, Hunt D, Ignarra CM, Jacobsen RG, Jahangir O, James RS, Jeffery SN, Ji W, Johnson J, Kaboth AC, Kamaha AC, Kamdin K, Kasey V, Kazkaz K, Keefner J, Khaitan D, Khaleeq M, Khazov A, Khurana I, Kim YD, Kocher CD, Kodroff D, Korley L, Korolkova EV, Kras J, Kraus H, Kravitz S, Krebs HJ, Kreczko L, Krikler B, Kudryavtsev VA, Kyre S, Landerud B, Leason EA, Lee C, Lee J, Leonard DS, Leonard R, Lesko KT, Levy C, Li J, Liao FT, Liao J, Lin J, Lindote A, Linehan R, Lippincott WH, Liu R, Liu X, Liu Y, Loniewski C, Lopes MI, Lopez Asamar E, López Paredes B, Lorenzon W, Lucero D, Luitz S, Lyle JM, Majewski PA, Makkinje J, Malling DC, Manalaysay A, Manenti L, Mannino RL, Marangou N, Marzioni MF, Maupin C, McCarthy ME, McConnell CT, McKinsey DN, McLaughlin J, Meng Y, Migneault J, Miller EH, Mizrachi E, Mock JA, Monte A, Monzani ME, Morad JA, Morales Mendoza JD, Morrison E, Mount BJ, Murdy M, Murphy ASJ, Naim D, Naylor A, Nedlik C, Nehrkorn C, Neves F, Nguyen A, Nikoleyczik JA, Nilima A, O'Dell J, O'Neill FG, O'Sullivan K, Olcina I, Olevitch MA, Oliver-Mallory KC, Orpwood J, Pagenkopf D, Pal S, Palladino KJ, Palmer J, Pangilinan M, Parveen N, Patton SJ, Pease EK, Penning B, Pereira C, Pereira G, Perry E, Pershing T, Peterson IB, Piepke A, Podczerwinski J, Porzio D, Powell S, Preece RM, Pushkin K, Qie Y, Ratcliff BN, Reichenbacher J, Reichhart L, Rhyne CA, Richards A, Riffard Q, Rischbieter GRC, Rodrigues JP, Rodriguez A, Rose HJ, Rosero R, Rossiter P, Rushton T, Rutherford G, Rynders D, Saba JS, Santone D, Sazzad ABMR, Schnee RW, Scovell PR, Seymour D, Shaw S, Shutt T, Silk JJ, Silva C, Sinev G, Skarpaas K, Skulski W, Smith R, Solmaz M, Solovov VN, Sorensen P, Soria J, Stancu I, Stark MR, Stevens A, Stiegler TM, Stifter K, Studley R, Suerfu B, Sumner TJ, Sutcliffe P, Swanson N, Szydagis M, Tan M, Taylor DJ, Taylor R, Taylor WC, Temples DJ, Tennyson BP, Terman PA, Thomas KJ, Tiedt DR, Timalsina M, To WH, Tomás A, Tong Z, Tovey DR, Tranter J, Trask M, Tripathi M, Tronstad DR, Tull CE, Turner W, Tvrznikova L, Utku U, Va'vra J, Vacheret A, Vaitkus AC, Verbus JR, Voirin E, Waldron WL, Wang A, Wang B, Wang JJ, Wang W, Wang Y, Watson JR, Webb RC, White A, White DT, White JT, White RG, Whitis TJ, Williams M, Wisniewski WJ, Witherell MS, Wolfs FLH, Wolfs JD, Woodford S, Woodward D, Worm SD, Wright CJ, Xia Q, Xiang X, Xiao Q, Xu J, Yeh M, Yin J, Young I, Zarzhitsky P, Zuckerman A, Zweig EA. First Dark Matter Search Results from the LUX-ZEPLIN (LZ) Experiment. Phys Rev Lett 2023; 131:041002. [PMID: 37566836 DOI: 10.1103/physrevlett.131.041002] [Citation(s) in RCA: 5] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/18/2022] [Revised: 03/06/2023] [Accepted: 06/07/2023] [Indexed: 08/13/2023]
Abstract
The LUX-ZEPLIN experiment is a dark matter detector centered on a dual-phase xenon time projection chamber operating at the Sanford Underground Research Facility in Lead, South Dakota, USA. This Letter reports results from LUX-ZEPLIN's first search for weakly interacting massive particles (WIMPs) with an exposure of 60 live days using a fiducial mass of 5.5 t. A profile-likelihood ratio analysis shows the data to be consistent with a background-only hypothesis, setting new limits on spin-independent WIMP-nucleon, spin-dependent WIMP-neutron, and spin-dependent WIMP-proton cross sections for WIMP masses above 9 GeV/c^{2}. The most stringent limit is set for spin-independent scattering at 36 GeV/c^{2}, rejecting cross sections above 9.2×10^{-48} cm at the 90% confidence level.
Collapse
Affiliation(s)
- J Aalbers
- SLAC National Accelerator Laboratory, Menlo Park, California 94025-7015, USA
- Kavli Institute for Particle Astrophysics and Cosmology, Stanford University, Stanford, California 94305-4085 USA
| | - D S Akerib
- SLAC National Accelerator Laboratory, Menlo Park, California 94025-7015, USA
- Kavli Institute for Particle Astrophysics and Cosmology, Stanford University, Stanford, California 94305-4085 USA
| | - C W Akerlof
- University of Michigan, Randall Laboratory of Physics, Ann Arbor, Michigan 48109-1040, USA
| | - A K Al Musalhi
- University of Oxford, Department of Physics, Oxford OX1 3RH, United Kingdom
| | - F Alder
- University College London (UCL), Department of Physics and Astronomy, London WC1E 6BT, United Kingdom
| | - A Alqahtani
- Brown University, Department of Physics, Providence, Rhode Island 02912-9037, USA
| | - S K Alsum
- University of Wisconsin-Madison, Department of Physics, Madison, Wisconsin 53706-1390, USA
| | - C S Amarasinghe
- University of Michigan, Randall Laboratory of Physics, Ann Arbor, Michigan 48109-1040, USA
| | - A Ames
- SLAC National Accelerator Laboratory, Menlo Park, California 94025-7015, USA
- Kavli Institute for Particle Astrophysics and Cosmology, Stanford University, Stanford, California 94305-4085 USA
| | - T J Anderson
- SLAC National Accelerator Laboratory, Menlo Park, California 94025-7015, USA
- Kavli Institute for Particle Astrophysics and Cosmology, Stanford University, Stanford, California 94305-4085 USA
| | - N Angelides
- University College London (UCL), Department of Physics and Astronomy, London WC1E 6BT, United Kingdom
- Imperial College London, Physics Department, Blackett Laboratory, London SW7 2AZ, United Kingdom
| | - H M Araújo
- Imperial College London, Physics Department, Blackett Laboratory, London SW7 2AZ, United Kingdom
| | - J E Armstrong
- University of Maryland, Department of Physics, College Park, Maryland 20742-4111, USA
| | - M Arthurs
- University of Michigan, Randall Laboratory of Physics, Ann Arbor, Michigan 48109-1040, USA
| | - S Azadi
- University of California, Santa Barbara, Department of Physics, Santa Barbara, California 93106-9530, USA
| | - A J Bailey
- Imperial College London, Physics Department, Blackett Laboratory, London SW7 2AZ, United Kingdom
| | - A Baker
- Imperial College London, Physics Department, Blackett Laboratory, London SW7 2AZ, United Kingdom
| | - J Balajthy
- University of California, Davis, Department of Physics, Davis, California 95616-5270, USA
| | - S Balashov
- STFC Rutherford Appleton Laboratory (RAL), Didcot, OX11 0QX, United Kingdom
| | - J Bang
- Brown University, Department of Physics, Providence, Rhode Island 02912-9037, USA
| | - J W Bargemann
- University of California, Santa Barbara, Department of Physics, Santa Barbara, California 93106-9530, USA
| | - M J Barry
- Lawrence Berkeley National Laboratory (LBNL), Berkeley, California 94720-8099, USA
| | - J Barthel
- South Dakota Science and Technology Authority (SDSTA), Sanford Underground Research Facility, Lead, South Dakota 57754-1700, USA
| | - D Bauer
- Imperial College London, Physics Department, Blackett Laboratory, London SW7 2AZ, United Kingdom
| | - A Baxter
- University of Liverpool, Department of Physics, Liverpool L69 7ZE, United Kingdom
| | - K Beattie
- Lawrence Berkeley National Laboratory (LBNL), Berkeley, California 94720-8099, USA
| | - J Belle
- Fermi National Accelerator Laboratory (FNAL), Batavia, Illinois 60510-5011, USA
| | - P Beltrame
- University College London (UCL), Department of Physics and Astronomy, London WC1E 6BT, United Kingdom
- University of Edinburgh, SUPA, School of Physics and Astronomy, Edinburgh EH9 3FD, United Kingdom
| | - J Bensinger
- Brandeis University, Department of Physics, Waltham, Massachusetts 02453, USA
| | - T Benson
- University of Wisconsin-Madison, Department of Physics, Madison, Wisconsin 53706-1390, USA
| | - E P Bernard
- Lawrence Berkeley National Laboratory (LBNL), Berkeley, California 94720-8099, USA
- University of California, Berkeley, Department of Physics, Berkeley, California 94720-7300, USA
| | - A Bhatti
- University of Maryland, Department of Physics, College Park, Maryland 20742-4111, USA
| | - A Biekert
- Lawrence Berkeley National Laboratory (LBNL), Berkeley, California 94720-8099, USA
- University of California, Berkeley, Department of Physics, Berkeley, California 94720-7300, USA
| | - T P Biesiadzinski
- SLAC National Accelerator Laboratory, Menlo Park, California 94025-7015, USA
- Kavli Institute for Particle Astrophysics and Cosmology, Stanford University, Stanford, California 94305-4085 USA
| | - H J Birch
- University of Michigan, Randall Laboratory of Physics, Ann Arbor, Michigan 48109-1040, USA
- University of Liverpool, Department of Physics, Liverpool L69 7ZE, United Kingdom
| | - B Birrittella
- University of Wisconsin-Madison, Department of Physics, Madison, Wisconsin 53706-1390, USA
| | - G M Blockinger
- University at Albany (SUNY), Department of Physics, Albany, New York 12222-0100, USA
| | - K E Boast
- University of Oxford, Department of Physics, Oxford OX1 3RH, United Kingdom
| | - B Boxer
- University of California, Davis, Department of Physics, Davis, California 95616-5270, USA
- University of Liverpool, Department of Physics, Liverpool L69 7ZE, United Kingdom
| | - R Bramante
- SLAC National Accelerator Laboratory, Menlo Park, California 94025-7015, USA
- Kavli Institute for Particle Astrophysics and Cosmology, Stanford University, Stanford, California 94305-4085 USA
| | - C A J Brew
- STFC Rutherford Appleton Laboratory (RAL), Didcot, OX11 0QX, United Kingdom
| | - P Brás
- Laboratório de Instrumentação e Física Experimental de Partículas (LIP), University of Coimbra, P-3004 516 Coimbra, Portugal
| | - J H Buckley
- Washington University in St. Louis, Department of Physics, St. Louis, Missouri 63130-4862, USA
| | - V V Bugaev
- Washington University in St. Louis, Department of Physics, St. Louis, Missouri 63130-4862, USA
| | - S Burdin
- University of Liverpool, Department of Physics, Liverpool L69 7ZE, United Kingdom
| | - J K Busenitz
- University of Alabama, Department of Physics and Astronomy, Tuscaloosa, Alabama 34587-0324, USA
| | - M Buuck
- SLAC National Accelerator Laboratory, Menlo Park, California 94025-7015, USA
- Kavli Institute for Particle Astrophysics and Cosmology, Stanford University, Stanford, California 94305-4085 USA
| | - R Cabrita
- Laboratório de Instrumentação e Física Experimental de Partículas (LIP), University of Coimbra, P-3004 516 Coimbra, Portugal
| | - C Carels
- University of Oxford, Department of Physics, Oxford OX1 3RH, United Kingdom
| | - D L Carlsmith
- University of Wisconsin-Madison, Department of Physics, Madison, Wisconsin 53706-1390, USA
| | - B Carlson
- South Dakota Science and Technology Authority (SDSTA), Sanford Underground Research Facility, Lead, South Dakota 57754-1700, USA
| | - M C Carmona-Benitez
- Pennsylvania State University, Department of Physics, University Park, Pennsylvania 16802-6300, USA
| | - M Cascella
- University College London (UCL), Department of Physics and Astronomy, London WC1E 6BT, United Kingdom
| | - C Chan
- Brown University, Department of Physics, Providence, Rhode Island 02912-9037, USA
| | - A Chawla
- Royal Holloway, University of London, Department of Physics, Egham, TW20 0EX, United Kingdom
| | - H Chen
- Lawrence Berkeley National Laboratory (LBNL), Berkeley, California 94720-8099, USA
| | - J J Cherwinka
- University of Wisconsin-Madison, Department of Physics, Madison, Wisconsin 53706-1390, USA
| | - N I Chott
- South Dakota School of Mines and Technology, Rapid City, South Dakota 57701-3901, USA
| | - A Cole
- Lawrence Berkeley National Laboratory (LBNL), Berkeley, California 94720-8099, USA
| | - J Coleman
- Lawrence Berkeley National Laboratory (LBNL), Berkeley, California 94720-8099, USA
| | - M V Converse
- University of Rochester, Department of Physics and Astronomy, Rochester, New York 14627-0171, USA
| | - A Cottle
- University of Oxford, Department of Physics, Oxford OX1 3RH, United Kingdom
- Fermi National Accelerator Laboratory (FNAL), Batavia, Illinois 60510-5011, USA
| | - G Cox
- South Dakota Science and Technology Authority (SDSTA), Sanford Underground Research Facility, Lead, South Dakota 57754-1700, USA
- Pennsylvania State University, Department of Physics, University Park, Pennsylvania 16802-6300, USA
| | - W W Craddock
- SLAC National Accelerator Laboratory, Menlo Park, California 94025-7015, USA
| | - O Creaner
- Lawrence Berkeley National Laboratory (LBNL), Berkeley, California 94720-8099, USA
| | - D Curran
- South Dakota Science and Technology Authority (SDSTA), Sanford Underground Research Facility, Lead, South Dakota 57754-1700, USA
| | - A Currie
- Imperial College London, Physics Department, Blackett Laboratory, London SW7 2AZ, United Kingdom
| | - J E Cutter
- University of California, Davis, Department of Physics, Davis, California 95616-5270, USA
| | - C E Dahl
- Fermi National Accelerator Laboratory (FNAL), Batavia, Illinois 60510-5011, USA
- Northwestern University, Department of Physics & Astronomy, Evanston, Illinois 60208-3112, USA
| | - A David
- University College London (UCL), Department of Physics and Astronomy, London WC1E 6BT, United Kingdom
| | - J Davis
- South Dakota Science and Technology Authority (SDSTA), Sanford Underground Research Facility, Lead, South Dakota 57754-1700, USA
| | - T J R Davison
- University of Edinburgh, SUPA, School of Physics and Astronomy, Edinburgh EH9 3FD, United Kingdom
| | - J Delgaudio
- South Dakota Science and Technology Authority (SDSTA), Sanford Underground Research Facility, Lead, South Dakota 57754-1700, USA
| | - S Dey
- University of Oxford, Department of Physics, Oxford OX1 3RH, United Kingdom
| | - L de Viveiros
- Pennsylvania State University, Department of Physics, University Park, Pennsylvania 16802-6300, USA
| | - A Dobi
- Lawrence Berkeley National Laboratory (LBNL), Berkeley, California 94720-8099, USA
| | - J E Y Dobson
- University College London (UCL), Department of Physics and Astronomy, London WC1E 6BT, United Kingdom
| | - E Druszkiewicz
- University of Rochester, Department of Physics and Astronomy, Rochester, New York 14627-0171, USA
| | - A Dushkin
- Brandeis University, Department of Physics, Waltham, Massachusetts 02453, USA
| | - T K Edberg
- University of Maryland, Department of Physics, College Park, Maryland 20742-4111, USA
| | - W R Edwards
- Lawrence Berkeley National Laboratory (LBNL), Berkeley, California 94720-8099, USA
| | - M M Elnimr
- University of Alabama, Department of Physics and Astronomy, Tuscaloosa, Alabama 34587-0324, USA
| | - W T Emmet
- Yale University, Department of Physics, New Haven, Connecticut 06511-8499, USA
| | - S R Eriksen
- University of Bristol, H.H. Wills Physics Laboratory, Bristol, BS8 1TL, United Kingdom
| | - C H Faham
- Lawrence Berkeley National Laboratory (LBNL), Berkeley, California 94720-8099, USA
| | - A Fan
- SLAC National Accelerator Laboratory, Menlo Park, California 94025-7015, USA
- Kavli Institute for Particle Astrophysics and Cosmology, Stanford University, Stanford, California 94305-4085 USA
| | - S Fayer
- Imperial College London, Physics Department, Blackett Laboratory, London SW7 2AZ, United Kingdom
| | - N M Fearon
- University of Oxford, Department of Physics, Oxford OX1 3RH, United Kingdom
| | - S Fiorucci
- Lawrence Berkeley National Laboratory (LBNL), Berkeley, California 94720-8099, USA
| | - H Flaecher
- University of Bristol, H.H. Wills Physics Laboratory, Bristol, BS8 1TL, United Kingdom
| | - P Ford
- STFC Rutherford Appleton Laboratory (RAL), Didcot, OX11 0QX, United Kingdom
| | - V B Francis
- STFC Rutherford Appleton Laboratory (RAL), Didcot, OX11 0QX, United Kingdom
| | - E D Fraser
- University of Liverpool, Department of Physics, Liverpool L69 7ZE, United Kingdom
| | - T Fruth
- University of Oxford, Department of Physics, Oxford OX1 3RH, United Kingdom
- University College London (UCL), Department of Physics and Astronomy, London WC1E 6BT, United Kingdom
| | - R J Gaitskell
- Brown University, Department of Physics, Providence, Rhode Island 02912-9037, USA
| | - N J Gantos
- Lawrence Berkeley National Laboratory (LBNL), Berkeley, California 94720-8099, USA
| | - D Garcia
- Brown University, Department of Physics, Providence, Rhode Island 02912-9037, USA
| | - A Geffre
- South Dakota Science and Technology Authority (SDSTA), Sanford Underground Research Facility, Lead, South Dakota 57754-1700, USA
| | - V M Gehman
- Lawrence Berkeley National Laboratory (LBNL), Berkeley, California 94720-8099, USA
| | - J Genovesi
- South Dakota School of Mines and Technology, Rapid City, South Dakota 57701-3901, USA
| | - C Ghag
- University College London (UCL), Department of Physics and Astronomy, London WC1E 6BT, United Kingdom
| | - R Gibbons
- Lawrence Berkeley National Laboratory (LBNL), Berkeley, California 94720-8099, USA
- University of California, Berkeley, Department of Physics, Berkeley, California 94720-7300, USA
| | - E Gibson
- University of Oxford, Department of Physics, Oxford OX1 3RH, United Kingdom
| | - M G D Gilchriese
- Lawrence Berkeley National Laboratory (LBNL), Berkeley, California 94720-8099, USA
| | - S Gokhale
- Brookhaven National Laboratory (BNL), Upton, New York 11973-5000, USA
| | - B Gomber
- University of Wisconsin-Madison, Department of Physics, Madison, Wisconsin 53706-1390, USA
| | - J Green
- University of Oxford, Department of Physics, Oxford OX1 3RH, United Kingdom
| | - A Greenall
- University of Liverpool, Department of Physics, Liverpool L69 7ZE, United Kingdom
| | - S Greenwood
- Imperial College London, Physics Department, Blackett Laboratory, London SW7 2AZ, United Kingdom
| | | | - C B Gwilliam
- University of Liverpool, Department of Physics, Liverpool L69 7ZE, United Kingdom
| | - C R Hall
- University of Maryland, Department of Physics, College Park, Maryland 20742-4111, USA
| | - S Hans
- Brookhaven National Laboratory (BNL), Upton, New York 11973-5000, USA
| | - K Hanzel
- Lawrence Berkeley National Laboratory (LBNL), Berkeley, California 94720-8099, USA
| | - A Harrison
- South Dakota School of Mines and Technology, Rapid City, South Dakota 57701-3901, USA
| | - E Hartigan-O'Connor
- Brown University, Department of Physics, Providence, Rhode Island 02912-9037, USA
| | - S J Haselschwardt
- Lawrence Berkeley National Laboratory (LBNL), Berkeley, California 94720-8099, USA
| | - M A Hernandez
- University of Michigan, Randall Laboratory of Physics, Ann Arbor, Michigan 48109-1040, USA
| | - S A Hertel
- University of Massachusetts, Department of Physics, Amherst, Massachusetts 01003-9337, USA
| | - G Heuermann
- University of Michigan, Randall Laboratory of Physics, Ann Arbor, Michigan 48109-1040, USA
| | - C Hjemfelt
- South Dakota School of Mines and Technology, Rapid City, South Dakota 57701-3901, USA
| | - M D Hoff
- Lawrence Berkeley National Laboratory (LBNL), Berkeley, California 94720-8099, USA
| | - E Holtom
- STFC Rutherford Appleton Laboratory (RAL), Didcot, OX11 0QX, United Kingdom
| | - J Y-K Hor
- University of Alabama, Department of Physics and Astronomy, Tuscaloosa, Alabama 34587-0324, USA
| | - M Horn
- South Dakota Science and Technology Authority (SDSTA), Sanford Underground Research Facility, Lead, South Dakota 57754-1700, USA
| | - D Q Huang
- University of Michigan, Randall Laboratory of Physics, Ann Arbor, Michigan 48109-1040, USA
- Brown University, Department of Physics, Providence, Rhode Island 02912-9037, USA
| | - D Hunt
- University of Oxford, Department of Physics, Oxford OX1 3RH, United Kingdom
| | - C M Ignarra
- SLAC National Accelerator Laboratory, Menlo Park, California 94025-7015, USA
- Kavli Institute for Particle Astrophysics and Cosmology, Stanford University, Stanford, California 94305-4085 USA
| | - R G Jacobsen
- Lawrence Berkeley National Laboratory (LBNL), Berkeley, California 94720-8099, USA
- University of California, Berkeley, Department of Physics, Berkeley, California 94720-7300, USA
| | - O Jahangir
- University College London (UCL), Department of Physics and Astronomy, London WC1E 6BT, United Kingdom
| | - R S James
- University College London (UCL), Department of Physics and Astronomy, London WC1E 6BT, United Kingdom
| | - S N Jeffery
- STFC Rutherford Appleton Laboratory (RAL), Didcot, OX11 0QX, United Kingdom
| | - W Ji
- SLAC National Accelerator Laboratory, Menlo Park, California 94025-7015, USA
- Kavli Institute for Particle Astrophysics and Cosmology, Stanford University, Stanford, California 94305-4085 USA
| | - J Johnson
- University of California, Davis, Department of Physics, Davis, California 95616-5270, USA
| | - A C Kaboth
- STFC Rutherford Appleton Laboratory (RAL), Didcot, OX11 0QX, United Kingdom
- Royal Holloway, University of London, Department of Physics, Egham, TW20 0EX, United Kingdom
| | - A C Kamaha
- University at Albany (SUNY), Department of Physics, Albany, New York 12222-0100, USA
- University of Califonia, Los Angeles, Department of Physics and Astronomy, Los Angeles, California 90095-1547
| | - K Kamdin
- Lawrence Berkeley National Laboratory (LBNL), Berkeley, California 94720-8099, USA
- University of California, Berkeley, Department of Physics, Berkeley, California 94720-7300, USA
| | - V Kasey
- Imperial College London, Physics Department, Blackett Laboratory, London SW7 2AZ, United Kingdom
| | - K Kazkaz
- Lawrence Livermore National Laboratory (LLNL), Livermore, California 94550-9698, USA
| | - J Keefner
- South Dakota Science and Technology Authority (SDSTA), Sanford Underground Research Facility, Lead, South Dakota 57754-1700, USA
| | - D Khaitan
- University of Rochester, Department of Physics and Astronomy, Rochester, New York 14627-0171, USA
| | - M Khaleeq
- Imperial College London, Physics Department, Blackett Laboratory, London SW7 2AZ, United Kingdom
| | - A Khazov
- STFC Rutherford Appleton Laboratory (RAL), Didcot, OX11 0QX, United Kingdom
| | - I Khurana
- University College London (UCL), Department of Physics and Astronomy, London WC1E 6BT, United Kingdom
| | - Y D Kim
- IBS Center for Underground Physics (CUP), Yuseong-gu, Daejeon, Korea
| | - C D Kocher
- Brown University, Department of Physics, Providence, Rhode Island 02912-9037, USA
| | - D Kodroff
- Pennsylvania State University, Department of Physics, University Park, Pennsylvania 16802-6300, USA
| | - L Korley
- University of Michigan, Randall Laboratory of Physics, Ann Arbor, Michigan 48109-1040, USA
- Brandeis University, Department of Physics, Waltham, Massachusetts 02453, USA
| | - E V Korolkova
- University of Sheffield, Department of Physics and Astronomy, Sheffield S3 7RH, United Kingdom
| | - J Kras
- University of Wisconsin-Madison, Department of Physics, Madison, Wisconsin 53706-1390, USA
| | - H Kraus
- University of Oxford, Department of Physics, Oxford OX1 3RH, United Kingdom
| | - S Kravitz
- Lawrence Berkeley National Laboratory (LBNL), Berkeley, California 94720-8099, USA
| | - H J Krebs
- SLAC National Accelerator Laboratory, Menlo Park, California 94025-7015, USA
| | - L Kreczko
- Brookhaven National Laboratory (BNL), Upton, New York 11973-5000, USA
| | - B Krikler
- Brookhaven National Laboratory (BNL), Upton, New York 11973-5000, USA
| | - V A Kudryavtsev
- University of Sheffield, Department of Physics and Astronomy, Sheffield S3 7RH, United Kingdom
| | - S Kyre
- University of California, Santa Barbara, Department of Physics, Santa Barbara, California 93106-9530, USA
| | - B Landerud
- University of Wisconsin-Madison, Department of Physics, Madison, Wisconsin 53706-1390, USA
| | - E A Leason
- University of Edinburgh, SUPA, School of Physics and Astronomy, Edinburgh EH9 3FD, United Kingdom
| | - C Lee
- SLAC National Accelerator Laboratory, Menlo Park, California 94025-7015, USA
- Kavli Institute for Particle Astrophysics and Cosmology, Stanford University, Stanford, California 94305-4085 USA
| | - J Lee
- IBS Center for Underground Physics (CUP), Yuseong-gu, Daejeon, Korea
| | - D S Leonard
- IBS Center for Underground Physics (CUP), Yuseong-gu, Daejeon, Korea
| | - R Leonard
- South Dakota School of Mines and Technology, Rapid City, South Dakota 57701-3901, USA
| | - K T Lesko
- Lawrence Berkeley National Laboratory (LBNL), Berkeley, California 94720-8099, USA
| | - C Levy
- University at Albany (SUNY), Department of Physics, Albany, New York 12222-0100, USA
| | - J Li
- IBS Center for Underground Physics (CUP), Yuseong-gu, Daejeon, Korea
| | - F-T Liao
- University of Oxford, Department of Physics, Oxford OX1 3RH, United Kingdom
| | - J Liao
- Brown University, Department of Physics, Providence, Rhode Island 02912-9037, USA
| | - J Lin
- University of Oxford, Department of Physics, Oxford OX1 3RH, United Kingdom
- Lawrence Berkeley National Laboratory (LBNL), Berkeley, California 94720-8099, USA
- University of California, Berkeley, Department of Physics, Berkeley, California 94720-7300, USA
| | - A Lindote
- Laboratório de Instrumentação e Física Experimental de Partículas (LIP), University of Coimbra, P-3004 516 Coimbra, Portugal
| | - R Linehan
- SLAC National Accelerator Laboratory, Menlo Park, California 94025-7015, USA
- Kavli Institute for Particle Astrophysics and Cosmology, Stanford University, Stanford, California 94305-4085 USA
| | - W H Lippincott
- University of California, Santa Barbara, Department of Physics, Santa Barbara, California 93106-9530, USA
- Fermi National Accelerator Laboratory (FNAL), Batavia, Illinois 60510-5011, USA
| | - R Liu
- Brown University, Department of Physics, Providence, Rhode Island 02912-9037, USA
| | - X Liu
- University of Edinburgh, SUPA, School of Physics and Astronomy, Edinburgh EH9 3FD, United Kingdom
| | - Y Liu
- University of Wisconsin-Madison, Department of Physics, Madison, Wisconsin 53706-1390, USA
| | - C Loniewski
- University of Rochester, Department of Physics and Astronomy, Rochester, New York 14627-0171, USA
| | - M I Lopes
- Laboratório de Instrumentação e Física Experimental de Partículas (LIP), University of Coimbra, P-3004 516 Coimbra, Portugal
| | - E Lopez Asamar
- Laboratório de Instrumentação e Física Experimental de Partículas (LIP), University of Coimbra, P-3004 516 Coimbra, Portugal
| | - B López Paredes
- Imperial College London, Physics Department, Blackett Laboratory, London SW7 2AZ, United Kingdom
| | - W Lorenzon
- University of Michigan, Randall Laboratory of Physics, Ann Arbor, Michigan 48109-1040, USA
| | - D Lucero
- South Dakota Science and Technology Authority (SDSTA), Sanford Underground Research Facility, Lead, South Dakota 57754-1700, USA
| | - S Luitz
- SLAC National Accelerator Laboratory, Menlo Park, California 94025-7015, USA
| | - J M Lyle
- Brown University, Department of Physics, Providence, Rhode Island 02912-9037, USA
| | - P A Majewski
- STFC Rutherford Appleton Laboratory (RAL), Didcot, OX11 0QX, United Kingdom
| | - J Makkinje
- Brown University, Department of Physics, Providence, Rhode Island 02912-9037, USA
| | - D C Malling
- Brown University, Department of Physics, Providence, Rhode Island 02912-9037, USA
| | - A Manalaysay
- University of California, Davis, Department of Physics, Davis, California 95616-5270, USA
- Lawrence Berkeley National Laboratory (LBNL), Berkeley, California 94720-8099, USA
| | - L Manenti
- University College London (UCL), Department of Physics and Astronomy, London WC1E 6BT, United Kingdom
| | - R L Mannino
- University of Wisconsin-Madison, Department of Physics, Madison, Wisconsin 53706-1390, USA
| | - N Marangou
- Imperial College London, Physics Department, Blackett Laboratory, London SW7 2AZ, United Kingdom
| | - M F Marzioni
- University of Edinburgh, SUPA, School of Physics and Astronomy, Edinburgh EH9 3FD, United Kingdom
| | - C Maupin
- South Dakota Science and Technology Authority (SDSTA), Sanford Underground Research Facility, Lead, South Dakota 57754-1700, USA
| | - M E McCarthy
- University of Rochester, Department of Physics and Astronomy, Rochester, New York 14627-0171, USA
| | - C T McConnell
- Lawrence Berkeley National Laboratory (LBNL), Berkeley, California 94720-8099, USA
| | - D N McKinsey
- Lawrence Berkeley National Laboratory (LBNL), Berkeley, California 94720-8099, USA
- University of California, Berkeley, Department of Physics, Berkeley, California 94720-7300, USA
| | - J McLaughlin
- Northwestern University, Department of Physics & Astronomy, Evanston, Illinois 60208-3112, USA
| | - Y Meng
- University of Alabama, Department of Physics and Astronomy, Tuscaloosa, Alabama 34587-0324, USA
| | - J Migneault
- Brown University, Department of Physics, Providence, Rhode Island 02912-9037, USA
| | - E H Miller
- SLAC National Accelerator Laboratory, Menlo Park, California 94025-7015, USA
- Kavli Institute for Particle Astrophysics and Cosmology, Stanford University, Stanford, California 94305-4085 USA
- South Dakota School of Mines and Technology, Rapid City, South Dakota 57701-3901, USA
| | - E Mizrachi
- University of Maryland, Department of Physics, College Park, Maryland 20742-4111, USA
- Lawrence Livermore National Laboratory (LLNL), Livermore, California 94550-9698, USA
| | - J A Mock
- Lawrence Berkeley National Laboratory (LBNL), Berkeley, California 94720-8099, USA
- University at Albany (SUNY), Department of Physics, Albany, New York 12222-0100, USA
| | - A Monte
- University of California, Santa Barbara, Department of Physics, Santa Barbara, California 93106-9530, USA
- Fermi National Accelerator Laboratory (FNAL), Batavia, Illinois 60510-5011, USA
| | - M E Monzani
- SLAC National Accelerator Laboratory, Menlo Park, California 94025-7015, USA
- Kavli Institute for Particle Astrophysics and Cosmology, Stanford University, Stanford, California 94305-4085 USA
- Vatican Observatory, Castel Gandolfo, V-00120, Vatican City State
| | - J A Morad
- University of California, Davis, Department of Physics, Davis, California 95616-5270, USA
| | - J D Morales Mendoza
- SLAC National Accelerator Laboratory, Menlo Park, California 94025-7015, USA
- Kavli Institute for Particle Astrophysics and Cosmology, Stanford University, Stanford, California 94305-4085 USA
| | - E Morrison
- South Dakota School of Mines and Technology, Rapid City, South Dakota 57701-3901, USA
| | - B J Mount
- Black Hills State University, School of Natural Sciences, Spearfish, South Dakota 57799-0002, USA
| | - M Murdy
- University of Massachusetts, Department of Physics, Amherst, Massachusetts 01003-9337, USA
| | - A St J Murphy
- University of Edinburgh, SUPA, School of Physics and Astronomy, Edinburgh EH9 3FD, United Kingdom
| | - D Naim
- University of California, Davis, Department of Physics, Davis, California 95616-5270, USA
| | - A Naylor
- University of Sheffield, Department of Physics and Astronomy, Sheffield S3 7RH, United Kingdom
| | - C Nedlik
- University of Massachusetts, Department of Physics, Amherst, Massachusetts 01003-9337, USA
| | - C Nehrkorn
- University of California, Santa Barbara, Department of Physics, Santa Barbara, California 93106-9530, USA
| | - F Neves
- Laboratório de Instrumentação e Física Experimental de Partículas (LIP), University of Coimbra, P-3004 516 Coimbra, Portugal
| | - A Nguyen
- University of Edinburgh, SUPA, School of Physics and Astronomy, Edinburgh EH9 3FD, United Kingdom
| | - J A Nikoleyczik
- University of Wisconsin-Madison, Department of Physics, Madison, Wisconsin 53706-1390, USA
| | - A Nilima
- University of Edinburgh, SUPA, School of Physics and Astronomy, Edinburgh EH9 3FD, United Kingdom
| | - J O'Dell
- STFC Rutherford Appleton Laboratory (RAL), Didcot, OX11 0QX, United Kingdom
| | - F G O'Neill
- SLAC National Accelerator Laboratory, Menlo Park, California 94025-7015, USA
| | - K O'Sullivan
- Lawrence Berkeley National Laboratory (LBNL), Berkeley, California 94720-8099, USA
- University of California, Berkeley, Department of Physics, Berkeley, California 94720-7300, USA
| | - I Olcina
- Lawrence Berkeley National Laboratory (LBNL), Berkeley, California 94720-8099, USA
- University of California, Berkeley, Department of Physics, Berkeley, California 94720-7300, USA
| | - M A Olevitch
- Washington University in St. Louis, Department of Physics, St. Louis, Missouri 63130-4862, USA
| | - K C Oliver-Mallory
- Imperial College London, Physics Department, Blackett Laboratory, London SW7 2AZ, United Kingdom
- Lawrence Berkeley National Laboratory (LBNL), Berkeley, California 94720-8099, USA
- University of California, Berkeley, Department of Physics, Berkeley, California 94720-7300, USA
| | - J Orpwood
- University of Sheffield, Department of Physics and Astronomy, Sheffield S3 7RH, United Kingdom
| | - D Pagenkopf
- University of California, Santa Barbara, Department of Physics, Santa Barbara, California 93106-9530, USA
| | - S Pal
- Laboratório de Instrumentação e Física Experimental de Partículas (LIP), University of Coimbra, P-3004 516 Coimbra, Portugal
| | - K J Palladino
- University of Oxford, Department of Physics, Oxford OX1 3RH, United Kingdom
- University of Wisconsin-Madison, Department of Physics, Madison, Wisconsin 53706-1390, USA
| | - J Palmer
- Royal Holloway, University of London, Department of Physics, Egham, TW20 0EX, United Kingdom
| | - M Pangilinan
- Brown University, Department of Physics, Providence, Rhode Island 02912-9037, USA
| | - N Parveen
- University at Albany (SUNY), Department of Physics, Albany, New York 12222-0100, USA
| | - S J Patton
- Lawrence Berkeley National Laboratory (LBNL), Berkeley, California 94720-8099, USA
| | - E K Pease
- Lawrence Berkeley National Laboratory (LBNL), Berkeley, California 94720-8099, USA
| | - B Penning
- University of Michigan, Randall Laboratory of Physics, Ann Arbor, Michigan 48109-1040, USA
- Brandeis University, Department of Physics, Waltham, Massachusetts 02453, USA
| | - C Pereira
- Laboratório de Instrumentação e Física Experimental de Partículas (LIP), University of Coimbra, P-3004 516 Coimbra, Portugal
| | - G Pereira
- Laboratório de Instrumentação e Física Experimental de Partículas (LIP), University of Coimbra, P-3004 516 Coimbra, Portugal
| | - E Perry
- University College London (UCL), Department of Physics and Astronomy, London WC1E 6BT, United Kingdom
| | - T Pershing
- Lawrence Livermore National Laboratory (LLNL), Livermore, California 94550-9698, USA
| | - I B Peterson
- Lawrence Berkeley National Laboratory (LBNL), Berkeley, California 94720-8099, USA
| | - A Piepke
- University of Alabama, Department of Physics and Astronomy, Tuscaloosa, Alabama 34587-0324, USA
| | - J Podczerwinski
- University of Wisconsin-Madison, Department of Physics, Madison, Wisconsin 53706-1390, USA
| | - D Porzio
- Laboratório de Instrumentação e Física Experimental de Partículas (LIP), University of Coimbra, P-3004 516 Coimbra, Portugal
| | - S Powell
- University of Liverpool, Department of Physics, Liverpool L69 7ZE, United Kingdom
| | - R M Preece
- STFC Rutherford Appleton Laboratory (RAL), Didcot, OX11 0QX, United Kingdom
| | - K Pushkin
- University of Michigan, Randall Laboratory of Physics, Ann Arbor, Michigan 48109-1040, USA
| | - Y Qie
- University of Rochester, Department of Physics and Astronomy, Rochester, New York 14627-0171, USA
| | - B N Ratcliff
- SLAC National Accelerator Laboratory, Menlo Park, California 94025-7015, USA
| | - J Reichenbacher
- South Dakota School of Mines and Technology, Rapid City, South Dakota 57701-3901, USA
| | - L Reichhart
- University College London (UCL), Department of Physics and Astronomy, London WC1E 6BT, United Kingdom
| | - C A Rhyne
- Brown University, Department of Physics, Providence, Rhode Island 02912-9037, USA
| | - A Richards
- Imperial College London, Physics Department, Blackett Laboratory, London SW7 2AZ, United Kingdom
| | - Q Riffard
- Lawrence Berkeley National Laboratory (LBNL), Berkeley, California 94720-8099, USA
- University of California, Berkeley, Department of Physics, Berkeley, California 94720-7300, USA
| | - G R C Rischbieter
- University at Albany (SUNY), Department of Physics, Albany, New York 12222-0100, USA
| | - J P Rodrigues
- Laboratório de Instrumentação e Física Experimental de Partículas (LIP), University of Coimbra, P-3004 516 Coimbra, Portugal
| | - A Rodriguez
- Black Hills State University, School of Natural Sciences, Spearfish, South Dakota 57799-0002, USA
| | - H J Rose
- University of Liverpool, Department of Physics, Liverpool L69 7ZE, United Kingdom
| | - R Rosero
- Brookhaven National Laboratory (BNL), Upton, New York 11973-5000, USA
| | - P Rossiter
- University of Sheffield, Department of Physics and Astronomy, Sheffield S3 7RH, United Kingdom
| | - T Rushton
- University of Sheffield, Department of Physics and Astronomy, Sheffield S3 7RH, United Kingdom
| | - G Rutherford
- Brown University, Department of Physics, Providence, Rhode Island 02912-9037, USA
| | - D Rynders
- South Dakota Science and Technology Authority (SDSTA), Sanford Underground Research Facility, Lead, South Dakota 57754-1700, USA
| | - J S Saba
- Lawrence Berkeley National Laboratory (LBNL), Berkeley, California 94720-8099, USA
| | - D Santone
- Royal Holloway, University of London, Department of Physics, Egham, TW20 0EX, United Kingdom
| | - A B M R Sazzad
- University of Alabama, Department of Physics and Astronomy, Tuscaloosa, Alabama 34587-0324, USA
| | - R W Schnee
- South Dakota School of Mines and Technology, Rapid City, South Dakota 57701-3901, USA
| | - P R Scovell
- University of Oxford, Department of Physics, Oxford OX1 3RH, United Kingdom
- STFC Rutherford Appleton Laboratory (RAL), Didcot, OX11 0QX, United Kingdom
| | - D Seymour
- Brown University, Department of Physics, Providence, Rhode Island 02912-9037, USA
| | - S Shaw
- University of California, Santa Barbara, Department of Physics, Santa Barbara, California 93106-9530, USA
| | - T Shutt
- SLAC National Accelerator Laboratory, Menlo Park, California 94025-7015, USA
- Kavli Institute for Particle Astrophysics and Cosmology, Stanford University, Stanford, California 94305-4085 USA
| | - J J Silk
- University of Maryland, Department of Physics, College Park, Maryland 20742-4111, USA
| | - C Silva
- Laboratório de Instrumentação e Física Experimental de Partículas (LIP), University of Coimbra, P-3004 516 Coimbra, Portugal
| | - G Sinev
- South Dakota School of Mines and Technology, Rapid City, South Dakota 57701-3901, USA
| | - K Skarpaas
- SLAC National Accelerator Laboratory, Menlo Park, California 94025-7015, USA
| | - W Skulski
- University of Rochester, Department of Physics and Astronomy, Rochester, New York 14627-0171, USA
| | - R Smith
- Lawrence Berkeley National Laboratory (LBNL), Berkeley, California 94720-8099, USA
- University of California, Berkeley, Department of Physics, Berkeley, California 94720-7300, USA
| | - M Solmaz
- University of California, Santa Barbara, Department of Physics, Santa Barbara, California 93106-9530, USA
| | - V N Solovov
- Laboratório de Instrumentação e Física Experimental de Partículas (LIP), University of Coimbra, P-3004 516 Coimbra, Portugal
| | - P Sorensen
- Lawrence Berkeley National Laboratory (LBNL), Berkeley, California 94720-8099, USA
| | - J Soria
- Lawrence Berkeley National Laboratory (LBNL), Berkeley, California 94720-8099, USA
- University of California, Berkeley, Department of Physics, Berkeley, California 94720-7300, USA
| | - I Stancu
- University of Alabama, Department of Physics and Astronomy, Tuscaloosa, Alabama 34587-0324, USA
| | - M R Stark
- South Dakota School of Mines and Technology, Rapid City, South Dakota 57701-3901, USA
| | - A Stevens
- University of Oxford, Department of Physics, Oxford OX1 3RH, United Kingdom
- University College London (UCL), Department of Physics and Astronomy, London WC1E 6BT, United Kingdom
- Imperial College London, Physics Department, Blackett Laboratory, London SW7 2AZ, United Kingdom
| | - T M Stiegler
- Texas A&M University, Department of Physics and Astronomy, College Station, Texas 77843-4242, USA
| | - K Stifter
- SLAC National Accelerator Laboratory, Menlo Park, California 94025-7015, USA
- Kavli Institute for Particle Astrophysics and Cosmology, Stanford University, Stanford, California 94305-4085 USA
- Fermi National Accelerator Laboratory (FNAL), Batavia, Illinois 60510-5011, USA
| | - R Studley
- Brandeis University, Department of Physics, Waltham, Massachusetts 02453, USA
| | - B Suerfu
- Lawrence Berkeley National Laboratory (LBNL), Berkeley, California 94720-8099, USA
- University of California, Berkeley, Department of Physics, Berkeley, California 94720-7300, USA
| | - T J Sumner
- Imperial College London, Physics Department, Blackett Laboratory, London SW7 2AZ, United Kingdom
| | - P Sutcliffe
- University of Liverpool, Department of Physics, Liverpool L69 7ZE, United Kingdom
| | - N Swanson
- Brown University, Department of Physics, Providence, Rhode Island 02912-9037, USA
| | - M Szydagis
- University at Albany (SUNY), Department of Physics, Albany, New York 12222-0100, USA
| | - M Tan
- University of Oxford, Department of Physics, Oxford OX1 3RH, United Kingdom
| | - D J Taylor
- South Dakota Science and Technology Authority (SDSTA), Sanford Underground Research Facility, Lead, South Dakota 57754-1700, USA
| | - R Taylor
- Imperial College London, Physics Department, Blackett Laboratory, London SW7 2AZ, United Kingdom
| | - W C Taylor
- Brown University, Department of Physics, Providence, Rhode Island 02912-9037, USA
| | - D J Temples
- Northwestern University, Department of Physics & Astronomy, Evanston, Illinois 60208-3112, USA
| | - B P Tennyson
- Yale University, Department of Physics, New Haven, Connecticut 06511-8499, USA
| | - P A Terman
- Texas A&M University, Department of Physics and Astronomy, College Station, Texas 77843-4242, USA
| | - K J Thomas
- Lawrence Berkeley National Laboratory (LBNL), Berkeley, California 94720-8099, USA
| | - D R Tiedt
- University of Maryland, Department of Physics, College Park, Maryland 20742-4111, USA
- South Dakota Science and Technology Authority (SDSTA), Sanford Underground Research Facility, Lead, South Dakota 57754-1700, USA
- South Dakota School of Mines and Technology, Rapid City, South Dakota 57701-3901, USA
| | - M Timalsina
- South Dakota School of Mines and Technology, Rapid City, South Dakota 57701-3901, USA
| | - W H To
- SLAC National Accelerator Laboratory, Menlo Park, California 94025-7015, USA
- Kavli Institute for Particle Astrophysics and Cosmology, Stanford University, Stanford, California 94305-4085 USA
| | - A Tomás
- Imperial College London, Physics Department, Blackett Laboratory, London SW7 2AZ, United Kingdom
| | - Z Tong
- Imperial College London, Physics Department, Blackett Laboratory, London SW7 2AZ, United Kingdom
| | - D R Tovey
- University of Sheffield, Department of Physics and Astronomy, Sheffield S3 7RH, United Kingdom
| | - J Tranter
- University of Sheffield, Department of Physics and Astronomy, Sheffield S3 7RH, United Kingdom
| | - M Trask
- University of California, Santa Barbara, Department of Physics, Santa Barbara, California 93106-9530, USA
| | - M Tripathi
- University of California, Davis, Department of Physics, Davis, California 95616-5270, USA
| | - D R Tronstad
- South Dakota School of Mines and Technology, Rapid City, South Dakota 57701-3901, USA
| | - C E Tull
- Lawrence Berkeley National Laboratory (LBNL), Berkeley, California 94720-8099, USA
| | - W Turner
- University of Liverpool, Department of Physics, Liverpool L69 7ZE, United Kingdom
| | - L Tvrznikova
- University of California, Berkeley, Department of Physics, Berkeley, California 94720-7300, USA
- Yale University, Department of Physics, New Haven, Connecticut 06511-8499, USA
- Lawrence Livermore National Laboratory (LLNL), Livermore, California 94550-9698, USA
| | - U Utku
- University College London (UCL), Department of Physics and Astronomy, London WC1E 6BT, United Kingdom
| | - J Va'vra
- SLAC National Accelerator Laboratory, Menlo Park, California 94025-7015, USA
| | - A Vacheret
- Imperial College London, Physics Department, Blackett Laboratory, London SW7 2AZ, United Kingdom
| | - A C Vaitkus
- Brown University, Department of Physics, Providence, Rhode Island 02912-9037, USA
| | - J R Verbus
- Brown University, Department of Physics, Providence, Rhode Island 02912-9037, USA
| | - E Voirin
- Fermi National Accelerator Laboratory (FNAL), Batavia, Illinois 60510-5011, USA
| | - W L Waldron
- Lawrence Berkeley National Laboratory (LBNL), Berkeley, California 94720-8099, USA
| | - A Wang
- SLAC National Accelerator Laboratory, Menlo Park, California 94025-7015, USA
- Kavli Institute for Particle Astrophysics and Cosmology, Stanford University, Stanford, California 94305-4085 USA
| | - B Wang
- University of Alabama, Department of Physics and Astronomy, Tuscaloosa, Alabama 34587-0324, USA
| | - J J Wang
- University of Alabama, Department of Physics and Astronomy, Tuscaloosa, Alabama 34587-0324, USA
| | - W Wang
- University of Wisconsin-Madison, Department of Physics, Madison, Wisconsin 53706-1390, USA
- University of Massachusetts, Department of Physics, Amherst, Massachusetts 01003-9337, USA
| | - Y Wang
- Lawrence Berkeley National Laboratory (LBNL), Berkeley, California 94720-8099, USA
- University of California, Berkeley, Department of Physics, Berkeley, California 94720-7300, USA
| | - J R Watson
- Lawrence Berkeley National Laboratory (LBNL), Berkeley, California 94720-8099, USA
- University of California, Berkeley, Department of Physics, Berkeley, California 94720-7300, USA
| | - R C Webb
- Texas A&M University, Department of Physics and Astronomy, College Station, Texas 77843-4242, USA
| | - A White
- Brown University, Department of Physics, Providence, Rhode Island 02912-9037, USA
| | - D T White
- University of California, Santa Barbara, Department of Physics, Santa Barbara, California 93106-9530, USA
| | - J T White
- Texas A&M University, Department of Physics and Astronomy, College Station, Texas 77843-4242, USA
| | - R G White
- SLAC National Accelerator Laboratory, Menlo Park, California 94025-7015, USA
- Kavli Institute for Particle Astrophysics and Cosmology, Stanford University, Stanford, California 94305-4085 USA
| | - T J Whitis
- SLAC National Accelerator Laboratory, Menlo Park, California 94025-7015, USA
- University of California, Santa Barbara, Department of Physics, Santa Barbara, California 93106-9530, USA
| | - M Williams
- University of Michigan, Randall Laboratory of Physics, Ann Arbor, Michigan 48109-1040, USA
- Brandeis University, Department of Physics, Waltham, Massachusetts 02453, USA
| | - W J Wisniewski
- SLAC National Accelerator Laboratory, Menlo Park, California 94025-7015, USA
| | - M S Witherell
- Lawrence Berkeley National Laboratory (LBNL), Berkeley, California 94720-8099, USA
- University of California, Berkeley, Department of Physics, Berkeley, California 94720-7300, USA
| | - F L H Wolfs
- University of Rochester, Department of Physics and Astronomy, Rochester, New York 14627-0171, USA
| | - J D Wolfs
- University of Rochester, Department of Physics and Astronomy, Rochester, New York 14627-0171, USA
| | - S Woodford
- University of Liverpool, Department of Physics, Liverpool L69 7ZE, United Kingdom
| | - D Woodward
- Pennsylvania State University, Department of Physics, University Park, Pennsylvania 16802-6300, USA
| | - S D Worm
- STFC Rutherford Appleton Laboratory (RAL), Didcot, OX11 0QX, United Kingdom
| | - C J Wright
- Brookhaven National Laboratory (BNL), Upton, New York 11973-5000, USA
| | - Q Xia
- Lawrence Berkeley National Laboratory (LBNL), Berkeley, California 94720-8099, USA
| | - X Xiang
- Brown University, Department of Physics, Providence, Rhode Island 02912-9037, USA
- Brookhaven National Laboratory (BNL), Upton, New York 11973-5000, USA
| | - Q Xiao
- University of Wisconsin-Madison, Department of Physics, Madison, Wisconsin 53706-1390, USA
| | - J Xu
- Lawrence Livermore National Laboratory (LLNL), Livermore, California 94550-9698, USA
| | - M Yeh
- Brookhaven National Laboratory (BNL), Upton, New York 11973-5000, USA
| | - J Yin
- University of Rochester, Department of Physics and Astronomy, Rochester, New York 14627-0171, USA
| | - I Young
- Fermi National Accelerator Laboratory (FNAL), Batavia, Illinois 60510-5011, USA
| | - P Zarzhitsky
- University of Alabama, Department of Physics and Astronomy, Tuscaloosa, Alabama 34587-0324, USA
| | - A Zuckerman
- Brown University, Department of Physics, Providence, Rhode Island 02912-9037, USA
| | - E A Zweig
- University of Califonia, Los Angeles, Department of Physics and Astronomy, Los Angeles, California 90095-1547
| |
Collapse
|
8
|
Sukhanov S, Higashi Y, Yoshida T, Danchuk S, Alfortish M, Goodchild T, Scarboroogh A, Sharp T, Schumacher J, Sindi F, Bowles D, Ivy J, Tharp D, Rozenbaum Z, Jenkins J, Garcia D, Lefer D, Kolls J, Delafontaine P. Insulin-like growth factor I reduces human-like coronary atherosclerosis. Am J Med Sci 2023. [DOI: 10.1016/s0002-9629(23)00012-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
|
9
|
Laccourreye O, Garcia D, Mudry A. Total laryngectomy for laryngeal cancer 150 years after its first description: A boon more than a calamity: A STROBE analysis. Eur Ann Otorhinolaryngol Head Neck Dis 2023; 140:25-29. [PMID: 36210325 DOI: 10.1016/j.anorl.2022.09.001] [Citation(s) in RCA: 10] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
OBJECTIVE To illustrate the boon rather than a calamity that total laryngectomy can be for a patient with laryngeal cancer in the 21st century. MATERIAL AND METHOD An observational retrospective analysis using the STROBE guideline compared two cohorts of patients with previously untreated cancer, managed by total laryngectomy: the first consisting of 123 patients collected by Morell Mackenzie during the fifteen years (1873-1887) following the initial description, and the second consisting of 53 patients consecutively treated in a French university otorhinolaryngology department during the fifteen years (2006-2020) preceding the 150th anniversary of the first performance. The main endpoint was the comparison of survival and locoregional control estimates (Kaplan-Meier life table method). Secondary endpoints comprised mortality estimates and causes, adjuvant treatments, and phonation modalities. RESULTS The 26.2%, 13.1%, and 13.1% 1-, 3-, and 5-year actuarial survival estimates in the Makenzie cohort increased to 88.6%, 68.4%, and 60.9% in the recent French cohort (P<0.0001). The 50.1%, 40.4%, and 34.7% 1-, 3-, and 5-year actuarial locoregional control estimates in the Mackenzie cohort increased to 83.7% (P<0.0001). The 77.7% overall mortality in the Mackenzie cohort decreased to 37.7% (P<.0001). In the Mackenzie cohort, 97.8% of deaths were related to postoperative complications and locoregional recurrence, compared to 50% in the recent French cohort. Distant metastasis, metachronous second primary tumor and intercurrent diseases, not mentioned in the Mackenzie cohort, generated 45% of deaths in the French cohort. Adjunctive treatment was not used in the Mackenzie cohort, whereas neck dissection and postoperative radiation therapy were associated in respectively 98.1% and 69.8% of cases in the French cohort. Phonation was not documented in the Mackenzie cohort; 50% of survivors in the French cohort used a phonatory implant. CONCLUSIONS The 20th century witnessed an incredible turn-around. Total laryngectomy, with limited indications, has transformed the etiology of deaths and no longer leaves patients "in a state of abject misery" as Morell Mackenzie put it in 1888.
Collapse
Affiliation(s)
- O Laccourreye
- Service d'otorhinolaryngologie et de chirurgie cervico-faciale HEGP, université Paris Cité, AP-HP, 20-40, rue Leblanc, 75015 Paris, France.
| | - D Garcia
- Hôpital Français, Sô1 Phuong Mai, Dong Da District, Hanoi, Vietnam
| | - A Mudry
- Department of Otolaryngology, Head & Neck Surgery, Stanford University School of Medicine, 801 Welch Road, Stanford, CA, 94305-5739, USA
| |
Collapse
|
10
|
Swarthout JM, Chan EMG, Garcia D, Nadimpalli ML, Pickering AJ. Human Colonization with Antibiotic-Resistant Bacteria from Nonoccupational Exposure to Domesticated Animals in Low- and Middle-Income Countries: A Critical Review. Environ Sci Technol 2022; 56:14875-14890. [PMID: 35947446 DOI: 10.1021/acs.est.2c01494] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/15/2023]
Abstract
Data on community-acquired antibiotic-resistant bacterial infections are particularly sparse in low- and middle-income countries (LMICs). Limited surveillance and oversight of antibiotic use in food-producing animals, inadequate access to safe drinking water, and insufficient sanitation and hygiene infrastructure in LMICs could exacerbate the risk of zoonotic antibiotic resistance transmission. This critical review compiles evidence of zoonotic exchange of antibiotic-resistant bacteria (ARB) or antibiotic resistance genes (ARGs) within households and backyard farms in LMICs, as well as assesses transmission mechanisms, risk factors, and environmental transmission pathways. Overall, substantial evidence exists for exchange of antibiotic resistance between domesticated animals and in-contact humans. Whole bacteria transmission and horizontal gene transfer between humans and animals were demonstrated within and between households and backyard farms. Further, we identified water, soil, and animal food products as environmental transmission pathways for exchange of ARB and ARGs between animals and humans, although directionality of transmission is poorly understood. Herein we propose study designs, methods, and topical considerations for priority incorporation into future One Health research to inform effective interventions and policies to disrupt zoonotic antibiotic resistance exchange in low-income communities.
Collapse
Affiliation(s)
- Jenna M Swarthout
- Department of Civil and Environmental Engineering, Tufts University, Medford, Massachusetts 02155, United States
| | - Elana M G Chan
- Department of Civil and Environmental Engineering, Tufts University, Medford, Massachusetts 02155, United States
| | - Denise Garcia
- Department of Civil and Environmental Engineering, University of California, Berkeley, Berkeley, California 94720, United States
| | - Maya L Nadimpalli
- Department of Civil and Environmental Engineering, Tufts University, Medford, Massachusetts 02155, United States
- Stuart B. Levy Center for Integrated Management of Antimicrobial Resistance, Tufts University, Boston, Massachusetts 02111, United States
| | - Amy J Pickering
- Department of Civil and Environmental Engineering, Tufts University, Medford, Massachusetts 02155, United States
- Department of Civil and Environmental Engineering, University of California, Berkeley, Berkeley, California 94720, United States
- Stuart B. Levy Center for Integrated Management of Antimicrobial Resistance, Tufts University, Boston, Massachusetts 02111, United States
| |
Collapse
|
11
|
Garcia-Zamora S, Pulido L, Antoniolli M, Garcia D, Perez G, Priotti M, Zaidel E, Lopez-Santi R, Vazquez G, Chango-Azanza DX, Nunez-Mendez R, Cabral LT, Sosa-Liprandi A, Miranda-Arboleda AF, Baranchuk A. Aggression, mini-aggression, and abuse against health care workers during the COVID-19 pandemic. Eur Heart J 2022. [DOI: 10.1093/eurheartj/ehac544.2826] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Introduction
COVID-19 pandemic brought multiple negative consequences that go beyond the direct damage caused by the disease and that affect health systems as well. Complaints of attacks against health care workers became frequent and concerning. The objective of this survey was to characterize the frequency and type of violent behavior against front-line professionals in Latin America.
Material and methods
A cross-sectional electronic survey was carried out between January 11th to February 28th, 2022. Different health care workers from Latin America who have been delivering care at least from March 2020, regardless of whether they assist or not patients with COVID-19 were included. A non-probabilistic snowball sampling was performed, and the survey was
Results
The survey was responded by 3,544 participants from 19 countries (Figure 1); 58.5% were women, and the mean age was 41.9±11 years. The 70.8% were doctors, 16% nurses, 3.4% physiotherapists, and the remaining 9.8% had other functions within the health team. About 85.1% of physicians were specialists: 33.9% were cardiologists, 14.4% were intensivists or emergency physicians, 10.9% had some surgical specialty, 7.7% were pediatricians or related subspecialties, and the remaining 33.1% had other specialties. The 36.3% and 28.8% worked in public and private practice respectively, the remaining worked in both. Direct and regular care to COVID-19 patients was provided by 74.7% of all contestants.
Among the participants, 54.8% reported acts of violence: 95.6% suffered verbal violence, 11.1% physical violence, and 19.9% other types. 39.5% of respondents experienced it at least once a week. The acts of violence involved patients' relatives (32%), or patients together with their relatives (35.1%). The victims rated the stress level of these events with an average of 8.2±1.8 points (scale from 1 to 10). Approximately half of the health personnel who suffered an assault experienced psychosomatic symptoms after the traumatic event (Figure 2). Among the victims of violence, 56.2% considered changing their care tasks, and 33.6% abandoning their profession. However, only 23% of the health personnel attacked stated that they had made some type of legal action regarding these acts.
In a logistic regression model, doctors (OR 1.95, p<0.01), nurses (OR 1.77, p=0.001), and administrative staff (OR 3.20, p<0.01) suffered more violence than other health workers. Women more frequently suffered violence (OR 1.56, p<0.01), as well as those who worked with patients with COVID-19 (OR 3.59, p<0.01). Conversely, a lower probability of violence was observed at older ages (OR 0.96, p<0.01).
Conclusion
We detected a high prevalence of violence against health personnel in Latin America during the current pandemic. Those caring for COVID-19 patients, younger staff, and women were found to be more vulnerable. It is imperative to develop strategies to mitigate these acts and their repercussions on the health team.
Funding Acknowledgement
Type of funding sources: None.
Collapse
Affiliation(s)
- S Garcia-Zamora
- Interamerican Society of Cardiology (SIAC) , Rosario , Argentina
| | - L Pulido
- Interamerican Society of Cardiology (SIAC) , Rosario , Argentina
| | - M Antoniolli
- Interamerican Society of Cardiology (SIAC) , Buenos Aires , Argentina
| | - D Garcia
- Interamerican Society of Cardiology (SIAC) , Buenos Aires , Argentina
| | - G Perez
- Interamerican Society of Cardiology (SIAC) , Buenos Aires , Argentina
| | - M Priotti
- Interamerican Society of Cardiology (SIAC) , Rosario , Argentina
| | - E Zaidel
- Interamerican Society of Cardiology (SIAC) , Buenos Aires , Argentina
| | - R Lopez-Santi
- Interamerican Society of Cardiology (SIAC) , La Plata , Argentina
| | - G Vazquez
- Interamerican Society of Cardiology (SIAC) , Kingston , Canada
| | | | - R Nunez-Mendez
- Interamerican Society of Cardiology (SIAC) , Mexico City , Mexico
| | - L T Cabral
- Interamerican Society of Cardiology (SIAC) , Asuncion , Paraguay
| | - A Sosa-Liprandi
- Interamerican Society of Cardiology (SIAC) , Buenos Aires , Argentina
| | | | - A Baranchuk
- Interamerican Society of Cardiology (SIAC) , Kingston , Canada
| |
Collapse
|
12
|
Baldin M, Garcia D, Zanton GI, Hao F, Patterson AD, Harvatine KJ. Effect of 2-hydroxy-4-(methylthio)butanoate (HMTBa) on milk fat, rumen environment and biohydrogenation, and rumen protozoa in lactating cows fed diets with increased risk for milk fat depression. J Dairy Sci 2022; 105:7446-7461. [PMID: 35931483 DOI: 10.3168/jds.2022-21910] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2022] [Accepted: 05/06/2022] [Indexed: 11/19/2022]
Abstract
Biohydrogenation-induced milk fat depression (MFD) is a reduction in milk fat synthesis caused by bioactive fatty acids (FA) produced during altered ruminal microbial metabolism of unsaturated FA. The methionine analog 2-hydroxy-4-(methylthio)butanoate (HMTBa) has been shown to reduce the shift to the alternate biohydrogenation pathway and maintain higher milk fat yield in high-producing cows fed diets lower in fiber and higher in unsaturated FA. The objective of this experiment was to verify the effect of HMTBa on biohydrogenation-induced MFD and investigate associated changes in rumen environment and fermentation. Twenty-two rumen cannulated high-producing Holstein cows [168 ± 66 d in milk; 42 ± 7 kg of milk/d (mean ± standard deviation)] were used in a randomized design performed in 2 blocks (1 = 14 cows, 2 = 8 cows). Treatments were control (corn carrier) and HMTBa (0.1% of diet dry matter). The experiment included a 7-d covariate period followed by 3 phases that fed diets with increasing risk of MFD. The diet during the covariate and low-risk phase (7 d) was 32% neutral detergent fiber with no additional oil. The diet during the moderate-risk phase (17 d) was 29% neutral detergent fiber with 0.75% soybean oil. Soybean oil was increased to 1.5% for the last 4 d. The statistical model included the random effect of block and time course data were analyzed with repeated measures including the random effect of cow and tested the interaction of treatment and time. There was no effect of block or interaction of block and treatment or time. There was no overall effect of treatment or treatment by time interaction for dry matter intake, milk yield, and milk protein concentration and yield. Overall, HMTBa increased milk fat percent (3.2 vs. 3.6%) and yield (1,342 vs. 1,543 g/d) and there was no interaction of treatment and dietary phase. Additionally, HMTBa decreased the concentration of trans-10 18:1 in milk fat and rumen digesta. Average total ruminal concentration of volatile FA across the day and total-tract dry matter and fiber digestibility were not affected by HMTBa, but HMTBa increased average rumen butyrate and decreased propionate concentration and increased total protozoa abundance. Additionally, HMTBa increased the fractional rate of α-linoleic acid clearance from the rumen following a bolus predominantly driven by a difference in the first 30 min. Plasma insulin was decreased by HMTBa. In conclusion, HMTBa prevented the increase in trans FA in milk fat associated with MFD through a mechanism that is independent of total volatile FA concentration, but involves modification of rumen biohydrogenation. Decreased propionate and increased butyrate and ruminal protozoa may also have functional roles in the mechanism.
Collapse
Affiliation(s)
- M Baldin
- Department of Animal Science, Penn State University, University Park 16802
| | - D Garcia
- Department of Animal Science, Penn State University, University Park 16802
| | - G I Zanton
- Novus International Inc., St. Charles, MO 63304
| | - F Hao
- Center for Molecular Toxicology and Carcinogenesis, Department of Veterinary and Biomedical Sciences, The Pennsylvania State University, University Park 16802
| | - A D Patterson
- Center for Molecular Toxicology and Carcinogenesis, Department of Veterinary and Biomedical Sciences, The Pennsylvania State University, University Park 16802
| | - K J Harvatine
- Department of Animal Science, Penn State University, University Park 16802.
| |
Collapse
|
13
|
Garcia D. Letter to the Editor re "Short-term hearing outcome of malleus removal for surgery: An observational cohort study". Eur Ann Otorhinolaryngol Head Neck Dis 2022; 139:244. [PMID: 35718705 DOI: 10.1016/j.anorl.2022.06.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- D Garcia
- Oto-Rhino-Laryngologie et Chirurgie Cervico-Faciale, hôpital Français d'Hanoï, SO 1 Phuong Mai, Dong Da, Hanoi 100000, Vietnam.
| |
Collapse
|
14
|
Santana Peralta J, Cornelio A, Garcia D, Alvarez Santana RA, Polanco Mora T, Concepción Sanchez L, Paulino I, Mercedes I, Rodriguez Bautista E, Valdez Lorie T, Feriz A, Muñoz Louis R. AB0684 Fatigue Assessment in Systemic Sclerosis, Santo Domingo, Dominican Republic. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.2880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
BackgroundSystemic sclerosis (SSc) is a systemic autoimmune disease.1 Fatigue has been reported in 75% of SSc patients, and is the most problematic symptom due to impact on quality of life. Despite its high prevalence, origin is unknown.2 Some studies associate it with the degree of disease activity and decreased quality of life. Fatigue is defined as a feeling of exhaustion, also as a reduction in physical and mental capacity,3 scales such as FACIT-F (Functional Assessment of Chronic Illness Therapy-Fatigue) are used, which evaluates the last 7 days, with a score of 0-52. For the severity analysis, 4 grades are used: no or mild fatigue (40-52), moderate (27-39), severe (14-26) and extreme (0-13).4,5ObjectivesTo evaluate the frequency and degree of fatigue in systemic sclerosis.MethodsProspective, longitudinal, observational study of the cohort of patients of the Rheumatology service of the Hospital Docente Padre Billini. Patients were interviewed in November 2021. Inclusion criteria: ≥18 years, diagnosis of SSc according ACR/EULAR 2013 classification criteria. Exclusion criteria: previous diagnosis of fibromyalgia, depression or anxiety, treatment with antidepressants, antihistamines, beta-blockers. Measurement of FACIT-F, HAQ-DI, mRSS scales. Statistical analysis was performed with the Pearson correlation (rp) with p=>0.05. The data was analyzed by SPSS V23.Results54 met inclusion criteria. 100% female, mean age 53.3±15.1 years, mean disease duration 11.3 years, SScd 75.9% (41), SScl 24.1% (13), interstitial pneumonia 33.3% (18), gastrointestinal reflux disease 27.8% (15), HAP 20.37% (11). Frequency of fatigue 100% (54): moderate FACIT-F: 29.6% (16), severe FACIT-F 38.8% (21), extreme 31.5% (17). Correlation FACIT-F with mRSS and HAQ-DI: Moderate FACIT-F: mRSS mild 43.8% (7), moderate 12.5% (2), severe 18.8% (3), terminal 25% (4), HAQ-DI mild 25% (4), moderate 37.5% (6), severe 18.8% (3). Severe FACIT-F: mRSS normal 4.8% (1), mild 19% (4), moderate 91% (4), severe 33.3 % (7), terminal 23.8% (5), HAQ-DI mild 4.8% (1), moderate 19% (4), severe 47.6% (10). FACIT-F extreme: mRSS mild 7.61% (3), moderate 29.4% (5), severe 35.3% (6), terminal 17.6% (3), HAQ-DI moderate 11.8% (2), severe 52.9% (9). rp=. 246 p>0.05ConclusionThe study demonstrated a high frequency of fatigue. The most frequent degree was severe. A statistically significant linear association was observed between skin involvement and the degree of functional limitation.References[1]Basta F, Afeltra A, Margiotta DPE. Fatigue in systemic sclerosis: a systematic review. Clin Exp Rheumatol. 2018.[2]Chernis, J., Buni, M., Kazzaz, S., Ying, J., Lyons, M., Assassi, S. and Mayes, M., 2021. Predictors of Perceived Functional Status in Early Systemic Sclerosis: A Prospective Longitudinal Study of the GENISOS Cohort. Arthritis Care & Research.[3]Stamm, T., Mosor, E., Omara, M., Ritschl, V., & Murphy, S. L. (2020). How can fatigue be addressed in individuals with systemic sclerosis? The Lancet Rheumatology, 2(3), e128-e129.[4]Nakayama, A., Tunnicliffe, D., Thakkar, V., Singh-Grewal, D., O’Neill, S., Craig, J. and Tong, A., 2016. Patients’ Perspectives and Experiences Living with Systemic Sclerosis: A Systematic Review and Thematic Synthesis of Qualitative Studies. The Journal of Rheumatology, 43(7), pp.1363-1375.[5]Acaster, S., Dickerhoof, R., DeBusk, K., Bernard, K., Strauss, W. and Allen, L., 2015. Qualitative and quantitative validation of the FACIT-fatigue scale in iron deficiency anemia. Health and Quality of Life Outcomes, 13(1).Disclosure of InterestsNone declared
Collapse
|
15
|
Alvarez Santana RA, Garcia D, Santana Peralta J, Cornelio A, Polanco Mora T, Concepción Sanchez L, Paulino I, Mercedes I, Rodriguez Bautista E, Valdez T, Feriz A, Muñoz Louis R. AB0217 FREQUENCY OF SEXUAL DYSFUNCTION IN RHEUMATOID ARTHRITIS, SANTO DOMINGO, DOMINICAN REPUBLIC. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.4202] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
BackgroundRheumatoid arthritis (RA) is an inflammatory, autoimmune systemic disease that affects the synovial membrane of small joints.1 Kamissoko et al found the frequency of sexual dysfunction in RA to be 69.2%.2 Pain is considered to have a fundamental role associated with the decrease in the frequency of sexual intercourse.3 The CSFQ-14 (Changes in Sexual Functioning Questionnaire), evaluates the changes in sexual functioning due to a disease and/or treatment in 5 domains with a score range of 14-70; cut-off point indicating sexual dysfunction <41 men and <47 women.4ObjectivesTo evaluate the frequency and degree of sexual dysfunction in patients with rheumatoid arthritis.MethodsProspective, observational, cross-sectional study of a cohort of patients of the Rheumatology Service at Hospital Docente Padre Billini. Patients were interviewed in July 2021. Inclusion criteria: > 18 years, diagnosis of RA according to the ACR/EULAR 2010 classification criteria, at least 1 sexual intercourse. Exclusion criteria: previous diagnosis of another autoimmune disease, depression, diabetes, treatment with antidepressants, antiepileptics, narcotics. Scales measured: CSFQ-14, DAS28. Statistical analysis was performed with the Pearson correlation (rp) with p>0.05. Data were analyzed in IBM-SPSS v23.ResultsOf the RA cohort, 483 met inclusion criteria. 93.4% (451) female, mean age 58±12.6 years, mean duration of diagnosis 8 years, married 53.8% (260), single 27.7% (134), widowed 16.6% (80), hypertension 73.9% (357), dyslipidemia 21.5% (104), obesity 18.0% (87), smoking 9.9% (48). Frequency of sexual dysfunction 61.3% (296). Sexual dysfunction in women 93.9% (278) and men 6.1% (18). Global domains: desire/interest 55.7% (165), desire/frequency 56.4% (167), pleasure 58.1% (172), arousal/excitement 67.2% (199), orgasm/completion 50.0% (148). Female: desire/interest 94.5% (156), desire/frequency 93.4% (156), pleasure 93.6% (161), arousal/excitement 93.0% (185), orgasm/completion 93.9% (139). Male: desire/interest 5.5% (9), desire/frequency 11.6% (11), pleasure 6.4% (11), arousal/excitement 7.0% (14), orgasm/completion 6.1% (9). Desire/interest dysfunction: DAS28 remission or low activity 28.5% (47), moderate 53.3% (88), high activity 4.8% (8). Desire/frequency: DAS28 remission or low activity 35.3% (59), moderate 47.3% (79), high activity 3.6% (6). Pleasure: DAS28 remission or low activity 30.2% (52), moderate 50.0% (86), high activity 2.9% (5). Arousal/excitement: DAS28 remission or low activity 25.1% (50), moderate 55.8% (111), high activity 6.0% (12). Orgasm/completion: DAS28 remission or low activity 43.2% (64), moderate 38.5% (57), high activity 6.1% (9).ConclusionThe study showed a high frequency of sexual dysfunction, observing greater dysfunction in females. In the population, the most affected global domain was arousal/excitement, and it was the most frequent in female and male.References[1]Gomero García, D., 2018. Artritis reumatoide, epidemiología, fisiopatología, criterios diagnósticos y tratamiento. Revista de Medicina e Investigación Universidad Autónoma del Estado de México, 6(2).[2]Kamissoko, A.B., Edikou, T.N.R., Barry, A., Sanda, M., Fofana, K., Irie, L.N.E., Diallo, M.L. and Oniankitan, O. (2021) Sexuality of Women with Rheumatoid Arthritis in a West African Hospital. Open Journal of Rheumatology and Autoimmune Diseases, 11, 152-159[3]Bay, L. et al. Sexual Health and Dysfunction in Patients With Rheumatoid Arthritis: A Cross-sectional Single-Center Study. Sexual Medicine, 8(4), pp.615-630.[4]Clayton AH, McGarvey EL, Clavet GJ. The Changes in Sexual Functioning Questionnaire (CSFQ): development, reliability, and validity. Psychopharmacol Bull. 1997;33(4):731-45. PMID: 9493486.Disclosure of InterestsNone declared
Collapse
|
16
|
Cornelio A, Polanco Mora T, Santana Peralta J, Alvarez Santana RA, Garcia D, Rodriguez Bautista E, Paulino I, Concepción Sanchez L, Mercedes I, Valdez T, Feriz A, Muñoz Louis R. AB0827 Frequency of sexual dysfunction axial spondyloarthritis, Santo Domingo, Dominican Republic. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.3262] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
BackgroundAxial spondyloarthritis (SpAa) is a chronic inflammatory disease of unknown etiology that affects the axial skeleton, affecting peripheral joints, entheses and extra-articular structures, with a prevalence of 0.5-1% associated with HLA-B27+.1 The impact of Chronic disease is often multifactorial that affects physical, hormonal and psychological alterations, leading to problems of sexuality.2 The CSFQ-14 (Changes in Sexual Functioning Questionnaire), evaluates changes in sexual functioning due to disease and/or or treatment in 5 domains with a score range of 14-70; cut-off point indicating sexual dysfunction <41 men and <47 women.3,4ObjectivesTo evaluate the frequency and degree of sexual dysfunction in patients with axial spondyloarthritis.MethodsProspective, observational, cross-sectional study. of the SpAa cohort of the Hospital Docente Padre Billini rheumatology service Patients were interviewed in July 2021. Inclusion criteria: > 18 years, diagnosis of SpAa according to the ASAS 2009 classification criteria, at least 1 sexual. Exclusion criteria: previous diagnosis of another autoimmune disease, depression, diabetes mellitus (DM), treatment with antidepressants, antiepileptics, narcotics. Measurement of: CSFQ-14, BASDAI. Statistical analysis was performed with the Pearson correlation (rP) with p>0.05. The data was analyzed by SPSS V23.ResultsOf the SpAa cohort, 87 met the inclusion criteria. Male 67.8% (59), female 32.2% (28), mean age 45.7±8 years, mean diagnosis 7, married 67.8%(59), single 24.1%(21), widowed 8%(7), HLA-B27 + 51.1 %, hypertension 8% (7), diabetes 6.8% (6), dyslipidemia 10.3%(9), smokers 4.5%(4), 100% (87) bDMARD´s, 13.6% (12) combined with csDMARD´s, Frequency of sexual dysfunction 24.1%(21). Sexual dysfunction in women 6.9% (6) and men 17.2% (15) by CSFQ-14. Global domains: Desire/Interest 2.3% (2), Desire/Frequency 2.3% (2), Pleasure 5.7% (5), Arousal 2.3% (2), Orgasm/Completion 2.3% (2). Female: Desire/interest 6.8% (4), desire/Frequency 3.4% (2), pleasure 8.5% (5). Male: Desire/interest 3.4% (2), desire/Frequency 3.4% (2), pleasure 8.5% (5), arousal 6.8% (4), orgasm/completion 3.4% (2). Correlation CSFQ-14 domains with BASDAI: rp =. -0.088 p>0.05: Desire/interest dysfunction: inactive BASDAI 71.4% (15). Desire/frequency: inactive BASDAI 90.5% (20). Pleasure: inactive BASDAI 23.8% (5), active 23.8% (5). Excitation: inactive BASDAI 14.3% (3). Orgasm/completion> inactive BASDAI 90.5% (20)ConclusionThe study showed a low frequency of sexual dysfunction, being more frequent in males. The greatest dysfunction was found in the pleasure domain in both sexes. A statistically significant inverse linear association was found between sexual dysfunction and disease activity.References[1]Gunaydin, R., Karatepe, AG, Cesmeli, N. & Kaya, T. Fatiga en pacientes con espondilitis anquilosante: relaciones con variables específicas de la enfermedad, depresión y trastornos del sueño. Reumatología clínica 28, 1045-1051 (2009).[2]Helland, Y. et al. Enfermedades reumáticas y sexualidad: impacto de la enfermedad y estrategias de autocuidado. Arthritis Care Res. (Hoboken)63, 743–750 (2011).[3]Badley EM (2008) Enhancing the conceptual clarity of the activity and participation components of the International Classification of Functioning, Disability and Health. Soc Sci Med 66: 2335–2345[4]Clayton AH, McGarvey EL, Clavet GJ. The Changes in Sexual Functioning Questionnaire (CSFQ): development, reliability, and validity. Psychopharmacol Bull. 1997;33(4):731-45. PMID: 9493486.Disclosure of InterestsNone declared
Collapse
|
17
|
Alvarez Santana RA, Garcia D, Santana Peralta J, Cornelio A, Concepción Sanchez L, Polanco Mora T, Paulino I, Mercedes I, Rodriguez Bautista E, Valdez T, Feriz A, Muñoz Louis R. AB0216 FATIGUE ASSESSMENT IN RHEUMATOID ARTHRITIS, SANTO DOMINGO, DOMINICAN REPUBLIC. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.4193] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
BackgroundRheumatoid arthritis (RA) is an inflammatory, systemic autoimmune disease affecting the synovial membrane of small joints.1 Wagan A. et al demonstrated that the frequency of fatigue in rheumatoid arthritis is 62%,2 Hammam et al described a higher rate of fatigue associated with higher disease activity. Fatigue is as a feeling of exhaustion, also as a reduction in physical and mental capacity,3,4 it can be measured with the scale FACIT-F (Functional Assessment of Chronic Illness Therapy-Fatigue), which evaluates the last 7 days, with a score of 0-52. For the severity analysis, 4 grades are used: no or mild fatigue (40-52), moderate (27-39), severe (14-26) and extreme fatigue (0-13).2,5ObjectivesTo evaluate the frequency and degree of fatigue in rheumatoid arthritis.MethodsProspective, observational, cross-sectional study of a cohort of patients of the Rheumatology Service of the Hospital Docente Padre Billini. Patients were interviewed in July 2021. Inclusion criteria: ≥ 18 years, diagnosis of RA according to the ACR/EULAR 2010 classification criteria. Exclusion criteria: previous diagnosis of fibromyalgia, depression or anxiety, treatment with antidepressants, antihistamines, beta-blockers. Scales measured: FACIT-F, DAS28, CDAI, and HAQ-DI. Statistical analysis was performed with the Pearson correlation (rp). Data were analyzed in IBM-SPSS v23.Results597 patients met inclusion criteria. 93% female, mean age 58.5±12.4 years, mean disease duration 7.5 years. HT 73.9% (441), DM 14.2% (85), dyslipidemia 21.3% (127), obesity 17.9% (107), smoking 9.9% (59), high ESR 60.0% (358), high CRP 49.7% (297), scDMARD8 2.7% (494), bDMARDS 36.8% (218), tsDMARDS 18.1 (108). Frequency of fatigue 19.9% (119): moderate 12.9% (77), severe 7.0% (42). Correlation of FACIT-F with DAS28, CDAI and HAQ-DI: No fatigue FACIT-F 80.1% (478): DAS28 remission or low activity 84.9% (406), CDAI remission or low activity 93.5% (447), moderate 4.0% (19), high activity 2.5% (12), HAQ-DI mild 75.9% (363), moderate 16.5% (79), severe 7.5% (36). Moderate FACIT-F 12.9% (77): DAS28 remission or low activity 19.5% (15), moderate 80.5% (62), CDAI moderate 48.1% (37), high activity 51.9% (40), HAQ-DI mild 24.7% (19), moderate 63.6% (49), severe 11.7% (9). Severe FACIT-F 7.0% (42): DAS28 remission or low activity 4.8% (2), high activity 95.2% (40), CDAI low activity or remission 35.7% (15), high activity 64.3% (27), HAQ-DI mild 7.1% (3), moderate 23.8% (10), severe 69.0% (29). Correlation between FACIT-F/DAS28 (rp= .673, p< .001) and FACIT-F/CDAI (rp= .701, p < .001) were strong.ConclusionThe study showed a low frequency of fatigue; the degree of fatigue most found was moderate. The group of patients with fatigue had a statistically significant linear association with disease activity and degree of functional limitation. There were no patients with extreme fatigue.References[1]Gomero García, D., 2018. Rheumatoid arthritis, epidemiology, pathophysiology, diagnostic criteria and treatment. Journal of Medicine and Research Universidad Autónoma del Estado de México, 6(2).[2]Wagan AA, Raheem A, Bhatti A, Zafar T. Fatigue assessment by FACIT-F scale in Pakistani cohort with Rheumatoid Arthritis (FAF-RA) study. Pak J Med Sci. 2021;37(4).[3]Hammam N, Gamal RM, Rashed AM, Elfetoh NA, Mosad E, Khedr EM. Fatigue in Rheumatoid Arthritis Patients: Association With Sleep Quality, Mood Status, and Disease Activity. Rheumatol Clin (Engl Ed). 2020 Sep-Oct;16(5 Pt 1):339-344.[4]James K, Al-Ali S, Tarn J, Cockell SJ, Gillespie CS, Hindmarsh V, et al. (2015) A Transcriptional Signature of Fatigue Derived from Patients with Primary Sjögren’s Syndrome. PLoS ONE.[5]Cella D. The Functional Assessment of Cancer Therapy-Anemia (FACT-An) Scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol. 1997 Jul;34(3 Suppl 2):13-9.Disclosure of InterestsNone declared
Collapse
|
18
|
Santana Peralta J, Cornelio A, Garcia D, Alvarez Santana RA, Polanco Mora T, Concepción Sanchez L, Paulino I, Mercedes I, Rodriguez Bautista E, Valdez Lorie T, Feriz A, Muñoz Louis R. AB0963 Frequency of sexual dysfunction in psoriatic arthritis, Santo Domingo, Dominican Republic. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.5114] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
BackgroundPsoriatic arthritis (PsA) is an inflammatory joint disease that cause structural damage, disability, and an impairment of quality of life.1Sexual function is a neglected area of quality of life in patients with PsA, with a high prevalence of dissatisfaction.2 It has been described that there is no relationship between the activity of the disease and the degree of joint dysfunction.3 In 1 out of 5 patients consider that the disease negatively impacts their sexuality.4 CSFQ-14 (Changes in Sexual Functioning Questionnaire), evaluates changes in sexual functioning due to an illness or treatment in 5 domains with a score range 14-70; cut-off point indicating sexual dysfunction -41 men and -47 women.5ObjectivesTo evaluate the frequency and degree of sexual dysfunction in patients with psoriatic arthritis.MethodsProspective, observational, cross-sectional study. The patients of the outpatient clinic of the rheumatology service of the Padre Billini teaching hospital were interviewed during November 2021. Inclusion criteria: ≥18 years, PsA diagnosis according to CASPAR classification criteria 2006. Exclusion criteria: diagnosis of another autoimmune disease, depression, treatment with antidepressants. We analyzed the data in SPSS23 and used the Pearson correlation coefficient with a statistical significance p=<0.05 (rp) to relate the data.Results58 met inclusion criteria. 63.8% (37) female, male 36.2% (21), mean age 54.8 + 11.75 y, mean diagnosis 7.9 y, married 55.2% (32), unmarried 39.7% (23), widowed 5.2% (3). Frequency of sexual dysfunction 39.7% (23), CSFQ-14 indicative of dysfunction in women 35.1% (23), men 47.6% (10). Female Domains: Pleasure dysfunction 35.1% (13), desire/interest 32.4% (12), desire/frequency 32.4% (12), arousal 24.3% (9), orgasm/completion 43.2% (16). Male Domains: Pleasure dysfunction 38.1% (8), desire/interest 47.6% (10), desire/frequency 33.3% (7), arousal 23.8% (5), orgasm/completion 42.9% (9). Correlation CSFQ-14/DAPSA28 domains: Pleasure dysfunction: DAPSA remission 19.2% (5), low 32.1% (9), moderate 50% (2). Desire/interest: DAPSA remission 34.6% (9), low 32.1% (9), moderate 100% (4). Desire/frequency: DAPSA remission 30.8% (8), low 37.5% (10), moderate 25% (1). Excitation: DAPSA remission 30.8% (8), low 17.9% (5), moderate 25% (1). Orgasm/completion: DAPSA remission 50% (13), low 37.5% (10), moderate 50% (2). rp=. 042 p<0.05.ConclusionThe study showed a modest frequency of global sexual dysfunction. In men it was superior. The orgasm/completion domain proved to be the most dysfunctional in both sexes. A statistically significant linear association of sexual dysfunction and disease activity was evident.References[1]Reygaerts T. Effect of Biologics on Fatigue in Psoriatic Arthritis: A Systematic Literature Review with Metaanalysis, Joint Bone Spine (2018).[2]Esteve E et al. Preliminary development of a questionnaire assessing the impact of psoriasis and psoriatic arthritis on patient’s perception of sexuality. Medicine (Baltimore). 2018[3]Aguiar R, Ambrósio C. Sexuality in spondyloarthritis-the impact of the disease. Acta Reumatol Port. 2014 Apr-Jun;39(2):152-7. PMID: 25254264.[4]G Haugeberg, (2020): Perceived influence of health status on sexual activity in patients with psoriatic arthritis, Scandinavian Journal of Rheumatology.[5]Clayton AH, McGarvey EL. The Changes in Sexual Functioning Questionnaire (CSFQ): development, reliability, and validity. Psychopharmacol Bull. 1997;33(4):731-45.Disclosure of InterestsNone declared
Collapse
|
19
|
Santana Peralta J, Cornelio A, Garcia D, Alvarez Santana RA, Polanco Mora T, Concepción Sanchez L, Paulino I, Mercedes I, Rodriguez Bautista E, Valdez Lorie T, Feriz A, Muñoz Louis R. AB0682 Frequency of sexual dysfunction in systemic sclerosis, Santo Domingo, Dominican Republic. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.2862] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
BackgroundSystemic sclerosis (SSc) is a systemic autoimmune disease.1 Sexual function has been associated with a high prevalence of dissatisfaction.2,3,4 Various factors have been implicated as causes of impaired sexual function.5 CSFQ-14 (Changes in Sexual Functioning Questionnaire) assesses changes in sexual functioning due to disease and/or treatment in 5 domains with a score range of 14-70; cut-off point indicating sexual dysfunction < 41 men and < 47 women.6ObjectivesTo evaluate the frequency and degree of sexual dysfunction in patients with systemic sclerosis.MethodsProspective, observational, cross-sectional study of the cohort of the Rheumatology service at Hospital Docente Padre Billini. Patients were interviewed in November 2021. Inclusion criteria: > 18 years, diagnosis of SSc by ACR/EULAR 2013 classification criteria, at least 1 sexual relationship. Exclusion criteria: previous diagnosis of another autoimmune disease, depression, diabetes, treatment with antidepressants, antiepileptics, narcotics. Measurement of CSFQ-14, mRSS. Statistical analysis was performed with the Pearson correlation (rp) with p=>0.05. The data was analyzed by SPSS V23.ResultsOf 63 patients, 54 met the inclusion criteria. 100% female, mean age 53 + 15.07 years, mean duration 11.3 years, lSSc 24.1% (13), dSSc 75.9% (41), single 50% (27), married 44.4% (24), widowed 5.6% (3). Frequency of sexual dysfunction 81.5% (44). Domains: pleasure 79.6% (43), desire/interest 37% (20), frequency desire 81.5% (44), arousal 46.3% (25), orgasm/completion 75.9% (41). Correlation CSFQ-14 with mRSS: Pleasure dysfunction: normal mRSS 2.3% (1), mild 23.3% (10), moderate 20.9% (9), severe 32.6% (14), terminal 20.9% (9). Desire/interest dysfunction: mild mRSS 35% (7), moderate 20% (4), severe 35% (7), terminal 10% (2). Frequency desire dysfunction: normal mRSS 2.3% (1), mild 25% (11), moderate 15.7% (12), severe 36.4% (16), terminal 20.5% (9). Arousal dysfunction: normal mRSS 4% (1), mild 16% (4), moderate 16% (4), severe 36% (9), terminal 28% (7). Orgasm/completion dysfunction: normal mRSS 2.4% (1), mild 22% (9), moderate 22% (9), severe 26.8% (11), terminal 26.8% (11). rp=. 065 p> 0.05.ConclusionThe study demonstrated a high frequency of sexual dysfunction in most of the population studied. The desire/frequency dysfunction domain turned out to be the one with the highest presentation, followed by the orgasm/completion domain. A statistically significant linear association between sexual dysfunction and cutaneous activity of the disease was evidenced.References[1]Basta F, Afeltra A, Margiotta DPE. Fatigue in systemic sclerosis: a systematic review. Clin Exp Rheumatol. 2018[2]Heřmánková, B., 2019. Sexual Dysfunction in Patients with Systemic Sclerosis. New Insights into Systemic Sclerosis[3]Gao, R., Qing, P., Sun, X., Zeng, X., Hu, X., Zhang, S., Yang, Y. and Qin, L., 2021. Prevalence of Sexual Dysfunction in People With Systemic Sclerosis and the Associated Risk Factors: A Systematic Review. Sexual Medicine, 9(4), p.100392.[4]Frikha, F., Masmoudi, J., Saidi, N. and Bahloul, Z., 2014. Sexual dysfunction in married women with systemic sclerosis. Pan African Medical Journal, 17.[5]Levis B, Burri A, Hudson M, Baron M, Thombs BD, et al. (2012) Sexual Activity and Impairment in Women with Systemic Sclerosis Compared to Women from a General Population Sample. PLoS ONE 7(12): e52129.[6]Clayton AH, McGarvey EL, Clavet GJ. The Changes in Sexual Functioning Questionnaire (CSFQ): development, reliability, and validity. Psychopharmacol Bull. 1997;33(4):731-45.Disclosure of InterestsNone declared
Collapse
|
20
|
Jothidasan A, Husain M, Garcia D, Berman M, Currie I, Stock U. Direct Lung Procurement with Ongoing Abdominal Normothermic Regional Perfusion. J Heart Lung Transplant 2022. [DOI: 10.1016/j.healun.2022.01.1503] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
21
|
Husain M, Jothidasan A, Zeschky C, Garcia D, Smail H, Padukone A, Ahmed H, Khoshbin E, Stock U. Direct Procurement of Thoracic Organs Along with Abdominal Normothermic Regional Perfusion in Donation After Circulatory Death. J Heart Lung Transplant 2022. [DOI: 10.1016/j.healun.2022.01.1476] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022] Open
|
22
|
Mladenov N, Parsons D, Kinoshita AM, Pinongcos F, Mueller M, Garcia D, Lipson DA, Grijalva LM, Zink TA. Groundwater-surface water interactions and flux of organic matter and nutrients in an urban, Mediterranean stream. Sci Total Environ 2022; 811:152379. [PMID: 34914998 DOI: 10.1016/j.scitotenv.2021.152379] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/28/2021] [Revised: 11/23/2021] [Accepted: 12/09/2021] [Indexed: 06/14/2023]
Abstract
The chemical quality of dissolved organic matter (DOM) and the speciation of nitrogen exported from urban catchments is of great importance to biogeochemical cycling in riverine and coastal receiving waters. Many urban streams in Mediterranean climates have a flashy hydrologic regime, which would suggest a rapid pulsing and shunting of solutes downstream. However, the role of these systems both as passive pipes for solute transport or as reactors for DOM and nutrient transformation is still an open question for urban, Mediterranean streams. To address this question, we evaluated changes in concentrations of inorganic and organic solutes and DOM optical properties in Alvarado Creek, a perennially-flowing, urban, first-order tributary of the San Diego River in San Diego, CA, USA, during dry weather (baseflow) conditions and during four storm events in 2016-2018. Chloride and sulfate concentrations corroborate the supposed saline groundwater supply that maintains perennial flow and brackish nature in this urban stream. During dry weather, high proportions of protein-like fluorescent component (AC4) and downstream decreases in total dissolved nitrogen (TDN) and nitrate imply in-stream processing (nitrification and denitrification). By contrast, storm hysteresis curves indicate that the supply of DOM and TDN was not exhausted over the duration of a storm event, whereas nitrate was eventually depleted, presumably because nitrification could not keep up with the export of nitrate from source areas. Rapid decreases in chloride during the storm hydrograph coincided with a shift in specific ultraviolet absorbance (SUVA) and fluorescence index (FI) to more terrestrially-derived and aromatic carbon sources, most likely from interflow of stormwater through vadose zone soils. On an annual basis, the export of microbially-derived DOM during dry weather was higher than the export of terrestrially-derived DOM during storm events; both represent important carbon inputs to coastal waters.
Collapse
Affiliation(s)
- Natalie Mladenov
- Department of Civil, Construction, and Environmental Engineering, San Diego State University, United States of America.
| | - Daniel Parsons
- Department of Civil, Construction, and Environmental Engineering, San Diego State University, United States of America
| | - Alicia M Kinoshita
- Department of Civil, Construction, and Environmental Engineering, San Diego State University, United States of America
| | - Federick Pinongcos
- Department of Civil, Construction, and Environmental Engineering, San Diego State University, United States of America
| | - Margot Mueller
- Department of Civil, Construction, and Environmental Engineering, San Diego State University, United States of America
| | - Denise Garcia
- Department of Civil, Construction, and Environmental Engineering, San Diego State University, United States of America
| | - David A Lipson
- Department of Biology, San Diego State University, United States of America
| | - Lorelay Mendoza Grijalva
- Department of Civil, Construction, and Environmental Engineering, San Diego State University, United States of America
| | - Thomas A Zink
- Soil Ecology and Restoration Group, San Diego State University Research Foundation, United States of America
| |
Collapse
|
23
|
Brown H, Chen R, Cooks R, Garcia D, Chaichana K, Quinones-Hinojosa A, Jentoft M, Middlebrooks E. Intraoperative Assessment of IDH Mutation Status and Tumor Invasioni in Glioma. Am J Clin Pathol 2021. [DOI: 10.1093/ajcp/aqab191.302] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Introduction/Objective
Maximizing surgical resection in gliomas, while avoiding compromising non-infiltrated tissue, is associated with survival benefit. Current methodologies are suboptimal in providing rapid, intraoperative molecular characterization of tissue. We address this unmet need by using desorption electrospray ionization mass spectrometry (DESI-MS) for the intraoperative molecular assessment of gliomas.
Methods/Case Report
This prospective study uses intraoperative DESI-MS analysis of fresh tissue to evaluate IDH mutations via 2-hydroxyglutarate intensity and TCP via measurement of N-acetylaspartic acid (NAA) intensity and characteristic lipid profiles in less than three minutes. Blinded review of the tissue smears by a neuropathologist is used to validate IDH mutation status and TCP estimates.
Results (if a Case Study enter NA)
Presently, 529 biopsies from 85 enrolled patients have been collected and analyzed at two institutions. TCP assessment based on NAA intensity in 203 biopsies at the first institution yielded sensitivity, specificity, and accuracy values of 91, 76, and 83%, whereas TCP estimates via characteristic lipid profiles yielded 76, 85, and 81%, respectively. Assessment of IDH mutation status of 71 core biopsies yielded sensitivity, specificity, and accuracy values of 89, 100, and 94%. Ongoing validation of the methodology is being performed at a second institution, where we have collected 282 biopsies from 36 patients. IDH mutation assessment of the first 15 patients indicate 100% sensitivity, specificity, and accuracy.
Conclusion
This study represents the first and largest study using DESI-MS for the intraoperative evaluation of IDH status and TCP measurement in gliomas. Prospectively, we propose to modify our DESI-MS system to allow estimation of IDH mutation status and TCP in surgical cavities without the need for a biopsy by placing a surgical material along the margin and transferring material from the blot to a microscope slide prior to DESI-MS analysis. We envision molecular analysis by DESI-MS as a complementary technique to histopathology capable of providing additional clinical information in near real-time.
Collapse
Affiliation(s)
- H Brown
- Chemistry, Purdue University, West Lafayette, Indiana, UNITED STATES
| | - R Chen
- Chemistry, Purdue University, West Lafayette, Indiana, UNITED STATES
| | - R Cooks
- Chemistry, Purdue University, West Lafayette, Indiana, UNITED STATES
| | - D Garcia
- Neurosurgery, Mayo Clinic, Jacksonville, Florida, UNITED STATES
| | - K Chaichana
- Neurosurgery, Mayo Clinic, Jacksonville, Florida, UNITED STATES
| | | | - M Jentoft
- Laboratory Medicine and Pathology, Mayo Clinic, Jacksonville, Florida, UNITED STATES
| | - E Middlebrooks
- Radiology, Mayo Clinic, Jacksonville, Florida, UNITED STATES
| |
Collapse
|
24
|
Head WT, Garcia D, Mukherjee R, Kahn S, Lesher A. Virtual Visits for Outpatient Burn Care during the COVID-19 Pandemic. J Burn Care Res 2021; 43:300-305. [PMID: 34687201 DOI: 10.1093/jbcr/irab202] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
Abstract
Burn-injured patients must frequently travel long distances to regional burn centers, creating a burden on families and impairing clinical outcomes. Recent federal policies in response to the coronavirus pandemic have relaxed major barriers to conducting synchronous videoconference visits in the home. However, the efficacy and benefits of virtual visits relative to in-person visits remained unclear for burn patients. Accordingly, a clinical quality assurance database maintained during the coronavirus pandemic (3/3/2020 to 9/8/2020) for virtual and/or in-person visits at a comprehensive adult and pediatric burn center was queried for demographics, burn severity, visit quality, and distance data. A total of 143 patients were included in this study with 317 total outpatient encounters (61 virtual and 256 in-person). The savings associated with the average virtual visit were 130 ± 125 miles (mean ± standard deviation), 164 ± 134 travel minutes, &104 ± 99 driving costs, and &81 ± 66 foregone wage earnings. Virtual visit technical issues were experienced by 23% of patients and were significantly lower in pediatric (5%) than in adult patients (44%; p=0.006). This study is the first to assess the efficacy of synchronous videoconference visits in the home setting for outpatient burn care. The findings demonstrate major financial and temporal benefits for burn patients and their families. Technical issues remain an important barrier, particularly for the adult population. A clear understanding of these and other barriers may inform future studies as healthcare systems and payors move toward improving access to burn care through remote healthcare delivery services.
Collapse
Affiliation(s)
- William T Head
- College of Medicine, Medical University of South Carolina, Charleston, SC
| | - Denise Garcia
- Department of Surgery, Medical University of South Carolina, Charleston, SC
| | - Rupak Mukherjee
- Department of Surgery, Medical University of South Carolina, Charleston, SC
| | - Steven Kahn
- Department of Surgery, Medical University of South Carolina, Charleston, SC
| | - Aaron Lesher
- Department of Surgery, Medical University of South Carolina, Charleston, SC
| |
Collapse
|
25
|
Fernandez G, Brogger M, Garcia S, Ochoa J, De La Higuera L, Fernandez X, Garcia D, Lamounier A, Valverde M, Cardenas Reyes I, Ortiz M, Monserrat L, McKenna W. Molecular characterization of a cohort of individuals referred to genetic testing with suspected CPVT. Eur Heart J 2021. [DOI: 10.1093/eurheartj/ehab724.0633] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Catecholaminergic polymorphic ventricular tachycardia (CPVT) is one of the most lethal inherited arrhythmogenic diseases and it mainly affects the young, in the absence of structural heart disease. This condition is difficult to diagnose and the first expression of disease can be an arrhythmic death. In the last years, genetic testing has become a useful tool in the challenging task of CPVT diagnosis.
The diagnostic yield of the genetic study is highly variable and dependent on the phenotypic characteristics of the individuals evaluated.
Purpose
This study aimed to address the clinical characteristics and genetic testing (GT) results in a cohort of individuals referred to genetic analysis with a non-definitive diagnosis of CPVT, in a real world-setting.
Methods
This is a retrospective cohort study of patients referred for GT with clinical suspicion of CPVT, but who did not strictly meet the diagnostic criteria for this disease (according to current guidelines). NGS genotyping was performed with a library of 251 genes. NGS-based genomic testing was performed with classification of identified variants according to American College of Medical Genetics and Genomics guidelines.
Results
One hundred and sixteen unrelated patients with available clinical information (patients' characteristics are summarized in TABLE1) were included in the analysis. Mean age at GT was 36 y/o (±19), 47% were women and 18% had a familial history of sudden cardiac death.
The first clinical manifestation was: exercise or stress induced syncope in 36%, exercise induced ventricular tachycardia in 30% and sudden cardiac arrest in 15.5% (78% during emotional or physical stress - 89% aborted sudden death). Mean age at sudden death was 20 y/o (±14).
GT was positive in 49.1% (n=57), negative in 37.9% (n=44) and inconclusive in 12.9% (n=15). We had identified pathogenic/likely pathogenic variants in CPVT-related genes in 40% of the referred patients: RYR2 (70.2%-n: 40), KCNJ2 (8.8%-n: 5), CASQ2 in homozygous/compound heterozygous carriers (3.5%-n: 2). In the RYR2 gene we detected 36 different genetic variants (13 were novel) in 40 different individuals. In addition, relevant variants were also identified in other genes associated with channelopathies (SCN5A, 3.5%, n: 2 and KCNQ1, 1.7%, n: 1) and in genes associated with structural heart disease: desmosomal genes (6.8%-DSP n: 1 and PKP2 n: 3) and sarcomeric genes (5.1%- MYBPC3 and MYH7) (figure 1A-B).
Conclusions
In our cohort of patients with non-definitive diagnosis of CPVT, the diagnostic yield of genetic testing was almost 50%. GT allowed confirmation of the suspicion of CPVT in 40% of the patients and, in addition, we were able to detect relevant genetic variants in other genes not associated with CPVT in 10% (differential diagnosis). The use of wide genetic panels would be useful in this context.
Funding Acknowledgement
Type of funding sources: None. Suspected CPVT. Genetic Testing.
Collapse
Affiliation(s)
| | | | | | - J.P Ochoa
- University Hospital Puerta de Hierro Majadahonda, Cardiology, Madrid, Spain
| | | | | | | | | | | | | | - M Ortiz
- Health in Code, A Coruna, Spain
| | | | | |
Collapse
|
26
|
Mignini Renzini M, Dal Canto M, Guglielmo MC, Garcia D, De Ponti E, La Marca A, Vassena R, Buratini J. Sperm donation: an alternative to improve post-ICSI live birth rates in advanced maternal age patients. Hum Reprod 2021; 36:2148-2156. [PMID: 34143887 DOI: 10.1093/humrep/deab148] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/22/2021] [Revised: 04/25/2021] [Indexed: 01/26/2023] Open
Abstract
STUDY QUESTION Can sperm donation increase live birth rates following ICSI in advanced maternal age (AMA) patients? SUMMARY ANSWER Sperm donation increases the live birth rate in AMA ICSI cycles. WHAT IS KNOWN ALREADY In ICSI practice, sperm donation has been predominantly applied to overcome male infertility. The involvement of paternal age and lower sperm quality in the severe reduction in fertility observed in AMA patients remains to be clarified. STUDY DESIGN, SIZE, DURATION Retrospective multicenter cohort study including data generated between 2015 and 2019 from 755 ICSI cycles achieving a fresh embryo transfer, of which 337 were first homologous cycles (normozoospermic partner sperm and homologous oocytes) and 418 were first sperm donation cycles (donor sperm and homologous oocytes). The association of sperm origin (partner vs donor) with live birth was assessed by multivariate analysis in non-AMA (<37 years, n = 278) and AMA (≥37 years, n = 477) patients, separately, including in the model all variables previously found to be associated with live birth in a univariate analysis (number of MII oocytes recovered, number of embryos transferred, and maternal age). ICSI outcomes were compared between sperm donation and homologous cycles in overall, non-AMA and AMA patients. PARTICIPANTS/MATERIALS, SETTING, METHODS The study was conducted in three fertility clinics and included 755 Caucasian patients aged 24-42 years undergoing their first homologous or sperm donation ICSI cycle achieving a fresh embryo transfer. MAIN RESULTS AND THE ROLE OF CHANCE The multivariate analysis revealed that sperm donation was positively associated with the likelihood of a live birth independently of all other variables tested in AMA (P = 0.02), but not in non-AMA patients. Live birth, delivery, and miscarriage rates differed substantially between sperm donation and homologous AMA cycles; live birth and delivery rates were 70-75% higher (25.4% vs 14.5% and 22.5% vs 13.5%, respectively; P < 0.01), while miscarriage occurrence was less than half (18.0% vs 39.5%; P < 0.01) in sperm donation compared to homologous AMA cycles. LIMITATIONS, REASONS FOR CAUTION This study is limited by its retrospective nature, differences in patients profiles between sperm donation and homologous-control groups and varying proportion of donor cycles between fertility centers, although these variations have been controlled for in the statistical analysis. WIDER IMPLICATIONS OF THE FINDINGS The findings suggest that sperm donation increases live birth rates while reducing miscarriage occurrence in AMA patients, and thus may be a valid strategy to improve ICSI outcomes in this growing and challenging patient group. STUDY FUNDING/COMPETING INTEREST(S) N/A. TRIAL REGISTRATION NUMBER N/A.
Collapse
Affiliation(s)
- M Mignini Renzini
- Clinica EUGIN, Modena, Italy.,Biogenesi Reproductive Medicine Centre, Istituti Clinici Zucchi, Monza, Italy
| | - M Dal Canto
- Clinica EUGIN, Modena, Italy.,Biogenesi Reproductive Medicine Centre, Istituti Clinici Zucchi, Monza, Italy
| | - M C Guglielmo
- Clinica EUGIN, Modena, Italy.,Biogenesi Reproductive Medicine Centre, Istituti Clinici Zucchi, Monza, Italy
| | | | - E De Ponti
- ASST Monza, Department of Medical Physics, Monza, Italy
| | - A La Marca
- Clinica EUGIN, Modena, Italy.,Department of Medical and Surgical Sciences of the Mother, Children and Adults, University of Modena and Reggio Emilia, Modena, Italy
| | | | - J Buratini
- Clinica EUGIN, Modena, Italy.,Biogenesi Reproductive Medicine Centre, Istituti Clinici Zucchi, Monza, Italy.,Department of Structural and Functional Biology, Institute of Biosciences, Sao Paulo State University, Botucatu, Brazil
| |
Collapse
|
27
|
Blazquez A, Garcia D, Calvillo P, Vassena R, Rodriguez A. P–079 A spontaneous LH peak before triggering for intrauterine insemination with donor sperm (IUI-D) is associated to lower live birth rates. Hum Reprod 2021. [DOI: 10.1093/humrep/deab130.078] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Study question
Are live birth rates after IUI with donor sperm (IUI-D) and controlled ovarian stimulation comparable between women with a spontaneous LH peak vs those without?
Summary answer
Biochemical, clinical, ongoing pregnancy rates and live birth rates were higher among women without an LH peak.
What is known already
It is common clinical practice to trigger ovulation in IUI cycles once specific criteria are met; if a natural LH surge appears, adjusting the IUI timing may become necessary. Pregnancy rates seem to be slightly better when IUI is scheduled in relation to the presence or absence of an LH peak in non-stimulated cycles. In IUI with stimulated cycles, however, there is no consensus in the medical literature regarding the best moment to program the IUI, due to different inclusion criteria, different IUI timing and definition of LH peak among studies.
Study design, size, duration
Retrospective cohort study of 9,657 IUI-D cycles performed between 2012 and 2019 in one fertility center. IUI-D without LH peak (n = 6,679) versus IUI-D with LH peak (n = 2,978) were compared. Differences in pregnancy outcomes between study groups were evaluated using a Pearson’s Chi2 test. A p < 0.05 was considered statistically significant.
Participants/materials, setting, methods
The definition used to define an LH peak is > 10UI/L in the last follicular control. In cases without an LH peak, when at least one dominant follicle reached 17mm, ovulation was triggered with human chorionic gonadotropin in the following 24h, and IUI-D was performed 38h after triggering. In cases with an LH peak, ovulation was triggered the 6h following the detection, and IUI-D was also performed 38h later.
Main results and the role of chance
The women BMI and age were comparable between groups, with a mean±SD of 35.2±4.8 years old, and 24.3±4.7 for BMI. Other characteristics such as number of previous inseminations, type of stimulation drug, initial dose, total dose, stimulation length and number of follicles > 16mm in the last follicular control were also comparable. As expected, the LH level at the last follicular control was different between groups, with a mean of 5.1UI/L in the no-LH peak and 21.4IU/L in the LH peak group. The group without an LH peak had higher biochemical, clinical, ongoing and live birth rates compared to the group with LH peak: 27.7% vs. 20.7%; 19.5% vs. 15.5%; 17.7% vs. 13.7%; 16.3% vs. 12.6%, respectively (p-value<0.001).
Limitations, reasons for caution
The main limitation of the study is its retrospective nature. Also, a definition of LH peak based in absolute values was used; a definition based in relative values may lead to different results.
Wider implications of the findings: A definition of LH peak based on absolute numbers is imprecise, and the cut-off of 10UI/L does not allow a good scheduling for IUI. A LH peak based on relative values could improve the detection of patients starting ovulation and the accuracy in programming IUI.
Trial registration number
Not applicable
Collapse
Affiliation(s)
- A Blazquez
- Clinica Eugin, Medical Department, Barcelona, Spain
| | - D Garcia
- Clinica Eugin, Scientific Department, Barcelona, Spain
| | - P Calvillo
- Clinica Eugin, Medical Department, Barcelona, Spain
| | - R Vassena
- Clinica Eugin, Scientific Department, Barcelona, Spain
| | - A Rodriguez
- Clinica Eugin, Corporate Medical Department, Barcelona, Spain
| |
Collapse
|
28
|
Esiso F, Lai F, Cunningham D, Garcia D, Barrett B, Sakkas D. P–225 The effect of rapid and delayed insemination on reproductive outcome in conventional insemination and intracytoplasmic sperm injection invitro-fertilization cycles. Hum Reprod 2021. [DOI: 10.1093/humrep/deab130.224] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Study question
Does rapid or delayed insemination after egg retrieval affect fertilization, blastocyst development and live birth rates in CI and ICSI cycles?
Summary answer
When performing CI or ICSI <1.5h and >6.5h after retrieval, detrimental effects are moderate on fertilization but do not impact blastocyst usage and birth rates.
What is known already
Several studies have shown that CIor ICSI performed between 3 to 5 h after oocyte retrieval has improved laboratory outcomes. However, some studies indicate that insemination of oocytes, by either CI or ICSI, within 2 hours or more than 8 hours after oocyte retrieval has a detrimental effect on the reproductive outcome. With some ART centres experiencing an increase in workload, respecting these exact time intervals is frequently challenging.
Study design, size, duration
A single-center retrospective cohort analysis was performed on 6559 patients (9575 retrievals and insemination cycles) between January 1st2017 to July 31st2019. The main outcome measures were live-birth rates. Secondary outcomes included analysis of fertilization per all oocytes retrieved, blastocyst utilization, clinical pregnancy, and miscarriage rates. All analyses used time of insemination categorized in both CI and ICSI cycles. Fertilization rates across categories was analyzed by ANOVA and pregnancy outcomes compared using Chi-square tests.
Participants/materials, setting, methods
As part of laboratory protocol, oocyte retrieval was performed 36 h post-trigger. Cycles involving injection with testicular/epidydimal sperm, donor or frozen oocytes were excluded. The time interval between oocyte retrieval and insemination was analyzed in eight categories: 0 (0- <0.5h), 1 (0.5-<1.5h), 2 (1.5-<2.5h), 3 (2.5-<3.5h), 4 (3.5-<4.5), 5 (4.5-<5.5), 6 (5.5-<6.5) and 7 (6.5-<8h). The number of retrievals in each group (0–7) was 586, 1594, 1644, 1796, 1836, 1351, 641 and 127 respectively.
Main results and the role of chance
This study had a mean patient age of 36.0 years and mean of 12.2 oocytes per retrieval in each category. There were 4,955 CI and 4,620 ICSI retrievals. The smallest groups were time category 7 and 0 for CI and ICSI respectively. The results showed that the mean fertilization rate per egg retrieved for CI ranged from 54.1 to 64.9% with a significant difference between time category 0 and 5 (p < 0.001) and category 1 and 5 (p < 0.0.001). Mean fertilization rate for ICSI per egg retrieved ranged from 52.8 to 67.3% with no significant difference between time categories compared to category 5. Blastocyst utilization rate for CI and ICSI were not significantly different for all time categories. In the CI and ICSI groups there were 6,540 and 6,178 total fresh and frozen transfers. The miscarriage and clinical pregnancy rate in CI and ICSI were not significantly different across time categories. The overall mean live birth rate for CI was 32.4% (range: 23.1 to 35.5%). Live-birth rates differed significantly (p = 0.04) in CI with time categories 0 and 7 the lowest. In the ICSI group, the overall mean live birth rate was 30.8% (range: 29.1 to 35.7%),with no significant differences between time categories.
Limitations, reasons for caution
As this is a retrospective study, the influence of uncontrolled variables cannot be excluded. The group spread was uneven with the early and late time categories having the lowest number of representative retrievals and this could have affected the results obtained.
Wider implications of the findings: Our results indicate that both CI and ICSI are optimal when performed between 1.5–6.5 hours after oocyte retrieval. Further prospective studies on reproductive outcomes related to time of insemination are warranted. This data indicates a minimal detrimental effect when it is untenable to follow strict insemination time intervals.
Trial registration number
2015P000122
Collapse
Affiliation(s)
- F Esiso
- BSM-University Pompeo Fabrau, Masters in Human Assisted Reproduction Technology, Barcelona, Spain
| | - F Lai
- Boston IVF, Embryology, Waltham, USA
| | | | - D Garcia
- Clínica Eugin, Department of Research and Development, Barcelona, Spain
| | - B Barrett
- Boston IVF, Embryology, Waltham, USA
| | - D Sakkas
- Boston IVF, Embryology, Waltham, USA
| |
Collapse
|
29
|
Karamtzioti P, Tiscornia G, Garcia D, Rodriguez A, Vernos I, Vassena R. O-171 Altered meiotic spindle morphology and composition in in vitro matured oocytes. Hum Reprod 2021. [DOI: 10.1093/humrep/deab127.052] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Study question
How does the meiotic spindle tubulin PTMs of MII oocytes matured in vitro compare to that of MII oocytes matured in vivo?
Summary answer
MII cultured in vitro present detyrosinated tubulin in the spindle microtubules, while MII oocytes matured in vivo do not.
What is known already
A functional spindle is required for chromosomal segregation during meiosis, but the role of tubulin post-translational modifications (PTMs) in spindle meiotic dynamics remains poorly characterized. In contrast with GVs matured in vitro within the cumulus oophorous, in vitro maturation of denuded GVs to the MII stage (GV-MII) is associated with spindle abnormalities, chromosome misalignment and compromised developmental potential. Although aneuploidy rates in GV-MII are not higher than in vivo matured MII, disorganized chromosomes may contribute to compromised developmental potential. However, to date, spindle PTMs morphology of GV-MII has not been compared to that of in vivo cultured MII oocytes.
Study design, size, duration
GV (n = 125), and MII oocytes (n = 24) were retrieved from hormonally stimulated women, aged 20 to 35 years old. GVs were matured to the MII stage in vitro in G-2 PLUS medium for 30h; the maturation rate was 68,2%; the 46 GV-MII oocytes obtained were vitrified, stored, and warmed before fixing and subjecting to immunofluorescent analysis. In vivo matured MII oocytes donated to research were used as controls.
Participants/materials, setting, methods
Women were stimulated using a GnRH antagonist protocol, with GnRH agonist trigger. Trigger criterion was ≥2 follicles ≥18mm; oocytes were harvested 36h later. Spindle microtubules were incubated with antibodies against alpha tubulin and tubulin PTMs (acetylation, tyrosination, polyglutamylation, Δ2-tubulin, and detyrosination); chromosomes were stained with Hoechst 33342 and samples subjected to confocal immunofluorescence microscopy (ZEISS LSM780), with ImageJ software analysis. Differences in spindle morphometric parameters were assessed by non-parametric Kruskal–Wallis and Fisher’s exact tests.
Main results and the role of chance
Qualitatively, Δ2-tubulin, tyrosination and polyglutamylation were similar for both groups. Acetylation was also present in both groups, albeit in different patterns: while in vivo matured MII oocytes showed acetylation at the poles, GV-MII showed a symmetrical distribution of signal intensity, but discontinuous signal on individual microtubule tracts, suggesting apparent islands of acetylation. In contrast, detyrosination was detected in in vivo matured MII oocytes but was absent from GV-MII. Regarding spindle pole morphology, of the four possible phenotypes described in the literature (double flattened and double focused; flattened-focused, focused-flattened, with the first word characterizing the cortex side of the spindle), we observed double flat shaped spindle poles in 86% of GV-MII oocytes (25/29) as opposed to 40.5% (15/37) for the in vivo matured MII oocytes (p = 0.0004, Fisher’s exact test). Further morphometric analysis of the spindle size (maximum projection, major and minor axis length) and the metaphase plate position (proximal to distal ratio, angle) revealed decreased spindle size in GV-MII oocytes (p = 0.019, non parametric Kruskal- Wallis test).
Limitations, reasons for caution
Oocytes retrieved from hyperstimulation cycles could be intrinsically impaired since they failed to mature in vivo. Our conclusions should not be extrapolated to IVM in non-stimulated cycles, as in this model, the cumulus oophorus is a major factor in oocyte maturation and correlation with spindle dynamics has been inferred.
Wider implications of the findings
The metaphase II spindle stability compared to the mitotic or metaphase I meiotic one justifies the presence of PTMs such as acetylation and glutamylation, which are found in stable, long-lived microtubules. The significance of the absence of detyrosinated microtubules in the MII-GV group remains to be determined
Trial registration number
not applicable
Collapse
Affiliation(s)
| | | | | | | | - I Vernos
- Centre for Genomic Regulation CRG- Barcelona Institute of Science and Technology, Research, Barcelona, Spain
- Institució Catalana de Recerca I Estudis Avançats ICREA, research, Barcelona, Spain
| | | |
Collapse
|
30
|
Torra M, Tutusaus M, Garcia D, Vassena R, Rodríguez A. P–013 Sperm freezing does not affect live birth rates: results from 6,594 cycles in normozoospermic patients. Hum Reprod 2021. [DOI: 10.1093/humrep/deab130.012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Study question
Does sperm cryopreservation influence the reproductive outcomes of normozoospermic patients undergoing elective ICSI?
Summary answer
After controlling for confounders, the use of cryopreserved semen from normozoospermic patients does not affect pregnancy and live birth rates after ICSI.
What is known already
Sperm cryopreservation with slow freezing is a common practice in ART. While frozen-thawed semen typically presents reduced motility and vitality, its use for ICSI is generally considered adequate in terms of reproductive outcomes. Nevertheless, most studies comparing reproductive outcomes between fresh versus cryopreserved sperm include patients with oligo- and/or asthenozoospermia, where the altered quality of the sample can partially mask the full effect of freezing/thawing. The objective of this study is to ascertain whether ICSI using fresh or cryopreserved semen from normozoospermic patients results in similar fertilization rates and reproductive outcomes.
Study design, size, duration
Retrospective cohort of 6,594 couples undergoing their first elective ICSI cycle between January 2011 and December 2019, using normozoospermic partner semen (fresh or cryopreserved). All cycles involved a fresh embryo transfer, either at cleavage or blastocyst stage. Cycles were divided in 4 groups: fresh semen with partner’s oocytes (FSPO, n = 1.878), cryopreserved semen with partner’s oocytes (CSPO, n = 142), fresh semen with donor oocytes (FSDO, n = 2.413), and cryopreserved semen with donor oocytes (CSDO, n = 2.161).
Participants/materials, setting, methods
A slow freezing protocol using GM501 SpermStore medium (Gynemed, Lensahn) was used for all sperm cryopreservation. Sperm washing, capacitation, and selection prior to ICSI were performed equally for fresh and frozen-thawed samples, using pellet swim-up in IVF® medium (Vitrolife, Göteborg). Fertilization rate (FR), pregnancy (biochemical, clinical, and ongoing) and live birth (LB) rates were compared among study groups using Pearson’s Chi square and Student’s t-test. A p-value <0.05 was considered statistically significant.
Main results and the role of chance
Male and female age, sperm concentration and motility after ejaculation, and number of oocytes inseminated were similar between study groups compared (FSPO vs. CSPO, FSDO vs. CSDO). As expected, oocyte donation cycles resulted in higher LB rate than cycles in which partner’s oocytes were used (30.04% vs 18.17%, p < 0.001). In cycles using partner’s oocytes, no significant differences were observed between fresh and cryopreserved sperm in FR, pregnancy and LB rates (p > 0.05 for all outcomes). However, in oocyte donation, the mean FR after ICSI using cryopreserved semen (73.6 ± 19.6) was lower than the FR obtained with fresh semen (75.1 ± 19.2), p = 0.010. Similarly, in oocyte donation cycles, the biochemical pregnancy rate was significantly lower when using cryopreserved semen (48.5% in CSDO vs. 52.3% in FSDO, p = 0.009), while clinical, ongoing pregnancy and LB rates were similar between both semen status (p > 0.05). In oocyte donation, a subgroup analysis including only the ICSI cycles with embryo transfer at blastocyst stage (n = 1.187 for FSDO, n = 337 for CSDO) confirmed that the LB rate was comparable between fresh and cryopreserved semen groups (34.7% vs 35.6% respectively, p = 0.76), without significant differences in pregnancy rates neither (p > 0.05 for all outcomes).
Limitations, reasons for caution
Caution should be exerted when extrapolating these results to different protocols for sperm cryopreservation and selection, or to IVM and classical IVF cycles, which were excluded from analysis. Due to the retrospective nature of the study, some uncontrolled for variables may affect the results.
Wider implications of the findings: Sperm cryopreservation does not affect pregnancy and live birth rates in normozoospermic patients, although it may lower slightly fertilization rates. In line with previous studies including patients with an apparent male factor detected after routine semen analysis, sperm cryopreservation is a safe and convenient technique.
Trial registration number
Not applicable
Collapse
Affiliation(s)
- M Torra
- Euvitro SL, Research, Barcelona, Spain
| | - M Tutusaus
- Eugin, UPF Barcelona School of Management, Barcelona, Spain
| | - D Garcia
- Euvitro SL, Research, Barcelona, Spain
| | - R Vassena
- Euvitro SL, Research, Barcelona, Spain
| | | |
Collapse
|
31
|
Mignin. Renzini MR, Da. Canto M, Guglielmo MC, Garcia D, Ponti ED, Marca AL, Vassena R, Buratini J. P–093 The use of donor sperm improves post-ICSI live birth rates in advanced maternal age women. Hum Reprod 2021. [DOI: 10.1093/humrep/deab130.092] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Study question
Can the use of donor sperm improve post-ICSI live birth rate in advanced maternal age (AMA) patients?
Summary answer
The use of donor sperm increases post-ICSI live birth rate while substantially reducing abortion occurrence in AMA patients.
What is known already
Oocyte DNA repair capacity decreases with maternal age, when sperm DNA integrity is particularly important to avoid the transfer of gene truncations and de novo mutations to the zygote. Optimal DNA repair activity in the zygote requires paternal inheritance of 8-oxoguanine DNA glycosylase (OGG1), a rate-limiting enzyme in the base excision repair pathway. However, the involvement of paternal aging and sperm quality in the severe drop in fertility observed in AMA patients has not been addressed. While strategies to mitigate the impact of AMA on fertility have exclusively targeted oocyte quality, the sperm contribution in this scenario remains somehow neglected.
Study design, size, duration
Retrospective, multicentric, international study including 755 first ICSI cycles with patients’ own oocytes achieving a fresh ET between 2015 and 2019, 337 of which using normozoospermic partner semen and 418 using donor sperm. The association of sperm origin (partner vs. donor) with live birth was assessed by univariate/multivariate analysis in non-AMA (<37 years, n = 278) and AMA (≥37 years, n = 477) patients. ICSI outcomes were compared between partner and donor sperm in non-AMA and AMA patients.
Participants/materials, setting, methods
The study was conducted in 3 fertility clinics including 755 Caucasian patients aged 24 to 42 years. Univariate/multivariate analyses were performed to test the association of sperm origin with live birth; infertility factor, maternal age, oocyte yield and number of embryos transferred were included in the model as confounding variables. In addition, ICSI outcomes were compared between donor and partner sperm groups with the Chi-square (percentages) or with the Wilcoxon sum rank (continuous variables) tests.
Main results and the role of chance
The multivariate analysis revealed that the use of donor sperm was positively and independently associated with live birth occurrence in AMA [1.82 OR (1.08–3.07) 95% IC; p = 0.024], but not in non-AMA patients [1.53 (0.94–2.51); p = 0.090]. Maternal age [0.75 (0.64–0.87); p < 0.001], number of MII oocytes recovered [1.14 (1.05–1.23); p = 0.001] and number of embryos transferred [1.90 (1.27–2.86); p = 0.002] were also independently associated with live birth in AMA patients. Live birth and delivery rates were 70–75% higher, while miscarriage rate was less than half in donor sperm compared to partner sperm AMA cycles (LBR: 25.4% vs. 14.5%, p = 0.003; DR: 22.5% vs. 13.5%, p = 0.008; MR: 18.0% vs. 39.5%; p = 0.009). Implantation (17.4% vs. 13.5%; p = 0.075) and clinical pregnancy rates (27.5% vs. 22.3%; p = 0.121) did not significantly differ between sperm donation and partner sperm AMA cycles. Male age was substantially lower (23.6 ± 5.2 vs. 41.4 ± 5.0; p < 0.0001) and oocyte yield was higher (5.1 ± 3.1 vs. 4.3 ± 2.6; p < 0.0001) in sperm donation compared to partner sperm AMA cycles, while maternal age did not vary (39.8 ± 1.6 vs. 39.6 ± 1.7; p = 0.348).
Limitations, reasons for caution
This study is limited by its retrospective nature and by differences in patients’ profiles between sperm donation and homologous cycles, although this variation has been controlled for in the statistical analysis.
Wider implications of the findings: The findings suggest that donor sperm can improve live birth rates by drastically reducing miscarriage occurrence in AMA patients. Therefore, the present results may influence AMA treatment decisions and, above all, contribute for AMA patients to achieve a healthy birth.
Trial registration number
Not applicable
Collapse
Affiliation(s)
- M R Mignin. Renzini
- Biogenesi- Reproductive Medicine Centre, Istituti Clinici Zucchi, Monza, Italy
| | - M Da. Canto
- Biogenesi- Reproductive Medicine Centre, Istituti Clinici Zucchi, Monza, Italy
| | - M C Guglielmo
- Biogenesi- Reproductive Medicine Centre, Istituti Clinici Zucchi, Monza, Italy
| | - D Garcia
- Clinica Eugin, Research, Barcelona, Spain
| | | | | | - R Vassena
- Clinica Eugin, Research, Barcelona, Spain
| | - J Buratini
- Biogenesi- Reproductive Medicine Centre, Istituti Clinici Zucchi, Monza, Italy
| |
Collapse
|
32
|
Zamora MJ, Katsouni I, Garcia D, Vassena R, Rodríguez A. P–159 Slow-growing embryos should be frozen on day 5. Hum Reprod 2021. [DOI: 10.1093/humrep/deab130.158] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Study question
What is the live birth rate after frozen embryo transfer (FET) of slow-growing embryos frozen on day 5 (D5) or on day 6 (D6)?
Summary answer
The live birth rate after single FET is significantly higher for slow-growing embryos frozen on D5 compared to those frozen on D6.
What is known already
Most data on the outcomes of blastocyst transfer stem from studies that evaluate fresh transfer from normal growing D5 blastocyst ET. However not all embryos will begin blastulation nor reach the fully expanded stage by D5; those are the slow-growing embryos. Studies that compare D5 to D6 embryos in FET cycles show contradictory results. Some have reported higher clinical pregnancy rates after D5 FET, while others have reported similar outcomes for D5 and D6 cryopreserved blastocyst transfers. There is a lack of evidence regarding the best approach for vitrifying embryos that exhibit a slow developmental kinetic.
Study design, size, duration
This retrospective cohort study included 821 single FET of slow-growing embryos frozen on D5 or D6, belonging to patients undergoing in vitro fertilization with donor oocytes between January 2011 and October 2019, in a single fertility center. The origin of blastocysts was either supernumerary embryos after fresh embryo transfer or blastocysts from freeze-all cycles. All embryos were transferred 2- 4h after thawing.
Participants/materials, setting, methods
We compared reproductive outcomes of slow-growing embryos frozen on D5 versus (n = 442) slow-growing embryos frozen on D6 (n = 379). D5 group consisted in embryos graded 0, 1, 2 of Gardner scale and frozen on D5. Similarly, D6 group consisted in embryos graded 3, 4, 5 of Gardner scale (blastocyst stage) and frozen on D6. Differences in pregnancy rates between study groups were compared using a Chi2 test. A p-value <0.05 was considered statistically significant.
Main results and the role of chance
Baseline characteristics were comparable between study groups. Overall, mean age of the woman was 42.3±5.4 years old; donor sperm was used in 25% of cycles, and it was frozen in 73.2% of cycles. Pregnancy rates were significantly higher when transferring slow D5 embryos compared to D6 for all the pregnancy outcomes analyzed: biochemical pregnancy rate was 27.7% vs 20.2%, p < 0.016; clinical pregnancy rate was 17.5% vs 10.2%, p < 0.004); ongoing pregnancy rate was: 15.7% vs 7.8% (p < 0.001); live birth rate was: 15.4% vs 7.5%, (p < 0.001). These results suggest that when embryos exhibit a slow development behavior (not reaching full blastocysts at D5), waiting until D6 for blastulation and expansion does not improve clinical outcomes. Vitrification at D5 will should the preferred option in cases where the oocyte is assumed of high quality
Limitations, reasons for caution
The retrospective design of the study is its main limitation. Also, morphology as sole selection criterion for transfer. However, blastocyst morphology is a very good predictor of implantation and pregnancy, and a good indicator of the embryo’s chromosomal status (higher euploidy rate in higher morphological quality blastocysts).
Wider implications of the findings: These results can help to the standardization of laboratory protocols. As the decision of vitrifying slow developing embryos on D5 or D6 is made by the laboratory team or by the gynaecologist in agreement with the patient, having an evidence based strategy simplifies patient counselling and decision making.
Trial registration number
Not applicable
Collapse
Affiliation(s)
| | - I Katsouni
- Eugin, Eugin, Barcelona, Spain
- UPF, Barcelona School of Management, Barcelona, Spain
| | | | | | | |
Collapse
|
33
|
Franch‐Sarto M, Garcia‐Calduch O, Rivas A, Lopez A, Gonzalez‐Barca E, Sureda A, Baile M, Martin A, Salar A, Gutierrez A, Bastos M, Rodriguez M, Gonzalez S, Queizán J, Cordoba R, Montalbán C, Luzardo HD, Abrisqueta P, Garcia D, Hong A, Peñalver F, Moreno M, Sancho J. CENTRAL NERVOUS SYSTEM RELAPSE IN PATIENTS WITH DIFFUSE LARGE B‐CELL LYMPHOMA TREATED WITH R‐CHOP: STUDY OF THE SPANISH LYMPHOMA GROUP GELTAMO. Hematol Oncol 2021. [DOI: 10.1002/hon.91_2880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- M. Franch‐Sarto
- Hospital Universitari Germans Trias i Pujol Hematology Badalona Spain
| | - O. Garcia‐Calduch
- Hospital Universitari Germans Trias i Pujol Hematology Badalona Spain
| | - A. Rivas
- Hospital Universitari Clinic Hematology Barcelona Spain
| | - A. Lopez
- Hospital Universitari Clinic Hematology Barcelona Spain
| | | | - A. Sureda
- Hospital Duran i Reynalds Hematology Bellvitge Spain
| | - M. Baile
- Hospital Universitario de Salamanca and IBSAL. Hematology Salamanca Spain
| | - A. Martin
- Hospital Universitario de Salamanca and IBSAL. Hematology Salamanca Spain
| | - A. Salar
- Hospital del Mar Hematology Barcelona Spain
| | | | - M. Bastos
- Hospital Universitario Gregorio Marañón Hematology Madrid Spain
| | - M.‐J. Rodriguez
- Hospital Universitario de Canarias Hematology Canarias Spain
| | - S. Gonzalez
- Hospital Universitario Marqués de Valdecilla Hematology Santander Spain
| | - J.‐A. Queizán
- Hospital General de Segovia Hematology Segovia Spain
| | - R. Cordoba
- Fundación Jiméndez Díaz Hematology Madrid Spain
| | - C. Montalbán
- MD Anderson Cancer Center Hematology Madrid Spain
| | - H. D. Luzardo
- Hospital Universitario de Gran Canarias Dr Negrín Hematology Las Palmas de Gran Canaria Spain
| | - P. Abrisqueta
- Hospital Universitari Vall d'Hebron Hematology Barcelona Spain
| | - D. Garcia
- Hospital La Zarzuela Hematology Madrid Spain
| | - A. Hong
- Hospital de Lanzarote Hematology Lanzarote Spain
| | | | - M. Moreno
- Hospital Universitari Germans Trias i Pujol Hematology Badalona Spain
| | - J.‐M. Sancho
- Hospital Universitari Germans Trias i Pujol Hematology Badalona Spain
| |
Collapse
|
34
|
Margineanu I, Mor Z, Garcia D, Gilpin C, Dhawan S, Ritz N, Zenner D. TB and COVID-19 in migrants - the need to focus on both conditions. Int J Tuberc Lung Dis 2021; 25:333-335. [PMID: 33977899 DOI: 10.5588/ijtld.21.0067] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
Affiliation(s)
- I Margineanu
- Department of Clinical Pharmacy and Pharmacology, University Medical Centrum Groningen, Rijksuniversiteit Groningen, Groningen, the Netherlands
| | - Z Mor
- Tel Aviv Department of Health, Ministry of Health, Tel Aviv, Israel, Ashkelon Academic College, School of Health Sciences, Ashkelon, Israel
| | - D Garcia
- Migrant Clinicians Network, Austin, TX, USA
| | - C Gilpin
- International Organization for Migration, Geneva, Switzerland
| | - S Dhawan
- Partasia Biopharm, New Delhi, India, SHARE INDIA, Delhi, India
| | - N Ritz
- Paediatric Infectious Diseases and Vaccinology Unit, Mycobacterial and Migrant Health Research, University Children´s Hospital Basel, University of Basel, Basel, Switzerland
| | - D Zenner
- Centre for Global Public Health, Institute for Population Health Sciences, Queen Mary University of London, London, UK
| |
Collapse
|
35
|
Vaughan DA, Tirado E, Garcia D, Datta V, Sakkas D. DNA fragmentation of sperm: a radical examination of the contribution of oxidative stress and age in 16 945 semen samples. Hum Reprod 2021; 35:2188-2196. [PMID: 32976601 DOI: 10.1093/humrep/deaa159] [Citation(s) in RCA: 33] [Impact Index Per Article: 11.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/25/2020] [Revised: 05/28/2020] [Indexed: 02/07/2023] Open
Abstract
STUDY QUESTION What is the relationship between sperm DNA fragmentation and oxidative stress (OS) with increasing male age? SUMMARY ANSWER Sperm DNA fragmentation increases with age and is likely related to both defective spermatogenesis and increasing OS levels. WHAT IS KNOWN ALREADY Sperm quality declines with age. The presence of DNA damage in a high fraction of spermatozoa from a raw semen sample is associated with lower male fertility in natural conception and intrauterine insemination. STUDY DESIGN, SIZE, DURATION A retrospective cohort study of 16 945 semen samples analysed at a single reference laboratory between January 2010 and December 2018. PARTICIPANTS/MATERIALS, SETTING, METHODS All males were undergoing an infertility evaluation. The cohort was divided into seven age categories: <30, 30-34, 35-39, 40-44, 45-49, 50 to <54 and ≥55 years. The mean age was 37.6 years (SD 6.8). Sperm DNA fragmentation index (DFI) and high DNA stainability (HDS) were calculated using flow cytometry. OS levels were measured using the oxidative stress adducts (OSA) test, by spectrophotometry. ANOVA with weighted polynomial contrast analysis was used to evaluate trends for DFI, OSA and HDS values across age categories. MAIN RESULTS AND THE ROLE OF CHANCE Mean DFI significantly increased across all age groups (Ptrend < 0.001). OSA was lowest in patients <30 years old (mean 3.6, SD 1.0) and also increased as age increased (Ptrend < 0.001). There was a statistically significant difference between age groups for each of the three parameters (P < 0.001). There was a significant linear trend for DFI, OSA and HDS across the seven age categories (P < 0.001). Among patients with high DFI, there was a decreasing age-dependent trend in the patients observed with high OSA (P < 0.001). LIMITATIONS, REASONS FOR CAUTION This is a retrospective study. All males included in the study were undergoing a work-up for infertility and may not be representative of a fertile population. Additional patient demographics and clinical data were not available. WIDER IMPLICATIONS OF THE FINDINGS DNA and/or oxidative damage in sperm may be just as important to understand as the chromosomal aberrations that are carried in the oocyte. Further studies are needed to evaluate the effect of advancing paternal age on the male genome and, ultimately, on the health of the offspring. STUDY FUNDING/COMPETING INTEREST(S) No funding was obtained for this study. V.D. is an employee of Reprosource/Quest Diagnostics. D.S. reports he was a Scientific Advisor to Cooper Surgical. TRIAL REGISTRATION NUMBER N/A.
Collapse
Affiliation(s)
- D A Vaughan
- Department of Obstetrics and Gynecology, Beth Israel Deaconess Medical Center, Boston, MA 02115, USA.,Department of Obstetrics, Gynecology and Reproductive Biology, Harvard Medical School, Boston, MA 02115, USA.,Boston IVF, Waltham, MA 02445, USA
| | - E Tirado
- ReproSource Fertility Diagnostics, Marlborough, MA 01752, USA
| | - D Garcia
- Clinica EUGIN, Barcelona 08029, Spain
| | - V Datta
- ReproSource Fertility Diagnostics, Marlborough, MA 01752, USA
| | - D Sakkas
- Boston IVF, Waltham, MA 02445, USA
| |
Collapse
|
36
|
Bosch F, Wang TF, Di Nisio M, Segers A, Connors J, Garcia D, Mulder F, Weitz J, Buller H, Carrier M, Verhamme P, Grosso M, Raskob G, van Es N. OC-14 Risk factors for recurrence in patients with cancer-associated venous thromboembolism: results from the Hokusai-VTE cancer study. Thromb Res 2021. [DOI: 10.1016/s0049-3848(21)00156-0] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
37
|
Penrod Y, Garcia D, Dunn ST. Evaluation of transport media for laboratory detection of SARS-CoV-2 in upper respiratory tract swab specimens. J Med Virol 2021; 93:2774-2781. [PMID: 33128389 DOI: 10.1002/jmv.26643] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/13/2020] [Accepted: 09/24/2020] [Indexed: 11/09/2022]
Abstract
The reduced availability of commercial swabs and transport media for testing and administrative demands for increased testing capacity during the coronavirus disease 2019 (COVID-19) public health emergency has seriously challenged national laboratory testing programs, forcing many to use nontraditional collection devices, often without typical analytical assessment of their suitability in testing. Five common transport media (four commercial and one in-house) were evaluated for their suitability in the collection of nasopharyngeal swab specimens for subsequent molecular detection of severe acute respiratory syndrome-associated coronavirus 2 (SARS-CoV-2). Results suggest that these transport media provide dependable temporal stability of the SARS-CoV-2 virus without significant analytical interference of molecular assays. These findings are not only important for addressing critical laboratory supply chain shortages of transport media in the current COVID-19 health crisis but also for future pandemic planning, when again supplies of commercially available transport media might be depleted.
Collapse
Affiliation(s)
- Yvonne Penrod
- Oklahoma State Department of Health, Public Health Laboratory, Oklahoma, Oklahoma, USA
| | - Denise Garcia
- Oklahoma State Department of Health, Public Health Laboratory, Oklahoma, Oklahoma, USA
| | - S Terence Dunn
- Oklahoma State Department of Health, Public Health Laboratory, Oklahoma, Oklahoma, USA
| |
Collapse
|
38
|
Pokorney S, Garonzik S, Chertow G, Washam J, Mussina K, Bansal N, Gadegbeku C, Garcia D, Lopes R, Mahaffey K, Middleton J, Thadhani R, Thomas K, Winkelmayer W, Granger C. Pharmacokinetics of apixaban in patients with end stage renal disease on hemodialysis and atrial fibrillation: results from the RENAL-AF trial. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.3373] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
Abstract
Background/Introduction
Apixaban use is increasing for stroke prevention in patients with atrial fibrillation (AF) and end stage renal disease (ESRD) on hemodialysis. There is uncertainty as to the optimal dose in this population in part related to the limited available pharmacokinetic (PK) data.
Purpose
We comprehensively evaluated the PK of apixaban collected over 1 month of apixaban dosing in 63 patients with AF and ESRD on hemodialysis.
Methods
Patients with AF and ESRD on hemodialysis were randomized to warfarin versus apixaban within the RENAL-AF trial with 5 mg BID dosing, except for 2.5 mg BID in those age ≥80 years or weight ≤60 kg. The 5 mg BID dose could be reduced to 2.5mg BID for minor bleeding. Day 1 PK data was collected on all patients pre- and post-hemodialysis. Day 3 and 1 month pre- and post-hemodialysis PK samples were collected in 49 patients. The timing of apixaban dosing and hemodialysis relative to PK samples was recorded. Dosing history, hemodialysis, and PK samples were chronologically integrated with patient specific data such as body size, age, race and gender. This dataset was combined with the ARISTOTLE dataset, and the published PK model from ARISTOTLE describing exposures in the AF population was updated to incorporate an additional clearance term for hemodialysis. The model estimated apixaban exposures (AUC) in RENAL-AF were compared to ARISTOLTE AUC values.
Results
There were 285 PK concentrations collected among 63 patients in the RENAL-AF trial. Patients had median age 69 years with 41% women (N=26) and a median weight of 84 kg (49, 157). The median AUCs for patients with ESRD on hemodialysis were 5,452 and 2,990 for patients treated with 5mg BID and 2.5mg BID doses, respectively. The median AUCs for patients treated with 5mg BID from ARISTOTLE increased from 2,802 for patients with class 1 CKD to 5,863 for class 4 CKD, while they increased from 2,392 for class 1 CKD to 2,881 for class 4 CKD in patients treated with 2.5mg BID. The median AUC for patients with ESRD on hemodialysis were within 50% of the exposure of patients from ARISTOTLE for all classes of CKD for the 2.5mg BID dose and for classes 2, 3A, 3B, and 4 CKD for the 5mg BID dose (Figure).
Conclusions
The steady state apixaban exposure data in patients with AF and ESRD on hemodialysis were modestly higher but consistent with the results of non-ESRD patients from ARISTOTLE, using 5 mg BID unless patients had age ≥80 years or weight ≤60 kg. Additional clinical outcomes data on the use of apixaban in patients with AF and ESRD on hemodialysis are needed.
Funding Acknowledgement
Type of funding source: Private grant(s) and/or Sponsorship. Main funding source(s): Investigator sponsored grant from Bristol-Myers Squibb and Pfizer
Collapse
Affiliation(s)
- S Pokorney
- Duke University, Durham, United States of America
| | - S Garonzik
- Bristol Myers Squibb, Princeton, United States of America
| | - G.M Chertow
- Stanford University, Palo Alto, United States of America
| | - J.B Washam
- Duke University, Durham, United States of America
| | - K Mussina
- Frenova Renal Research, Waltham, United States of America
| | - N Bansal
- University of Washington, Seattle, United States of America
| | - C Gadegbeku
- Temple University School of Medicine, Philadelphia, United States of America
| | - D Garcia
- University of Washington, Seattle, United States of America
| | - R.D Lopes
- Duke University, Durham, United States of America
| | - K.W Mahaffey
- Stanford University, Palo Alto, United States of America
| | - J Middleton
- Duke University, Durham, United States of America
| | - R Thadhani
- Cedars-Sinai Medical Center, Los Angeles, United States of America
| | - K.L Thomas
- Duke University, Durham, United States of America
| | - W Winkelmayer
- Baylor College of Medicine, Houston, United States of America
| | - C.B Granger
- Duke University, Durham, United States of America
| |
Collapse
|
39
|
Cicerchia M, Ochoa J, Cardenas-Reyes I, Fernandez Ferro G, Brogger M, Fernandez X, Garcia Hernandez S, Garcia D, Salazar Mendiguchia J, Ortiz M, Monserrat L. Genotype/Phenotype correlation and prognosis for undescribed ACTC1 missense variants. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.2075] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Purpose
Establish the genotype/phenotype correlation for missense undescribed variants in ACTC1, and evaluate their prognostic implications.
Methods
A systematic screening for the ACTC1 gene was performed using NGS in 17,683 individuals with inherited cardiovascular disease, 6,984 of them with hypertrophic cardiomyopathy, 3,507 with dilated cardiomyopathy, and 760 left ventricular non-compaction. These phenotypes were clinically diagnosed by each center prior to the genetic study. Frequency of the variants was compared with gene gnomAD and ClinVar databases. A systematic review of the literature was performed to search for previously reported variants.
We evaluated available follow up data and constructed Kaplan-Meier survival curves free from cardiovascular death (sudden death, Heart transplant, heart failure death, appropriate ICD discharge and stroke related death). Log-rank test was used to compare event-free survival time between males and females.
Results
39 missense variants were identified in 283 carriers (125 index cases; 158 first-degree relatives). Twenty-two have not been previously described or identified in public databases. 17 have been reported in gnomAD or Clinvar. Carriers phenotypes were: 120 HCM; 43 LVNC; 16 DCM; three had cardiac septal defect and two had sudden death. Some of the carriers had overlapped or combined phenotypes: 7 HCM and LVNC, 7 septal defects and LVNC, 3 HCM and septal defects, 4 MCD and LVNC. 24 were healthy carriers, and we have no phenotypic data of the remaining individuals. Family studies were performed in 12 families out of the 22 undescribed variants, showing cosegregation in 8 variants. One case was “de novo”.
Interestingly, a rare variant, previously identified as VUS in ClinVar, showed a clearly cosegregation with HCM. The Leu10Met variant with a frequency of 9/282084 alleles in gnomAD (1/15671 individuals) was identified in 20 index cases, which represents 1/884 of all the genotyped (0.11%), and 1/387 patients with HCM (0.35%). We found it in 2/9289 patients with other phenotypes (p<0.001).
51 patients (18%) presented an event during follow up. In several cases, carriers developed early atrial fibrillation.
The survival curve shows adverse events from the first decade of life, with a 10% cumulative rate of events at age 40, 80% survival at age 60, and a 60% survival at age 70. No significant differences in the incidence of cardiovascular death between men and women were observed.
Conclusion
HCM is the most frequent phenotype in carriers of ACTC1 variants, followed by LVNC, and DCM. Septal defects are not rare, and they are usually described in combination with cardiomyopathies.
Disease course seems to have a good prognosis. Sudden death is an exception at early ages and appears to be associated with severe morphological expression.
Given the presence of cosegregation with disease in rare variants, many of the ACTC1 variants may have an incomplete penetrance, and late disease expression.
ACTC1
Funding Acknowledgement
Type of funding source: Private company. Main funding source(s): Health in Code
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | - M Ortiz
- Health in Code, A Coruna, Spain
| | | |
Collapse
|
40
|
Vixege F, Courand PY, Blanc-Benon P, Mendez S, Nicoud F, Vray D, Garcia D. Intraventricular vector flow mapping 3-D by triplane Doppler echocardiography. Comput Methods Biomech Biomed Engin 2020. [DOI: 10.1080/10255842.2020.1816300] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Affiliation(s)
| | - P. Y. Courand
- CREATIS UMR 5220, Lyon, France
- Hospices civils de Lyon, Lyon, France
| | | | | | | | - D. Vray
- CREATIS UMR 5220, Lyon, France
| | | |
Collapse
|
41
|
Garcia D, haubrick K. Food Insecurity with an EFNEP Intervention. J Acad Nutr Diet 2020. [DOI: 10.1016/j.jand.2020.08.069] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
42
|
Affiliation(s)
- D Garcia
- Oto-Rhino-Laryngologie et Chirurgie Cervico-Faciale, Clinique d'Arcachon, avenue Jean-Hameau - TSA 11100, 33164 La Teste-de-Buch, France.
| |
Collapse
|
43
|
Pujol A, Zamora MJ, Obradors A, Garcia D, Rodriguez A, Vassena R. Comparison of two different oocyte vitrification methods: a prospective, paired study on the same genetic background and stimulation protocol. Hum Reprod 2020; 34:989-997. [PMID: 31116386 DOI: 10.1093/humrep/dez045] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/30/2018] [Revised: 02/01/2019] [Accepted: 03/08/2019] [Indexed: 01/29/2023] Open
Abstract
STUDY QUESTION Can two different methods for oocyte vitrification, one using an open tool and the other a closed tool, result in similar oocyte survival rates? SUMMARY ANSWER The oocyte survival rate was found to be higher in the closed method. WHAT IS KNOWN ALREADY Open vitrification is performed routinely in oocyte donation cycles. Closed oocyte vitrification may result in slower cooling rates and thus it is less used, even though it has been recommended in order to avoid the risk of cross-contamination between material from different patients. STUDY DESIGN, SIZE, DURATION This is a prospective cohort study with sibling oocytes carried out in a fertility center between July 2014 and January 2016. The study included 83 oocyte donors each providing a minimum of 12 mature oocytes (metaphase II: MII) at oocyte retrieval. Oocyte survival rate and fertilization rate, as well as reproductive outcomes (biochemical, clinical, ongoing pregnancy and live birth rates) per embryo transfer and also cumulatively between the two methods were compared by Chi2 tests. PARTICIPANTS/MATERIALS, SETTING, METHODS Donor oocytes were denuded and six MII oocytes from each donor were vitrified using an open method and later assigned to one recipient, while another six MII oocytes were vitrified using a closed method and assigned to a different recipient (paired analysis). ICSI was used in all cases and embryo transfer was performed on Day 2-3 in all cases. MAIN RESULTS AND THE ROLE OF CHANCE Oocyte donors were 24.8 years old on average (SD 4.7). Recipient age (average 41.2 years, SD 4.7) and BMI (mean 23.8 kg/m2, SD 4.0) were similar between recipient groups. Oocytes vitrified using the closed method had higher survival rate (94.5% versus 88.9%, P = 0.002), but lower fertilization rate (57.1% versus 69.8%, P < 0.001) compared to the open method. The number of fresh embryos transferred in the two groups was 1.8 on average (SD 0.4). Biochemical (45% closed versus 50% open), clinical (40% versus 50%) and ongoing (37.5% versus 42.5%) pregnancy rates were not different between groups (P > 0.05) and neither were live birth rates (37.5% versus 42.5%, P > 0.05). Cumulative reproductive results (obtained after the transfer of all the embryos) were also similar between groups. LIMITATIONS, REASONS FOR CAUTION The participants of this study were oocyte donors, i.e. young women in good health, and care should be exerted in extending our results to other populations such as infertility patients, oncofertility patients and women freezing oocytes to delay childbearing. WIDER IMPLICATIONS OF THE FINDINGS Our results suggest that, in spite of different survival and fertilization rates, closed and open oocyte vitrification methods should offer similar reproductive outcomes up to cumulative live birth rates. STUDY FUNDING/COMPETING INTEREST(S) The authors report no conflict of interest. Vitrolife provided the media and the closed method tool needed for the study at no cost.
Collapse
Affiliation(s)
- A Pujol
- Clínica EUGIN, Travessera de les Corts, Barcelona, Spain.,CIRH, Plaça Eguilaz, Barcelona, Spain
| | - M J Zamora
- Clínica EUGIN, Travessera de les Corts, Barcelona, Spain
| | - A Obradors
- Clínica EUGIN, Travessera de les Corts, Barcelona, Spain.,FIV Obradors, Avda, Salvador Dalí, Figueres, Girona, Spain
| | - D Garcia
- Clínica EUGIN, Travessera de les Corts, Barcelona, Spain
| | - A Rodriguez
- Clínica EUGIN, Travessera de les Corts, Barcelona, Spain
| | - R Vassena
- Clínica EUGIN, Travessera de les Corts, Barcelona, Spain
| |
Collapse
|
44
|
Mulder F, van Es N, Kraaijpoel N, Di Nisio M, Carrier M, Duggal A, Gaddh M, Garcia D, Grosso M, Kakkar A, Mercuri M, Middeldorp S, Royle G, Segers A, Shivakumar S, Verhamme P, Wang T, Weitz J, Zhang G, Büller H, Raskob G. Corrigendum to “Edoxaban for treatment of venous thromboembolism in patient groups with different types of cancer: Results from the Hokusai VTE Cancer study” [Thromb. Res. vol. 185, January 2020, pages 13–19]. Thromb Res 2020; 191:156-159. [DOI: 10.1016/j.thromres.2020.02.022] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
45
|
Garcia D, Siegel JB, Mahvi DA, Zhang B, Mahvi DM, Camp ER, Graybill W, Savage SJ, Giordano A, Giordano S, Carneiro-Pla D, Javid M, Lesher AP, Abbott A, DeMore NK. What is Elective Oncologic Surgery in the Time of COVID-19? A Literature Review of the Impact of Surgical Delays on Outcomes in Patients with Cancer. ACTA ACUST UNITED AC 2020; 3:1-11. [PMID: 34142081 PMCID: PMC8208646 DOI: 10.31487/j.cor.2020.06.05] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
Background The impact of the COVID-19 pandemic has spread beyond those infected with SARS-CoV-2. Its widespread consequences have affected cancer patients whose surgeries may be delayed in order to minimize exposure and conserve resources. Methods Experts in each surgical oncology subspecialty were selected to perform a review of the relevant literature. Articles were obtained through PubMed searches in each cancer subtype using the following terms: delay to surgery, time to surgery, outcomes, and survival. Results Delays in surgery > 4 weeks in breast cancer, ductal carcinoma in situ, T1 pancreatic cancer, ovarian cancer, and pediatric osteosarcoma, negatively impacted survival. Studies on hepatocellular cancer, colon cancer, and melanoma (Stage I) demonstrated reduced survival with delays > 3 months. Conclusion Studies have shown that short-term surgical delays can result in negative impacts on patient outcomes in multiple cancer types as well as in situ carcinoma. Conversely, other cancers such as gastric cancer, advanced melanoma and pancreatic cancer, well-differentiated thyroid cancer, and several genitourinary cancers demonstrated no significant outcome differences with surgical delays.
Collapse
Affiliation(s)
- Denise Garcia
- Department of Surgery, Medical University of South Carolina, Charleston, South Carolina, USA
| | - Julie B Siegel
- Department of Surgery, Medical University of South Carolina, Charleston, South Carolina, USA
| | - David A Mahvi
- Department of Surgery, Brigham and Women's Hospital, Boston, Boston, Massachusetts, USA
| | - Biqi Zhang
- Department of Surgery, Brigham and Women's Hospital, Boston, Boston, Massachusetts, USA
| | - David M Mahvi
- Department of Surgery, Medical University of South Carolina, Charleston, South Carolina, USA
| | - E Ramsay Camp
- Department of Surgery, Medical University of South Carolina, Charleston, South Carolina, USA
| | - Whitney Graybill
- Department of Obstetrics and Gynecology, Medical University of South Carolina, Charleston, South Carolina, USA
| | - Stephen J Savage
- Department of Urology, Medical University of South Carolina, Charleston, South Carolina, USA
| | - Antonio Giordano
- Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA
| | - Sara Giordano
- Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA
| | - Denise Carneiro-Pla
- Department of Surgery, Medical University of South Carolina, Charleston, South Carolina, USA.,Department of Surgery, Brigham and Women's Hospital, Boston, Boston, Massachusetts, USA.,Department of Obstetrics and Gynecology, Medical University of South Carolina, Charleston, South Carolina, USA.,Department of Urology, Medical University of South Carolina, Charleston, South Carolina, USA.,Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA
| | - Mahsa Javid
- Department of Surgery, Medical University of South Carolina, Charleston, South Carolina, USA
| | - Aaron P Lesher
- Department of Surgery, Medical University of South Carolina, Charleston, South Carolina, USA
| | - Andrea Abbott
- Department of Surgery, Medical University of South Carolina, Charleston, South Carolina, USA
| | - Nancy Klauber DeMore
- Department of Surgery, Medical University of South Carolina, Charleston, South Carolina, USA
| |
Collapse
|
46
|
Affiliation(s)
| | - P.Y Courand
- CREATIS UMR 5220, Lyon, France
- Hospices civils de Lyon, Lyon, France
| | | | - D. Vray
- CREATIS UMR 5220, Lyon, France
| | | |
Collapse
|
47
|
Wofford WO, Mukherjee R, Siegel J, Garcia D, Hilliard E, Nasarre P, Klauber-DeMore N, Javid M. MON-532 Characterization of the Angiogenic Factor SFRP2 in Papillary Thyroid Carcinoma. J Endocr Soc 2020. [PMCID: PMC7207464 DOI: 10.1210/jendso/bvaa046.032] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
Abstract
Over the last decade, there has been an average annual increase of 3.1% in thyroid cancer diagnosis in the U.S. Papillary thyroid carcinoma (PTC) accounts for 80% of all thyroid cancer diagnoses. However, few molecular markers exist to identify clinically aggressive phenotypes. The angiogenic factor, secreted frizzled-related protein 2 (SFRP2), is associated with a poor prognosis in several malignancies including breast cancer and melanoma. The role of SFRP2 in PTC has yet to be investigated. The aims of this study were to determine the differential expression of SFRP2 in PTC, benign thyroid adenomas, normal thyroid tissue (from patients without cancer), and normal adjacent tissue (NAT) (non-cancerous tissue from patients with PTC) and investigate the role of SFRP2 in tumor development in two PTC cell lines, PTC classical variant (PTC-CV) and PTC follicular variant (PTC-FV), upon treatment with a humanized anti-SFRP2 monoclonal antibody (hSFRP2 mAb). Immunohistochemistry (IHC) was performed using human tissue protein microarrays including 226 PTC, 79 benign adenomas, 112 NAT, and 30 normal thyroid tissue samples. In-vitro proliferation and apoptosis experiments were performed on MDA-T41 (PTC-CV) and MDA-T68 (PTC-FV) cell lines by treating with hSFRP2 mAb, Xolair IgG control, and a vehicle control. SFRP2 expression was significantly higher in PTC compared with benign adenomas and normal thyroid (mean expression scores 9, 6, and 1, respectively; p<0.05). SFRP2 expression was significantly higher in NAT than normal thyroid (mean expression score 4 and 0, respectively, p<0.05). Apoptotic rates were increased by 40% and 62% in the PTC-CV hSFRP2 mAb treatment group compared with the Xolair and vehicle treatment groups, respectively (p<0.05). Apoptotic rates were increased by 126% and 59% in the PTC-FV hSFRP2 mAb treatment group compared with the Xolair and vehicle treatment groups, respectively (p<0.05). Treatment with hSFRP2 mAb had no significant effect on proliferation in either cell line. In conclusion, SFRP2 expression is significantly higher in PTC than in benign adenomas and normal thyroid tissue. SFRP2 expression in NAT is significantly higher than in normal thyroid tissue and not significantly different from benign adenomas. SFRP2 expression in nonmalignant tissue adjacent to PTC could be due to expression in the tumor microenvironment. Treatment with a novel hSFPR2 mAb increases apoptotic rates in two different PTC cell lines. These data suggest that SFPR2 is involved in tumorigenesis of PTC.
Collapse
Affiliation(s)
| | | | - Julie Siegel
- Medical University of South Carolina, Charleston, SC, USA
| | - Denise Garcia
- Medical University of South Carolina, Charleston, SC, USA
| | | | | | | | - Mahsa Javid
- Medical University of South Carolina, Charleston, SC, USA
| |
Collapse
|
48
|
Albert A, Alfaro R, Alvarez C, Angeles Camacho JR, Arteaga-Velázquez JC, Arunbabu KP, Avila Rojas D, Ayala Solares HA, Baghmanyan V, Belmont-Moreno E, BenZvi SY, Brisbois C, Caballero-Mora KS, Capistrán T, Carramiñana A, Casanova S, Cotti U, Cotzomi J, Coutiño de León S, De la Fuente E, de León C, Dingus BL, DuVernois MA, Díaz-Vélez JC, Ellsworth RW, Engel K, Espinoza C, Fleischhack H, Fraija N, Galván-Gámez A, Garcia D, García-González JA, Garfias F, González MM, Goodman JA, Harding JP, Hernandez S, Hona B, Huang D, Hueyotl-Zahuantitla F, Hüntemeyer P, Iriarte A, Joshi V, Lara A, Lee WH, León Vargas H, Linnemann JT, Longinotti AL, Luis-Raya G, Lundeen J, López-Coto R, Malone K, Marinelli SS, Martinez-Castellanos I, Martínez-Castro J, Martínez-Huerta H, Matthews JA, Miranda-Romagnoli P, Morales-Soto JA, Moreno E, Nayerhoda A, Nellen L, Newbold M, Nisa MU, Noriega-Papaqui R, Omodei N, Peisker A, Pérez-Pérez EG, Rho CD, Rivière C, Rosa-González D, Rosenberg M, Ruiz-Velasco E, Salazar H, Salesa Greus F, Sandoval A, Schneider M, Schoorlemmer H, Sinnis G, Smith AJ, Springer RW, Surajbali P, Tabachnick E, Tanner M, Tibolla O, Tollefson K, Torres I, Torres-Escobedo R, Weisgarber T, Yodh G, Zepeda A, Zhou H. Constraints on Lorentz Invariance Violation from HAWC Observations of Gamma Rays above 100 TeV. Phys Rev Lett 2020; 124:131101. [PMID: 32302173 DOI: 10.1103/physrevlett.124.131101] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/18/2019] [Revised: 02/07/2020] [Accepted: 03/04/2020] [Indexed: 06/11/2023]
Abstract
Because of the high energies and long distances to the sources, astrophysical observations provide a unique opportunity to test possible signatures of Lorentz invariance violation (LIV). Superluminal LIV enables the decay of photons at high energy. The high altitude water Cherenkov (HAWC) observatory is among the most sensitive gamma-ray instruments currently operating above 10 TeV. HAWC finds evidence of 100 TeV photon emission from at least four astrophysical sources. These observations exclude, for the strongest of the limits set, the LIV energy scale to 2.2×10^{31} eV, over 1800 times the Planck energy and an improvement of 1 to 2 orders of magnitude over previous limits.
Collapse
Affiliation(s)
- A Albert
- Physics Division, Los Alamos National Laboratory, Los Alamos, New Mexico 87545, USA
| | - R Alfaro
- Instituto de Física, Universidad Nacional Autónoma de México, Ciudad de Mexico 04510, Mexico
| | - C Alvarez
- Universidad Autónoma de Chiapas, Tuxtla Gutiérrez, Chiapas 29050, Mexico
| | - J R Angeles Camacho
- Instituto de Física, Universidad Nacional Autónoma de México, Ciudad de Mexico 04510, Mexico
| | | | - K P Arunbabu
- Instituto de Geofísica, Universidad Nacional Autónoma de México, Ciudad de Mexico 04510, Mexico
| | - D Avila Rojas
- Instituto de Física, Universidad Nacional Autónoma de México, Ciudad de Mexico 04510, Mexico
| | - H A Ayala Solares
- Department of Physics, Pennsylvania State University, University Park, Pennsylvania 16802, USA
| | - V Baghmanyan
- Institute of Nuclear Physics Polish Academy of Sciences, PL-31342 IFJ-PAN, Krakow 31342, Poland
| | - E Belmont-Moreno
- Instituto de Física, Universidad Nacional Autónoma de México, Ciudad de Mexico 04510, Mexico
| | - S Y BenZvi
- Department of Physics & Astronomy, University of Rochester, Rochester, New York 14627, USA
| | - C Brisbois
- Department of Physics, Michigan Technological University, Houghton, Michigan 49931-1295, USA
| | - K S Caballero-Mora
- Universidad Autónoma de Chiapas, Tuxtla Gutiérrez, Chiapas 29050, Mexico
| | - T Capistrán
- Instituto Nacional de Astrofísica, Óptica y Electrónica, Puebla 72840, Mexico
| | - A Carramiñana
- Instituto Nacional de Astrofísica, Óptica y Electrónica, Puebla 72840, Mexico
| | - S Casanova
- Institute of Nuclear Physics Polish Academy of Sciences, PL-31342 IFJ-PAN, Krakow 31342, Poland
| | - U Cotti
- Universidad Michoacana de San Nicolás de Hidalgo, Morelia 58040, Mexico
| | - J Cotzomi
- Facultad de Ciencias Físico Matemáticas, Benemérita Universidad Autónoma de Puebla, Puebla 72570, Mexico
| | - S Coutiño de León
- Instituto Nacional de Astrofísica, Óptica y Electrónica, Puebla 72840, Mexico
| | - E De la Fuente
- Departamento de Física, CUCEI, Universidad de Guadalajara, Guadalajara 44430, Mexico
| | - C de León
- Universidad Michoacana de San Nicolás de Hidalgo, Morelia 58040, Mexico
| | - B L Dingus
- Physics Division, Los Alamos National Laboratory, Los Alamos, New Mexico 87545, USA
| | - M A DuVernois
- Department of Physics, University of Wisconsin-Madison, Madison, Wisconsin 53706, USA
| | - J C Díaz-Vélez
- Departamento de Física, Centro Universitario de los Valles, Universidad de Guadalajara, Guadalajara 46600, Mexico
| | - R W Ellsworth
- Department of Physics, University of Maryland, College Park, Maryland 20742-4111, USA
| | - K Engel
- Department of Physics, University of Maryland, College Park, Maryland 20742-4111, USA
| | - C Espinoza
- Instituto de Física, Universidad Nacional Autónoma de México, Ciudad de Mexico 04510, Mexico
| | - H Fleischhack
- Department of Physics, Michigan Technological University, Houghton, Michigan 49931-1295, USA
| | - N Fraija
- Instituto de Astronomía, Universidad Nacional Autónoma de México, Ciudad de Mexico 04510, Mexico
| | - A Galván-Gámez
- Instituto de Astronomía, Universidad Nacional Autónoma de México, Ciudad de Mexico 04510, Mexico
| | - D Garcia
- Instituto de Física, Universidad Nacional Autónoma de México, Ciudad de Mexico 04510, Mexico
| | - J A García-González
- Instituto de Física, Universidad Nacional Autónoma de México, Ciudad de Mexico 04510, Mexico
| | - F Garfias
- Instituto de Astronomía, Universidad Nacional Autónoma de México, Ciudad de Mexico 04510, Mexico
| | - M M González
- Instituto de Astronomía, Universidad Nacional Autónoma de México, Ciudad de Mexico 04510, Mexico
| | - J A Goodman
- Department of Physics, University of Maryland, College Park, Maryland 20742-4111, USA
| | - J P Harding
- Physics Division, Los Alamos National Laboratory, Los Alamos, New Mexico 87545, USA
| | - S Hernandez
- Instituto de Física, Universidad Nacional Autónoma de México, Ciudad de Mexico 04510, Mexico
| | - B Hona
- Department of Physics, Michigan Technological University, Houghton, Michigan 49931-1295, USA
| | - D Huang
- Department of Physics, Michigan Technological University, Houghton, Michigan 49931-1295, USA
| | | | - P Hüntemeyer
- Department of Physics, Michigan Technological University, Houghton, Michigan 49931-1295, USA
| | - A Iriarte
- Instituto de Astronomía, Universidad Nacional Autónoma de México, Ciudad de Mexico 04510, Mexico
| | - V Joshi
- Erlangen Centre for Astroparticle Physics, Friedrich-Alexander-Universität Erlangen-Nürnberg, 91058 Erlangen, Germany
| | - A Lara
- Instituto de Geofísica, Universidad Nacional Autónoma de México, Ciudad de Mexico 04510, Mexico
| | - W H Lee
- Instituto de Astronomía, Universidad Nacional Autónoma de México, Ciudad de Mexico 04510, Mexico
| | - H León Vargas
- Instituto de Física, Universidad Nacional Autónoma de México, Ciudad de Mexico 04510, Mexico
| | - J T Linnemann
- Department of Physics and Astronomy, Michigan State University, East Lansing, Michigan 48824, USA
| | - A L Longinotti
- Instituto Nacional de Astrofísica, Óptica y Electrónica, Puebla 72840, Mexico
| | - G Luis-Raya
- Universidad Politecnica de Pachuca, Pachuca, Hgo 42083, Mexico
| | - J Lundeen
- Department of Physics and Astronomy, Michigan State University, East Lansing, Michigan 48824, USA
| | - R López-Coto
- INFN and Universita di Padova, via Marzolo 8, I-35131, Padova, Italy
| | - K Malone
- Physics Division, Los Alamos National Laboratory, Los Alamos, New Mexico 87545, USA
| | - S S Marinelli
- Department of Physics and Astronomy, Michigan State University, East Lansing, Michigan 48824, USA
| | | | - J Martínez-Castro
- Centro de Investigación en Computación, Instituto Politécnico Nacional, México City 07738, Mexico
| | - H Martínez-Huerta
- Instituto de Física de São Carlos, Universidade de São Paulo, São Carlos, Sao Paolo 13566-590, Brasil
| | - J A Matthews
- Dept of Physics and Astronomy, University of New Mexico, Albuquerque, New Mexico 87131, USA
| | | | - J A Morales-Soto
- Universidad Michoacana de San Nicolás de Hidalgo, Morelia 58040, Mexico
| | - E Moreno
- Facultad de Ciencias Físico Matemáticas, Benemérita Universidad Autónoma de Puebla, Puebla 72570, Mexico
| | - A Nayerhoda
- Institute of Nuclear Physics Polish Academy of Sciences, PL-31342 IFJ-PAN, Krakow 31342, Poland
| | - L Nellen
- Instituto de Ciencias Nucleares, Universidad Nacional Autónoma de Mexico, Ciudad de Mexico 04510, Mexico
| | - M Newbold
- Department of Physics and Astronomy, University of Utah, Salt Lake City, Utah 84112, USA
| | - M U Nisa
- Department of Physics and Astronomy, Michigan State University, East Lansing, Michigan 48824, USA
| | | | - N Omodei
- Stanford University, Stanford, California 94305, USA
| | - A Peisker
- Department of Physics and Astronomy, Michigan State University, East Lansing, Michigan 48824, USA
| | - E G Pérez-Pérez
- Universidad Politecnica de Pachuca, Pachuca, Hgo 42083, Mexico
| | - C D Rho
- Department of Physics & Astronomy, University of Rochester, Rochester, New York 14627, USA
| | - C Rivière
- Department of Physics, University of Maryland, College Park, Maryland 20742-4111, USA
| | - D Rosa-González
- Instituto Nacional de Astrofísica, Óptica y Electrónica, Puebla 72840, Mexico
| | - M Rosenberg
- Department of Physics, Pennsylvania State University, University Park, Pennsylvania 16802, USA
| | - E Ruiz-Velasco
- Max-Planck Institute for Nuclear Physics, 69117 Heidelberg, Germany
| | - H Salazar
- Facultad de Ciencias Físico Matemáticas, Benemérita Universidad Autónoma de Puebla, Puebla 72570, Mexico
| | - F Salesa Greus
- Institute of Nuclear Physics Polish Academy of Sciences, PL-31342 IFJ-PAN, Krakow 31342, Poland
| | - A Sandoval
- Instituto de Física, Universidad Nacional Autónoma de México, Ciudad de Mexico 04510, Mexico
| | - M Schneider
- Department of Physics, University of Maryland, College Park, Maryland 20742-4111, USA
| | - H Schoorlemmer
- Max-Planck Institute for Nuclear Physics, 69117 Heidelberg, Germany
| | - G Sinnis
- Physics Division, Los Alamos National Laboratory, Los Alamos, New Mexico 87545, USA
| | - A J Smith
- Department of Physics, University of Maryland, College Park, Maryland 20742-4111, USA
| | - R W Springer
- Department of Physics and Astronomy, University of Utah, Salt Lake City, Utah 84112, USA
| | - P Surajbali
- Max-Planck Institute for Nuclear Physics, 69117 Heidelberg, Germany
| | - E Tabachnick
- Department of Physics, University of Maryland, College Park, Maryland 20742-4111, USA
| | - M Tanner
- Department of Physics, Pennsylvania State University, University Park, Pennsylvania 16802, USA
| | - O Tibolla
- Universidad Politecnica de Pachuca, Pachuca, Hgo 42083, Mexico
| | - K Tollefson
- Department of Physics and Astronomy, Michigan State University, East Lansing, Michigan 48824, USA
| | - I Torres
- Instituto Nacional de Astrofísica, Óptica y Electrónica, Puebla 72840, Mexico
| | - R Torres-Escobedo
- Departamento de Física, CUCEI, Universidad de Guadalajara, Guadalajara 44430, Mexico
- Department of Physics and Astronomy, Texas Tech University, Lubbock, Texas 79409-1051, USA
| | - T Weisgarber
- Department of Physics, University of Wisconsin-Madison, Madison, Wisconsin 53706, USA
| | - G Yodh
- Department of Physics and Astronomy, University of California, Irvine, Irvine, California 92697, USA
| | - A Zepeda
- Physics Department, Centro de Investigacion y de Estudios Avanzados del IPN, Mexico City 07360, Mexico
| | - H Zhou
- Physics Division, Los Alamos National Laboratory, Los Alamos, New Mexico 87545, USA
| |
Collapse
|
49
|
Abeysekara AU, Albert A, Alfaro R, Angeles Camacho JR, Arteaga-Velázquez JC, Arunbabu KP, Avila Rojas D, Ayala Solares HA, Baghmanyan V, Belmont-Moreno E, BenZvi SY, Brisbois C, Caballero-Mora KS, Capistrán T, Carramiñana A, Casanova S, Cotti U, Cotzomi J, Coutiño de León S, De la Fuente E, de León C, Dichiara S, Dingus BL, DuVernois MA, Díaz-Vélez JC, Ellsworth RW, Engel K, Espinoza C, Fleischhack H, Fraija N, Galván-Gámez A, Garcia D, García-González JA, Garfias F, González MM, Goodman JA, Harding JP, Hernandez S, Hinton J, Hona B, Huang D, Hueyotl-Zahuantitla F, Hüntemeyer P, Iriarte A, Jardin-Blicq A, Joshi V, Kaufmann S, Kieda D, Lara A, Lee WH, León Vargas H, Linnemann JT, Longinotti AL, Luis-Raya G, Lundeen J, López-Coto R, Malone K, Marinelli SS, Martinez O, Martinez-Castellanos I, Martínez-Castro J, Martínez-Huerta H, Matthews JA, Miranda-Romagnoli P, Morales-Soto JA, Moreno E, Mostafá M, Nayerhoda A, Nellen L, Newbold M, Nisa MU, Noriega-Papaqui R, Peisker A, Pérez-Pérez EG, Pretz J, Ren Z, Rho CD, Rivière C, Rosa-González D, Rosenberg M, Ruiz-Velasco E, Salesa Greus F, Sandoval A, Schneider M, Schoorlemmer H, Sinnis G, Smith AJ, Springer RW, Surajbali P, Tabachnick E, Tanner M, Tibolla O, Tollefson K, Torres I, Torres-Escobedo R, Villaseñor L, Weisgarber T, Wood J, Yapici T, Zhang H, Zhou H. Multiple Galactic Sources with Emission Above 56 TeV Detected by HAWC. Phys Rev Lett 2020; 124:021102. [PMID: 32004015 DOI: 10.1103/physrevlett.124.021102] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/18/2019] [Revised: 11/21/2019] [Indexed: 06/10/2023]
Abstract
We present the first catalog of gamma-ray sources emitting above 56 and 100 TeV with data from the High Altitude Water Cherenkov Observatory, a wide field-of-view observatory capable of detecting gamma rays up to a few hundred TeV. Nine sources are observed above 56 TeV, all of which are likely galactic in origin. Three sources continue emitting past 100 TeV, making this the highest-energy gamma-ray source catalog to date. We report the integral flux of each of these objects. We also report spectra for three highest-energy sources and discuss the possibility that they are PeVatrons.
Collapse
Affiliation(s)
- A U Abeysekara
- Department of Physics and Astronomy, University of Utah, Salt Lake City, Utah, USA
| | - A Albert
- Physics Division, Los Alamos National Laboratory, Los Alamos, New Mexico, USA
| | - R Alfaro
- Instituto de Física, Universidad Nacional Autónoma de México, Ciudad de Mexico, Mexico
| | - J R Angeles Camacho
- Instituto de Física, Universidad Nacional Autónoma de México, Ciudad de Mexico, Mexico
| | | | - K P Arunbabu
- Instituto de Geofísica, Universidad Nacional Autónoma de México, Ciudad de Mexico, Mexico
| | - D Avila Rojas
- Instituto de Física, Universidad Nacional Autónoma de México, Ciudad de Mexico, Mexico
| | - H A Ayala Solares
- Department of Physics, Pennsylvania State University, University Park, Pennsylvania, USA
| | - V Baghmanyan
- Institute of Nuclear Physics Polish Academy of Sciences, IFJ-PAN, Krakow, Poland
| | - E Belmont-Moreno
- Instituto de Física, Universidad Nacional Autónoma de México, Ciudad de Mexico, Mexico
| | - S Y BenZvi
- Department of Physics & Astronomy, University of Rochester, Rochester, New York, USA
| | - C Brisbois
- Department of Physics, University of Maryland, College Park, Maryland, USA
| | | | - T Capistrán
- Instituto Nacional de Astrofísica, Óptica y Electrónica, Puebla, Mexico
| | - A Carramiñana
- Instituto Nacional de Astrofísica, Óptica y Electrónica, Puebla, Mexico
| | - S Casanova
- Institute of Nuclear Physics Polish Academy of Sciences, IFJ-PAN, Krakow, Poland
| | - U Cotti
- Universidad Michoacana de San Nicolás de Hidalgo, Morelia, Mexico
| | - J Cotzomi
- Facultad de Ciencias Físico Matemáticas, Benemérita Universidad Autónoma de Puebla, Puebla, Mexico
| | - S Coutiño de León
- Instituto Nacional de Astrofísica, Óptica y Electrónica, Puebla, Mexico
| | - E De la Fuente
- Departamento de Física, Centro Universitario de Ciencias Exactase Ingenierias, Universidad de Guadalajara, Guadalajara, Mexico
- Department of Physics and Astronomy, Texas Tech University, Lubbock, Texas, USA
| | - C de León
- Universidad Michoacana de San Nicolás de Hidalgo, Morelia, Mexico
| | - S Dichiara
- Instituto de Astronomía, Universidad Nacional Autónoma de México, Ciudad de Mexico, Mexico
| | - B L Dingus
- Physics Division, Los Alamos National Laboratory, Los Alamos, New Mexico, USA
| | - M A DuVernois
- Department of Physics, University of Wisconsin-Madison, Madison, Wisconsin, USA
| | - J C Díaz-Vélez
- Departamento de Física, Centro Universitario de Ciencias Exactase Ingenierias, Universidad de Guadalajara, Guadalajara, Mexico
- Department of Physics and Astronomy, Texas Tech University, Lubbock, Texas, USA
| | - R W Ellsworth
- Department of Physics, University of Maryland, College Park, Maryland, USA
| | - K Engel
- Department of Physics, University of Maryland, College Park, Maryland, USA
| | - C Espinoza
- Instituto de Física, Universidad Nacional Autónoma de México, Ciudad de Mexico, Mexico
| | - H Fleischhack
- Department of Physics, Michigan Technological University, Houghton, Michigan, USA
| | - N Fraija
- Instituto de Astronomía, Universidad Nacional Autónoma de México, Ciudad de Mexico, Mexico
| | - A Galván-Gámez
- Instituto de Astronomía, Universidad Nacional Autónoma de México, Ciudad de Mexico, Mexico
| | - D Garcia
- Instituto de Física, Universidad Nacional Autónoma de México, Ciudad de Mexico, Mexico
| | - J A García-González
- Instituto de Física, Universidad Nacional Autónoma de México, Ciudad de Mexico, Mexico
| | - F Garfias
- Instituto de Astronomía, Universidad Nacional Autónoma de México, Ciudad de Mexico, Mexico
| | - M M González
- Instituto de Astronomía, Universidad Nacional Autónoma de México, Ciudad de Mexico, Mexico
| | - J A Goodman
- Department of Physics, University of Maryland, College Park, Maryland, USA
| | - J P Harding
- Physics Division, Los Alamos National Laboratory, Los Alamos, New Mexico, USA
| | - S Hernandez
- Instituto de Física, Universidad Nacional Autónoma de México, Ciudad de Mexico, Mexico
| | - J Hinton
- Max-Planck Institute for Nuclear Physics, Heidelberg, Germany
| | - B Hona
- Department of Physics, Michigan Technological University, Houghton, Michigan, USA
| | - D Huang
- Department of Physics, Michigan Technological University, Houghton, Michigan, USA
| | | | - P Hüntemeyer
- Department of Physics, Michigan Technological University, Houghton, Michigan, USA
| | - A Iriarte
- Instituto de Astronomía, Universidad Nacional Autónoma de México, Ciudad de Mexico, Mexico
| | - A Jardin-Blicq
- Max-Planck Institute for Nuclear Physics, Heidelberg, Germany
| | - V Joshi
- Erlangen Centre for Astroparticle Physics, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany
| | - S Kaufmann
- Universidad Politecnica de Pachuca, Pachuca, Hgo, Mexico
| | - D Kieda
- Department of Physics and Astronomy, University of Utah, Salt Lake City, Utah, USA
| | - A Lara
- Instituto de Geofísica, Universidad Nacional Autónoma de México, Ciudad de Mexico, Mexico
| | - W H Lee
- Instituto de Astronomía, Universidad Nacional Autónoma de México, Ciudad de Mexico, Mexico
| | - H León Vargas
- Instituto de Física, Universidad Nacional Autónoma de México, Ciudad de Mexico, Mexico
| | - J T Linnemann
- Department of Physics and Astronomy, Michigan State University, East Lansing, Michigan, USA
| | - A L Longinotti
- Instituto Nacional de Astrofísica, Óptica y Electrónica, Puebla, Mexico
| | - G Luis-Raya
- Universidad Politecnica de Pachuca, Pachuca, Hgo, Mexico
| | - J Lundeen
- Department of Physics and Astronomy, Michigan State University, East Lansing, Michigan, USA
| | - R López-Coto
- INFN and Universita di Padova, via Marzolo 8, Padova, Italy
| | - K Malone
- Physics Division, Los Alamos National Laboratory, Los Alamos, New Mexico, USA
- Department of Physics, Pennsylvania State University, University Park, Pennsylvania, USA
| | - S S Marinelli
- Department of Physics and Astronomy, Michigan State University, East Lansing, Michigan, USA
| | - O Martinez
- Facultad de Ciencias Físico Matemáticas, Benemérita Universidad Autónoma de Puebla, Puebla, Mexico
| | | | - J Martínez-Castro
- Centro de Investigación en Computación, Instituto Politécnico Nacional, México City, México
| | - H Martínez-Huerta
- Instituto de Física de São Carlos, Universidade de São Paulo, São Carlos, São Paulo, Brasil
| | - J A Matthews
- Dept of Physics and Astronomy, University of New Mexico, Albuquerque, New Mexico, USA
| | | | - J A Morales-Soto
- Universidad Michoacana de San Nicolás de Hidalgo, Morelia, Mexico
| | - E Moreno
- Facultad de Ciencias Físico Matemáticas, Benemérita Universidad Autónoma de Puebla, Puebla, Mexico
| | - M Mostafá
- Department of Physics, Pennsylvania State University, University Park, Pennsylvania, USA
| | - A Nayerhoda
- Institute of Nuclear Physics Polish Academy of Sciences, IFJ-PAN, Krakow, Poland
| | - L Nellen
- Instituto de Ciencias Nucleares, Universidad Nacional Autónoma de Mexico, Ciudad de Mexico, Mexico
| | - M Newbold
- Department of Physics and Astronomy, University of Utah, Salt Lake City, Utah, USA
| | - M U Nisa
- Department of Physics and Astronomy, Michigan State University, East Lansing, Michigan, USA
| | | | - A Peisker
- Department of Physics and Astronomy, Michigan State University, East Lansing, Michigan, USA
| | | | - J Pretz
- Department of Physics, Pennsylvania State University, University Park, Pennsylvania, USA
| | - Z Ren
- Dept of Physics and Astronomy, University of New Mexico, Albuquerque, New Mexico, USA
| | - C D Rho
- Department of Physics & Astronomy, University of Rochester, Rochester, New York, USA
| | - C Rivière
- Department of Physics, University of Maryland, College Park, Maryland, USA
| | - D Rosa-González
- Instituto Nacional de Astrofísica, Óptica y Electrónica, Puebla, Mexico
| | - M Rosenberg
- Department of Physics, Pennsylvania State University, University Park, Pennsylvania, USA
| | - E Ruiz-Velasco
- Max-Planck Institute for Nuclear Physics, Heidelberg, Germany
| | - F Salesa Greus
- Institute of Nuclear Physics Polish Academy of Sciences, IFJ-PAN, Krakow, Poland
| | - A Sandoval
- Instituto de Física, Universidad Nacional Autónoma de México, Ciudad de Mexico, Mexico
| | - M Schneider
- Department of Physics, University of Maryland, College Park, Maryland, USA
| | - H Schoorlemmer
- Max-Planck Institute for Nuclear Physics, Heidelberg, Germany
| | - G Sinnis
- Physics Division, Los Alamos National Laboratory, Los Alamos, New Mexico, USA
| | - A J Smith
- Department of Physics, University of Maryland, College Park, Maryland, USA
| | - R W Springer
- Department of Physics and Astronomy, University of Utah, Salt Lake City, Utah, USA
| | - P Surajbali
- Max-Planck Institute for Nuclear Physics, Heidelberg, Germany
| | - E Tabachnick
- Department of Physics, University of Maryland, College Park, Maryland, USA
| | - M Tanner
- Department of Physics, Pennsylvania State University, University Park, Pennsylvania, USA
| | - O Tibolla
- Universidad Politecnica de Pachuca, Pachuca, Hgo, Mexico
| | - K Tollefson
- Department of Physics and Astronomy, Michigan State University, East Lansing, Michigan, USA
| | - I Torres
- Instituto Nacional de Astrofísica, Óptica y Electrónica, Puebla, Mexico
| | - R Torres-Escobedo
- Departamento de Física, Centro Universitario de Ciencias Exactase Ingenierias, Universidad de Guadalajara, Guadalajara, Mexico
- Department of Physics and Astronomy, Texas Tech University, Lubbock, Texas, USA
| | - L Villaseñor
- Facultad de Ciencias Físico Matemáticas, Benemérita Universidad Autónoma de Puebla, Puebla, Mexico
| | - T Weisgarber
- Department of Physics, University of Wisconsin-Madison, Madison, Wisconsin, USA
| | - J Wood
- NASA Marshall Space Flight Center, Hunstville, Alabama, USA
| | - T Yapici
- Department of Physics & Astronomy, University of Rochester, Rochester, New York, USA
| | - H Zhang
- Department of Physics and Astronomy, Purdue University, West Lafayette, Indiana, USA
| | - H Zhou
- Physics Division, Los Alamos National Laboratory, Los Alamos, New Mexico, USA
| |
Collapse
|
50
|
Abstract
Abstract
A simple, 10-min immunoassay system has been developed that simultaneously screens for five different classes of drugs of abuse in a urine sample. This system tests for amphetamines, cannabinoids, cocaine metabolites, opiates, and phencyclidine, and each assay has a specific preset cutoff concentration. Accuracy is > 99% for reporting positive or negative results for samples with 200% or 50%, respectively, of the cutoff concentrations of the drugs. Tests of a panel of 96 compounds yielded only three cases of nonspecific reactivity (at a drug concentration of 100 mg/L). Another panel of 12 compounds that could normally be found in urine samples was also evaluated and no interferences were observed. Concordance was > 95% between this system and the comparable automated immunoassays for detecting drugs of abuse. Greater than 98% of GC/MS-confirmed positive samples gave positive results with this assay system.
Collapse
Affiliation(s)
- R G Parsons
- Diagnostics Division, Abbott Laboratories, North Chicago, IL 60064
| | - R Kowal
- Diagnostics Division, Abbott Laboratories, North Chicago, IL 60064
| | - D LeBlond
- Diagnostics Division, Abbott Laboratories, North Chicago, IL 60064
| | - V T Yue
- Diagnostics Division, Abbott Laboratories, North Chicago, IL 60064
| | - L Neargarder
- Diagnostics Division, Abbott Laboratories, North Chicago, IL 60064
| | - L Bond
- Diagnostics Division, Abbott Laboratories, North Chicago, IL 60064
| | - D Garcia
- Diagnostics Division, Abbott Laboratories, North Chicago, IL 60064
| | - D Slater
- Diagnostics Division, Abbott Laboratories, North Chicago, IL 60064
| | - P Rogers
- Diagnostics Division, Abbott Laboratories, North Chicago, IL 60064
| |
Collapse
|